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There are numerous vaccines available for the control of infectious bronchitis virus 
(IBV) in poultry, however protection is short-lived and poorly cross-protective 
between strains.  The vaccines must currently be grown in embryonated eggs, a 
cumbersome and expensive process.  The ability to grow vaccines on a cell-line such 
as Vero cells would be highly advantageous.   
 
The spike (S) glycoprotein of IBV is comprised of two subunits, S1 and S2, has a 
vital role in virulence in vivo and is responsible for cellular tropism in vitro.  This 
project aims to identify the amino acids present in the S glycoprotein involved in 
determination of cellular tropism and cell-to-cell fusion. 
 
The IBV Beaudette strain is able to replicate in both primary chick kidney (CK) cells 
and Vero cells, whereas the IBV M41 strain replicates in primary cells only.  
Recombinant IBVs with chimaeric S genes were generated using a reverse genetics 
system with the genomic background of Beaudette and part of the S gene from M41.  
Their growth characteristics and cellular tropism were investigated.  The S2 subunit 
of Beaudette was found to be sufficient to confer the ability to grow on Vero cells 
and swapping just three amino acids with corresponding ones from M41 was 
sufficient to remove the ability of the Beaudette S glycoprotein for growth on Vero 
cells.   
 
Beaudette was further adapted to syncytia formation on Vero cells by serial passage 
and isolates were sequenced to identify amino acid changes between parent and 
Vero-adapted viruses that are potentially involved in cell-to-cell fusion.   
 
Understanding the way in which IBV infects host cells is vital in order to rationally 
design better vaccination and treatment strategies and help to reduce the prevalence 
of IBV infection in poultry worldwide.  Using the IBV reverse genetics system, we 
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Chapter 1: Introduction 
 
The Nidovirales 
The Coronaviridae are members of the order Nidovirales, and comprise two 
subfamilies, the Coronavirinae and Torovirinae, which share a similar morphology. 
There are three genera of coronaviruses, alpha-, beta- and gammacoronaviruses 
(Figure 1.1; Carstens, 2010), which were so named for their visual resemblance to 





Figure 1.1. The Nidovirales.  Three families comprise the Nidovirales, the 
Coronaviridae, Roniviridae and Arteriviridae.  The Coronaviridae is split into two 
subfamilies, the Coronavirinae and the Torovirinae.  There are three genera in the 
Coronavirinae, alpha-, beta- and gammacoronavirus.  Representative virion 
diagrams of each of the Nidovirales genera are shown underneath (virion diagrams 
from ViralZone, Swiss Institute of Bioinformatics). 
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Figure 1.2.  Coronavirus structure and electron micrograph of Coronavirus 
particles. Coronaviruses are surrounded by spike glycoproteins (S), which are 
comprised of S1 and S2 subunits, membrane proteins (M) and a small number of 
envelope proteins (E), all of which are embedded in a lipid membrane.  The core 
structure is comprised of the nucleocapsid (N) protein and the RNA genome, which 
form a helical nucleocapsid.  Micrograph obtained from the CDC Public Health 
Image Library, ID number 4814.   
 
The Coronavirinae 
Representative members of each of the coronavirus genera are shown in Table 1.1.  
Coronaviruses are enveloped viruses with a single-stranded positive-sense RNA 
genome of 26 – 32kb, the largest genomes of all RNA viruses currently known.  The 
genome of infectious bronchitis virus (IBV) is 27.6kb (Boursnell et al., 1987).   
 
In addition to their large genomes, coronaviruses have a number of features that 
separate them from other positive-sense RNA viruses.  The genome is capped and 
polyadenylated and is associated with the N protein forming a helical nucleocapsid 
within the virus particles.  Although common among negative-sense RNA viruses, 




Table 1.1. Coronavirus genera and species  
Genus Species 
alphacoronavirus 
Canine coronavirus (CCoV) 
Feline coronavirus (FCoV) 
Human coronavirus 229E (HCoV-229E) 
Porcine epidemic diarrhoea virus (PEDV) 
Porcine transmissible gastroenteritis virus (TGEV) 
betacoronavirus 
Bovine coronavirus (BCoV) 
Human coronavirus HKU1 (HCoV-HKU1) 
Human coronavirus OC43 (HCoV-OC43) 
Human enteric coronavirus (HECoV) 
Murine hepatitis virus (MHV) 
Porcine haemagglutinating encephalomyelitis virus (HEV)  
Puffinosis coronavirus (PCoV) 
Rat coronavirus (RtCoV) 
Severe acute respiratory syndrome coronavirus (SARS-CoV) 
gammacoronavirus 
IBV-like avian 
Infectious bronchitis virus (IBV) 
Turkey coronavirus (TCoV) 
Pheasant coronavirus (PhCoV) 
Non-IBV-like 
avian 
Munia coronavirus (MunCoV) 
Bulbul coronavirus (BuCoV) 
Thrush coronavirus (ThCoV) 
Mammalian 
Beluga whale coronavirus SW1 (BeCoV) 







* The derivation of these species of gammacoronavirus has yet to be determined. 





The helical nucleocapsids are enclosed within lipid envelopes containing the S 
glycoprotein, M protein and E protein (Figure 1.2).  Some betacoronaviruses such as 
MHV and HCoV-OC43 also contain haemagglutinin esterase (HE) proteins in their 
envelopes.   
 
Coronavirus genome organisation 
The genomic RNA has a 5’ m7GpppN-cap and a 3’ polyA tail.  Untranslated regions 
(UTRs) are found at the 5’ and the 3’ ends that have been shown to be involved in 
replication and translation (Senanayake and Brian, 1999).  The same general genome 
organisation is shared within the genus:  5’ UTR – replicase gene – structural protein 
genes – UTR 3’ (Figure 1.3).  Gene 1 encompasses the first two-thirds of the entire 
genome and consists of two large open reading frames, ORF 1a and 1b (Boursnell et 
al., 1987).  ORF 1a and 1b overlap slightly and are translated by a -1 frameshift 
mechanism (Brierley et al., 1987), the signal for which lies in the overlapping region, 
using a pseudoknot structure and a slippery sequence located between ORF1a and 
1b.    The two overlapping ORFs result in two large replicase proteins, pp1a and 1ab, 
the latter being a fusion protein of the first ORF as a result of the -1 frameshift.  Both 
proteins are proteolytically cleaved by two or three virus-encoded proteases.  
Autoproteolytic processing of pp1a and 1ab polyproteins produces the fifteen (IBV) 
or sixteen (other coronaviruses) replicase proteins.  Two domains found within the 
ORF1b region are unique to the Nidovirales.  These are the zinc-binding domain and 
the uridylate-specific endoribonuclease (Gorbalenya et al., 2006).   
 
Coronaviruses produce a nested set of sub-genomic mRNAs during the replication 
cycle (Sawicki and Sawicki, 1995), which are, apart from the last mRNA, 
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structurally polycistronic but functionally monocistronic as only the translation 
initiation site closest to the 5’ terminus is utilised.  Each mRNA has the same 3’ 
terminus and short 5’ leader sequence, which is identical to the 5’ end of the genome 
(Lai et al., 1983).  
 
 
Figure 1.3.  IBV genome structure and subgenomic mRNAs.  Gene 1 is 
comprised of ORFs 1a and 1b, which are located proximal to the 5’ untranslated 
region (UTR) and the leader sequence.  These encode proteins associated with RNA 
replication and transcription. The S, E, M and N genes are located proximal to the 3’ 
UTR and encode the proteins found in virus particles. Interspersed between these 
structural protein genes are accessory genes encoding non-structural proteins 3a, 3b, 
5a and 5b, which are not essential for replication.  The nested set of IBV mRNAs 
(genome and subgenomic mRNAs 2 – 6) is shown below.  The genome-length 
mRNA shows the location of the transcription regulation sequences (TRS).  Gene 
lengths are not to scale. 
 
 
The 3’-proximal ORFs encode the structural proteins genes in the order S – E – M – 
N, with some betacoronaviruses also having an HE protein, the gene of which is 
situated upstream of the S gene in the genome.   In addition to the polymerase gene 
and structural protein genes, coronaviruses also have several polycistronic genes 
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encoding non-structural or accessory proteins.  IBV encodes four accessory proteins, 
3a, 3b, 5a and 5b (Figure 1.3), the functions of which are as yet unknown.  Some 
betacoronaviruses contain an internal ORF (I) within the N gene, which is expressed 
in a +1 frameshift to the N protein sequence (Fischer et al., 1997).      
 
Coronavirus replication cycle (Figure 1.4) 
The coronavirus S glycoprotein mediates attachment to host cell receptors and fusion 
of the virion membrane to the host cell membrane (Koch et al., 1990; Luo and 
Weiss, 1998).  Binding of the S1 subunit to the host cell receptor induces 
conformational changes in the spike (Zelus et al., 2003), leading to virus-cell fusion 
and release of the nucleocapsid into the cytoplasm (Risco et al., 1996).    
 
The entry mechanisms for the coronavirinae have not been fully elucidated.  The 
SARS coronavirus has been shown to utilise the clathrin-dependent endocytosis 
pathway before being transported to early endosomes (Inoue et al., 2007) where 
entry is pH-dependent (Yang et al., 2004).  The MHV strain A59 has also been 
shown to enter host cells via clathrin-dependent endocytosis (Eifart et al., 2007), 
however another variant of MHV, JHMV, is able to enter host cells directly from the 













Figure 1.4.  The replication cycle of IBV.  The virus particle attaches to the host 
cell receptor (as yet unknown) and fuses with the cell membrane via the S 
glycoprotein.   Genomic RNA is released from the N protein and acts as an mRNA 
for the translation of the replicase proteins.  A –1 frame shift from ORF1a to ORF1b 
in the replicase gene generates the replicase polyproteins, pp1a and pp1ab, in 
differing amounts.  Virus-encoded proteinases proteolytically cleave replicase 
polyproteins and they assemble in double membrane replication-transcription 
complexes (RTC).  Sub-genomic mRNAs are produced from the rest of the genomic 
RNA and express the structural and other non-structural viral proteins at the rough 
endoplasmic reticulum (ER) and assemble at the ER-Golgi intermediate 
compartment (ERGIC).  The N protein associates with the genomic RNA to form the 
nucleocapsid and is incorporated into the forming virions at the ERGIC.  Complete 




Conformational changes in the spike leading to virus-cell fusion may be caused by 
low pH within endosomes, as in the case of IBV.  Chu et al., (2006) used 
fluorescence-dequenching assays to determine that IBV undergoes direct low-pH-
dependent fusion activation within acidic endosomes.  Fusion was unaffected by the 
presence of protease inhibitors and did not occur at neutral pH.  Pre-treatment of 
virions at low pH did not affect virus entry, indicating that conformational changes in 
the IBV S glycoprotein are reversible (Chu et al., 2006).    In contrast, studies of 
MHV-A59 have indicated that low pH-triggered conformational changes of the spike 
are irreversible (Eifart et al., 2007). 
 
While it appears that entry of IBV and MHV both depend on low pH, proteases may 
be involved in entry of HCoV-229E and SARS-CoV.  The spike of HCoV-229E has 
been shown to be activated by the endosomal protease cathepsin L (Kawase et al., 
2009), as has that of SARS-CoV (Simmons et al., 2005), which has also been 
demonstrated to be activated by the transmembrane protease TMPRSS2 in the lung 
(Matsuyama et al., 2010).   The S subunits of HCoV-229E and SARS-CoV are not 
cleaved during biosynthesis, whereas the S subunits of MHV and IBV are cleaved 
during biosynthesis.   
 
A model for coronavirus transcription and translation (Figure 1.5) has been described 
by Sawicki and Sawicki (1995).  It is hypothesised that upon virus entry and 
uncoating, ORF1 of genomic RNA is directly translated, producing pp1a and pp1ab.  
The replicase polyproteins are cleaved by virus-encoded proteinases (Ziebuhr et al., 
2000) and form replication-transcription complexes (RTC), which copy the genome.  
Minus strand templates are synthesised from the genome; genome-length templates 
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are produced by continuous transcription, subgenome-length templates are produced 
by discontinuous transcription.   
 
A transcription regulation sequence (TRS) is found at the 5’ end of each gene and at 
the 3’ end of the leader sequence.  RNA synthesis of the negative-sense transcripts is 
thought to begin at the 3’ end of the genome and continue until a TRS is reached.  
The RTC either pauses and then continues on to the next TRS or switches to the TRS 
at the leader sequence and continues transcription to form the negative-sense sub-
genomic RNA with an anti-leader sequence at the 3’ end.  The method by which the 
3’ end of the nascent negative strand may relocate to the 5’ end of the genomic 
template is as yet unknown.  The negative sense genome-length and sub-genomic 
RNAs are used as templates for genomic and sub-genomic mRNA synthesis.   It is 
thought that the RTCs age, releasing the minus strand templates for degradation 
(reviewed by Sawicki et al., 2007).  Newly synthesised viral RNA is found 
associated with convoluted membranes and double-membrane vesicles (Gosert et al., 
2002) thought to originate from the endoplasmic reticulum (Knoops et al., 2008), 
although autophagy may also be involved (Prentice et al., 2004).  These membranes 
may serve to protect viral RNA from degradation and may provide an optimal 





Figure 1.5.  Coronavirus replication-transcription model.  Genomic RNA is 
translated, producing pp1a and pp1ab, which form RTCs.  The RTCs recognise cis-
acting elements at the 5' and 3' ends of the genome and copy the genome 
continuously into a genome-length negative-strand template or discontinuously into 
the sub-genomic negative-strand templates.  Negative strands are shown in blue and 
are used as templates for genomic and sub-genomic mRNA synthesis (shown in 
black).  TRSs are shown as grey boxes either 5' to each mRNA or at the 5' end of the 
genome corresponding to the leader junction site.  Anti-leader sequences are also 
shown in blue.  The RTCs age, releasing the minus strand templates for degradation.  




A nested set of sub-genomic mRNAs are produced, which express the structural and 
accessory viral proteins at the endoplasmic reticulum (ER).  Most sub-genomic 
mRNAs are functionally monocistronic and only the ORF at the 5’ end is translated 
by a cap-dependent mechanism.  Bi- or tricistronic sub-genomic mRNAs are 
translated via a leaky-scanning mechanism or by internal ribosome entry (Liu and 
Inglis, 1992; Le et al., 1994).  The nucleocapsid associates with the M protein 
(Sturman et al., 1980) and structural proteins assemble at the ER-Golgi intermediate 
compartment (ERGIC; Klumperman et al., 1994).  Complete virus particles bud off 
from the Golgi apparatus and exit the cell by exocytosis (Tooze et al., 1987).  
 
Replicase proteins 
Two large non-structural precursor polyproteins are produced from gene 1, pp1a and 
pp1ab, comprising 70 – 80 % and 20 – 30 % respectively (Ziebuhr et al., 2000).  
Proteolytic processing of pp1a and pp1ab by several ORF1a-encoded proteinases 
including a 3C-like cysteine proteinase results in ~ 16 non-structural proteins (nsp), 
which are involved in replication.  IBV does not have the equivalent to nsp1, 
however nsp2 to nsp16 correspond to those of the other coronaviruses.  ORF1a 
encodes nsp1 to nsp11 and ORF1b encodes nsp12 to nsp16.   
 
Gorbalenya et al. (1989) used comparative sequence analysis to identify several 
functions of the polyproteins encoded by gene 1 including an RNA-dependent RNA 
polymerase (RdRp), nucleic acid binding domain, two proteases and an RNA 
helicase.  The RNA helicase (nsp13) and RdRp (nsp12) are encoded by ORF1b 
(Gorbalenya et al., 1989) and are produced in less amounts than the ORF1a-encoded 
proteins, which are involved in proteolytic activity and membrane association (van 
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der Meer et al., 1999).  The replicase proteins assemble into RTCs, forming double-
membrane vesicles (DMV), the sites of viral RNA synthesis (Gosert et al., 2002).   
 
Nsp1 inhibits host protein synthesis by degrading host mRNAs (Kamitani et al., 
2006).  Nsp3 is involved in ADP ribosylation (Eckerle et al., 2006) and contains 1 or 
2 papain-like proteinase sites depending on the coronavirus group, which are 
involved in processing nsp1 and 2 (Graham and Denison, 2006).  Nsp5 encodes a 
3C-like proteinase, which processes the remaining nsps (Lu et al., 1996) and cleaves 
pp1a and pp1ab at conserved central and C-terminal regions (reviewed by Ziebuhr et 
al., 2000).  Nsp7 and nsp8 form a super-complex shaped like a hollow cylinder 
consisting of eight molecules of each that may act as a cofactor to RdRp (Zhai et al., 
2005).  The nsp7-nsp8 super-complex interacts with nsp9, an ssRNA and ssDNA 
binding protein (Sutton et al., 2004; Egloff et al., 2004).  Nsp8 and nsp9 bind tRNA, 
possibly suggesting an ability to interfere with host-cell translation (Ponnusamy et 
al., 2006).  Nsp 10 is involved in RNA synthesis (Donaldson et al., 2006).  Nsp14 
has 3’ – 5’ exonuclease activity, nsp15 is an endoribonuclease and nsp16 is an RNA 
methyltransferase (Eckerle et al., 2006).   
 
The functions of some replicase nsps remain to be elucidated.  Several nsps may be 
involved in the formation of the replication complex, which associates with host cell 
membranes, in particular the late endosomal membranes.  Membrane association of 
the replication complex is mediated by the replicase protein subunits (van der Meer 
et al., 1999).  Nsps 3, 4 and 6 have transmembrane domains and may be involved in 
anchoring the RTCs to host membranes (Oostra et al., 2007; Oostra et al., 2008).  
Nsp2 has been shown to be recruited to RTCs and no exchange of nsp2 between the 
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cytoplasm or other DMVs occurs (Hagemeijer et al., 2010).  Other nsps interact to 
mediate viral RNA synthesis in the host cell.   
 
Accessory proteins 
All coronaviruses encode a number of non-structural proteins not derived from gene 
1, which are interspersed between the structural genes and vary between different 
coronaviruses.  IBV has four accessory proteins, 3a, 3b, 5a and 5b that are not 
essential for virus replication (Casais et al., 2005; Hodgson et al., 2006).  The 
numbers indicate the relative location of the ORF within the genome.   
 
Gene 3 is well conserved between IBV-like avian gammacoronaviruses (Jia and 
Naqi, 1997) and is tricistronic, encoding two accessory proteins, 3a and 3b, and the 
structural envelope protein (E) corresponding to ORF 3c (Smith et al., 1990).  
Translation of ORF 3c is independent of the translation of ORFs 3a and 3b, the latter 
of which is translated via leaky ribosomal scanning (Liu and Inglis, 1992).  
Ribosomes bind to the cap structure at the 5’ end of the RNA and scan until they 
reach the initiation codon for ORF 3a, AUG, where translation starts (Kozak, 1981).  
Sometimes the first initiation codon is missed by the ribosome and it continues 
scanning until it reaches the initiation codon for ORF3b.  This is not the case for the 
initiation of ORF3c, however.  ORFs 3a and 3b form a unique folding region 
containing a sequence complementary to the 18s ribosome subunit situated 3’ from 
two pseudoknot structures prior to the 3c initiation codon (Le et al., 1994).  This acts 
as an internal ribosomal entry site (IRES) for the initiation of translation of 3c.   
Hodgson et al. (2006) showed that 3a and 3b are not essential for replication of IBV 
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in vitro, however the titres of recombinant IBVs lacking 3a declined earlier than the 
parent virus in tracheal organ cultures (TOCs). 
   
Gene 5 of IBV is bicistronic and contains ORFs 5a and 5b.  Casais et al. (2005) 
produced a series of recombinant IBVs in which the complete expression of gene 5 
products was prevented.  These recombinants were able to replicate to a similar titre 
to the parent virus, indicating that 5a and 5b are not essential for IBV replication in 
vitro.  
 
Although the role of IBV accessory proteins is unclear, the accessory proteins of 
MHV may be determinants of pathogenicity.  A study was carried out by de Haan et 
al. (2002) in which a series of recombinant viruses were produced with deleted 
accessory genes.  Replication of recombinant viruses was similar to parent virus in 
vitro however recombinants were attenuated in vivo.  A recent study has indicated 




The M glycoprotein 
Most abundant of the structural proteins is the 25 kDa M glycoprotein (formerly 
known as the E1 protein), which spans the viral envelope three times (Godeke et al., 
2000).  The first membrane-spanning domain targets the M protein to the cis Golgi 
(Machamer et al., 1990) and is sufficient for membrane binding, retention in the 
Golgi and formation of multimers (Tseng et al., 2010).  The M protein has a short N-
terminal ectodomain and a large C-terminal cytoplasmic domain that interacts with 
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the nucleocapsid and is involved in assembly of virus particles (Narayanan et al., 
2003).  Interaction of the M protein with the S glycoprotein retains the spike in the 
ERGIC (McBride et al., 2007).  A single tyrosine residue at amino acid position 195 
in the M protein of the SARS-CoV has been identified as being necessary for 
interaction of the S and M proteins and assembly of virions (McBride and 
Machamer, 2010).   
 
The E protein 
The E protein is membrane-associated and contains a transmembrane region of a 
hydrophobic domain flanked by two hydrophilic domains.  The cytoplasmic tail of 
the E protein contains Golgi targeting information (Corse and Machamer, 2002).  
The E protein is a minor component of the virus envelope and is the least abundant 
structural protein.  It is thought that interaction of the E and M proteins may cause 
membrane curvature (Fischer et al., 1998), promoting budding of virus particles and 
is fundamental for the assembly of virus particles (Lim and Liu, 2001).  The E 
protein forms cation-selective ion channels in the lipid envelope, enhancing 
membrane permeability (Wilson et al., 2004).  
 
The N protein 
The N protein is a phosphorylated, highly basic structural protein that forms a helical 
nucleocapsid when bound to the coronavirus RNA genome within the virus particles.  
The carboxy-terminal domain interacts with the M protein (Hurst et al., 2005) and is 
packaged into viral particles by the M protein when bound to genomic RNA 
(Narayanan et al., 2003).  The N protein does not have a transmembrane domain but 
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is dynamically associated with membrane-associated viral RTCs (Sims et al., 2000; 
Verheije et al., 2010).  
 
The S glycoprotein 
The spike glycoprotein is a 180 kDa membrane glycoprotein projecting 20 nm from 
the virus surface (Figure 1.6; Delmas and Laude, 1990).  Cellular tropism of IBV is 
determined by the S glycoprotein (Casais et al., 2003), which has two subunits, the 
N-terminal S1 subunit responsible for binding to host cell receptors (Koch et al., 
1990) and the C-terminal S2 subunit responsible for cell-cell and virus-cell fusion 
(Luo and Weiss, 1998).  The subunits are both approximately 80 kDa in size.  
 
The coronavirus S glycoprotein is synthesised as a single polypeptide chain, which 
oligomerises into homotrimers in the ER of the host cell and are processed in the 
Golgi apparatus (Delmas and Laude, 1990).  Oligosaccharides are added to the 
spikes co-translationally.  Studies with tunicamycin by Rottier et al., (1981) 
indicated that the S glycoprotein of MHV has N-glycosidically linked 
oligosaccharides while the M protein has O-linked oligosaccharides.  The S and M 
glycoproteins of IBV however were found to both have N-linked high-mannose type 
oligosaccharides (Cavanagh et al., 1983).  Sequence analysis has predicted that the 
SARS-CoV S glycoprotein has 23 potential N-linked glycosylation sites (Rota et al., 
2003), one of which (N330) was found to interact with mannose-binding lectin (Zhou 
et al., 2010).  A number of N-linked glycosylation sites were found to be critical for 
DC/L-SIGN-mediated virus entry and also to have facilitated zoonotic transmission 







Figure 1.6. IBV S glycoprotein structure.  The IBV S glycoprotein domains are 
organized with the S1 domain at the N-terminus and the S2 domain at the C-
terminus.  A signal peptide (SS) is located within S1 along with the receptor-binding 
domain.  Within the S2 subunit are two heptad repeats (HR1 and 2), a 
transmembrane domain (TM) and a cytoplasmic tail (Cyto).  The IBV S glycoprotein 
is cleaved by host cell proteases between the S1 and S2 subunits.   The Beaudette 
strain of IBV contains a putative heparan sulphate-binding site (HSBS) within the S2 
subunit.   
 
The spike of MHV is thought to regulate the transport of the viral genome from the 
cell surface to the ER (Zhu et al., 2009), from where the spike is transported to the 
ERGIC (Lontok et al., 2004).  The spike interacts with the M protein on pre-Golgi 
membranes forming multimeric complexes (Opstelten et al., 1995) and is 
incorporated into forming virions (de Haan et al., 1999).  Unlike the other 
membrane-bound proteins, however, the coronavirus S glycoprotein is not required 
for the assembly of virions (Baudoux et al., 1998).  Excess S protein can be 
transported to the plasma membrane where it may participate in cell-cell fusion, 
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although transport of spikes not incorporated into virions through the Golgi is very 
slow (Vennema et al., 1990). The IBV S protein contains a canonical dilysine ER 
retrieval signal (-KKXX-COOH) (Youn et al., 2005) and a tyrosine-based 
endocytosis signal in its cytoplasmic tail (Lontok et al., 2004).  
 
There is no clear consensus of the role of S glycoprotein cleavage in fusion.  The two 
S subunits of some coronaviruses including IBV, MHV and HCoV-OC43, are 
cleaved during biosynthesis by a furin-like protease in the Golgi apparatus (de Haan 
et al., 2004) but remain non-covalently linked. The S1/S2 junction in IBV strains 
Beaudette and M41 is situated at the amino acid sequence RRFRR at amino acid 
position 552 (Cavanagh et al., 1986).  Cleavage of the MHV S glycoprotein differs 
between strains and host cells (Frana et al., 1985) and is not required for infectivity 
(Bos et al., 1995) or for binding to cellular receptors (Zelus et al., 2003).  Cleavage 
inhibition of the MHV S glycoprotein affects cell-cell fusion but not virus-cell 
fusion, indicating that cell-cell and virus-cell fusion are distinct processes (de Haan 
et al., 2004).  Entry of IBV and MHV has been shown to be pH-dependent (Chu et 
al., 2006; Eifart et al., 2007).   
 
The S subunits of HCoV-229E and SARS-CoV are not cleaved during biosynthesis; 
however the S glycoprotein of SARS-CoV is susceptible to protease cleavage within 
the human airway, enhancing virus entry (Kam et al., 2009).  The HCov-229E and 
SARS-CoV S glycoproteins are both activated by proteases during viral entry 
(Kawase et al., 2009; Simmons et al., 2005).  Cleavage of the SARS-CoV S 




The receptor-binding domain (RBD) is an independently folded region of the spike 
responsible for interfacing with the viral receptor, usually 180 – 130 amino acids in 
length. Although all coronavirus RBDs are found within the S1 subunit, they are 
virus-specific and vary in position throughout the S1 domain.  The RBD of MHV is 
located at the N-terminus of S1 (Kubo et al., 1994) and the HCoV-229E RBD is 
located at the C-terminus of S1 (Bonavia et al., 2003).  The RBD of SARS-CoV is 
located at the C-terminus of the S1 subunit between residues 270 – 510 (Babcock et 
al., 2004), however the residues 217 – 234 are also critical for virus entry (Guo et al., 
2009).  The specific location of the RBD of IBV has yet to be elucidated, although 
studies by Cavanagh et al. (1986) have determined that it is present in the S1 subunit.  
 
The coronavirus S glycoprotein is a type I fusion protein (Bosch et al., 2003), which 
is characterised by the presence of a number of domains including a pair of extended 
α-helices, also known as heptad repeats (HR; Figure 1.6).  The two helical domains, 
HR1 and HR2, form a trimer of hairpins or six-helix bundle, creating a stalk structure 
anchored to the virion membrane by a transmembrane domain.  The heptad repeats 
draw the host cell and viral membranes together upon receptor binding.  This causes 
destabilisation of the membranes and may allow the entry of the viral nucleocapsid 
(Sainz et al., 2005). 
 
A fusion peptide consisting of around twenty hydrophobic amino acids is located at 
the amino-terminal end of the first HR and a cluster of aromatic amino acids is 
situated near a hydrophobic transmembrane domain (Chambers et al., 1990; Sainz et 
al., 2005).  Binding of the S1 subunit to the receptor is thought to induce a 
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conformational change, activating the fusion peptide (Matsuyama and Taguchi, 
2002b).   
 
The position of the SARS-CoV fusion peptide has been sought by several groups, 
however the exact location is still unknown.  Putative locations of the fusion peptide 
include the N-terminal region of HR1, a region C-terminal to an S2 cleavage site and 
the N-terminal region of S2 (Petit et al., 2005; Sainz et al., 2005; Madu et al., 2009).  
Putative fusion peptides for MHV have been identified within HR1 or immediately 
upstream of HR1 (Luo and Weiss, 1998; Xu et al., 2004).  The fusion peptide of IBV 
has yet to be elucidated. 
 
Class I fusion proteins of other viruses 
Whilst relatively little is currently known about the S glycoproteins of coronaviruses, 
the fusion proteins of some other viruses have been more widely studied and may 
offer insight into the fusion properties of coronaviruses.  Class I fusion proteins are 
produced by paramyxoviruses, orthomyxoviruses, retroviruses, filoviruses and 
arenaviruses.  There are three common modes of entry of enveloped viruses.  The 
fusion proteins of some, such as HIV, undergo conformational changes upon binding 
to cellular receptors which induce fusion of viral and cellular membranes.  Fusion 
may be activated by acidic pH, as in the case of influenza virus, or by proteolytic 
cleavage of the fusion protein like Ebola virus.     
 
The best studied of the viral fusion proteins is the haemagglutinin (HA) protein of 
influenza A and B viruses, which, like the coronavirus S glycoprotein, is responsible 
for both receptor binding and fusion (Gamblin et al., 2004).  The HA precursor 
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protein is cleaved into two subunits, HA1 and HA2, which form a homotrimer.  The 
HA1 subunits form the globular heads of the homotrimer and HA2 forms a triple-
stranded coiled-coil containing the fusion peptide.  Conformational changes in HA1 
and HA2 are triggered by low pH within endosomes mediating fusion of the viral 
envelope with the endosomal membrane.  The HA conformational changes are 
irreversible, unlike those of the IBV S glycoprotein, which is able to revert to its 
original form after exposure to low pH (Chu et al., 2006).  The fusion peptide is 
inserted into the endosomal membrane, bringing the viral envelope close.  It is 
thought that the membranes fuse by hemifusion, in which the outer layers of the viral 
and cellular membranes fuse followed by the inner layers, forming a pore (Melikyan 
et al., 1995). 
 
Entry of HIV occurs via the plasma membrane.  Similar to Influenza virus and 
coronaviruses, the HIV glycoprotein, gp160, is responsible for both receptor binding 
and fusion.  Gp160 is proteolytically cleaved into two subunits, gp120 and gp41, by 
cellular proteases.  Binding of gp120 to the receptor/coreceptor induces 
conformational changes and fusion activation of gp41, facilitating the fusion of the 
viral and cellular membranes by insertion of the fusion peptide into the host cell 
membrane (reviewed by Chan and Kim, 1998).   
 
Ebola virus enters host cells via endosomes, where cysteine proteases, cathepsin B 
and L, cleave the GP1 subunit of the glycoprotein (GP) and activate it for fusion 
(Chandran et al., 2005).  Cathepsin L is also involved in the fusogenic activation of 
the SARS-CoV and HCoV-229E S glycoproteins (Simmons et al., 2005; Kawase et 
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al., 2009), indicating the possibility that these coronaviruses may employ a similar 
manner of cellular entry to Ebola virus.        
 
Paramyxoviruses differ from coronaviruses in that they contain two glycoproteins 
within their envelopes, a fusion protein and an attachment protein.  The fusion 
protein has a globular head attached to a trimeric coiled-coil stalk (Yin et al., 2006).  
The homotrimeric fusion protein is proteolytically cleaved and undergoes a 
conformational change at neutral pH to promote fusion of the viral and host cell 
envelopes by inserting the fusion peptide into the host cell membrane and 
rearranging to form a six-helix bundle, bringing the fusion peptide and 
transmembrane domains close together. 
 
Class II fusion proteins are produced by members of the Flaviviridae, including 
flaviviruses, hepaciviruses and pestiviruses, and contain an internal fusion peptide 
and three parallel β-sheet domains (Garry and Dash, 2003). 
 
Coronavirus tropism and receptors 
Coronaviruses generally exhibit restricted cell and tissue tropism, which is dependent 
upon the S glycoprotein of individual coronavirus strains (Casais et al., 2003; 
Sanchez et al., 1999; Tekes et al., 2010).  Some strains of IBV, following adaptation, 
are able to replicate in primary chicken cells such as chick kidney (CK) cells, 
however the Beaudette strain exhibits an extended host range and can replicate in 
Vero and baby hamster kidney (BHK-21) cell lines (Casais et al., 2003; Otsuki et al., 




The host-cell receptors for several coronaviruses have been identified.  The 
alphacoronaviruses HCoV-229E and TGEV both use aminopeptidase N as host cell 
receptor (Delmas et al., 1992; Yeager et al., 1992), although binding of TGEV to 
sialic acid is required for enteropathogenicity.  This is not required for in vitro 
replication (Schwegmann-Wessels et al., 2002).   
 
The betacoronaviruses have been found to utilise a variety of different receptors.  
Major histocompatibility complex class I C has been identified as an attachment 
factor for HCoV-HKU1 (Chan et al., 2009).  SARS-CoV has been shown to use 
angiotensin-converting enzyme 2 (ACE2) as a receptor (Li et al., 2003) along with 
CD209L (Jeffers et al., 2004) and is also thought to use the C-type lectins DC-SIGN 
and L-SIGN as alternative receptors independent of ACE2 (Han et al., 2007).  
Bovine coronavirus utilises N-acetyl-9-O-acetylneuraminic acid as a receptor 
(Schultze and Herrler, 1992).  The principal receptor for MHV is murine 
carcinoembryonic antigen-related cell adhesion molecule (CEACAM; Williams et 
al., 1991) although the virus also attaches to O-acetylated sialic acid.  Surprisingly 
however, this is mediated by the HE protein rather than the S glycoprotein 
(Langereis et al., 2010).   
 
The most widely studied gammacoronavirus is IBV, the receptor for which has not 
yet been elucidated. It was suggested by Miguel et al., (2002) that the Arkansas 99 
strain of IBV may use feline aminopeptidase N as an entry receptor on feline cells, 
however this has been disputed (Chu et al., 2007).  A recent study has shown that 
two strains of IBV, M41 and Beaudette-US, use sialic acid as an attachment factor 
(Winter et al., 2006) and infection of the tracheal epithelium is dependent upon sialic 
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acid (Winter et al., 2008).  This has been confirmed by Madu et al., (2007), who 
have also identified a heparan sulfate (HS) binding site between amino acid residues 
686 – 691 within the S2 subunit of the Beaudette S glycoprotein and shown that HS 
may be involved as a cofactor in Beaudette virus entry to host cells.  Yamada and 
Liu, (2009) also identified a potential furin cleavage motif within the putative 
heparan sulphate binding site studied by Madu et al., (2007).   
 
Heparan sulphate is a glycosaminoglycan (GAG) found on the surface of mammalian 
cells (reviewed by Liu and Thorp, 2002).  The consensus sequence for a heparin-
binding site is XBBXBX, where B is a basic amino acid and X is a hydropathic 
amino acid (Cardin and Weintraub, 1989).  The sequence identified in the Beaudette 
S glycoprotein was SRRKRS or SRRRRS (Madu et al., 2007).  This sequence was 
not found in the S glycoprotein of any other strains of IBV, which is a possible 
explanation for the extended host range of Beaudette in comparison to M41.  A 
number of other viruses are able to use HS as an adhesion receptor, including foot 
and mouth disease virus and herpes simplex virus (Liu and Thorp, 2002). 
 
A variant of the betacoronavirus MHV derived from persistently infected murine 
cells was found to have the ability to infect baby hamster kidney-21 cells (BHK-21; 
Schickli et al., 1997).  The extended host range was mapped to the N-terminal region 
of the spike (Schickli et al., 2004; Thackray and Holmes, 2004).  This strain, 
MHV/BHK, has been identified as using heparan sulphate as an entry receptor (de 
Haan et al., 2005).   A cell-culture adapted strain of the alphacoronavirus FCoV, 
FCoV UCD1, has traded its ability to be cleaved at the S1/S2 junction by a furin-like 
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protease for the capacity to bind heparan sulphate and has gained an extended host 
range (de Haan et al., 2008).   
 
Infectious bronchitis  
Infectious bronchitis virus is the aetiological agent of the disease infectious 
bronchitis that affects poultry.  IBV replicates primarily in the respiratory tract but 
also in many other epithelial surfaces including enteric surfaces, oviducts and 
kidneys (Ambali and Jones, 1990) causing a highly contagious respiratory disease 
characterised by nasal discharge, snicking, tracheal ciliostasis and rales in chickens 
(Hodgson et al., 2004).  Egg production and quality may be impaired in layers and 
weight gain in broilers is reduced.   Infected birds are predisposed to secondary 
bacterial infections and mortality in young chicks is not uncommon.  Faecal 
excretion of the virus is a consequence of replication in the intestinal tract, however, 
this does not normally result in clinical disease.   
 
Infectious bronchitis was first described in the US in the 1930s and is prevalent in 
poultry farming across the world due to its intensive nature.  In a study carried out by 
DEFRA (2005), infectious bronchitis was found to cost the UK economy nearly £19 
million per year, mainly due to loss of egg production, and has serious implications 
for animal welfare, second only to skeletal problems.  The cost of control is 
approximately £5 million per year in the UK.   
 
IBV vaccines 
The most common vaccines against IBV are live attenuated vaccines, although other 
types of vaccines against IBV exist including inactivated virus and subunit vaccines 
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and some promising vector vaccines are under development (reviewed by Cavanagh, 
2007).  There are many different serotypes of IBV that are poorly cross-protective; 
however the S glycoprotein alone is sufficient to confer protective immunity (Koch 
et al., 1990; Tomley et al., 1987).  Since the advent of a reverse genetics system for 
IBV (Britton et al., 2005; Casais et al., 2001), there has been the possibility for 
rational design of recombinant IBV strains for vaccine development. 
 
Live attenuated IBV vaccines are currently produced by blind repeated passages of 
IBV field strains through embryonated eggs.  As serial passage reduces the 
immunogenicity of the virus, a balance between virus attenuation and loss of 
immunogenicity must be achieved by trial and error, as the molecular basis of 
attenuation is as yet unknown.   
 
The most commonly used current IBV vaccines include those based on H52 and 
H120, which were derived from the Massachusetts strain of IBV after 52 and 120 
passages in embryonated eggs respectively.   Protection is short-lived and both layers 
and broilers may be vaccinated more than once during their short life spans.   
 
IBV infection may predispose laying hens to secondary bacterial infections thus 
reducing egg production further.  In fact, inoculation of broilers with IBV vaccine 
strain H52 increased the susceptibility of the birds to colibacillosis even more so than 
infection with virulent IBV field strains M41 and D387 (Matthijs et al., 2003).  Some 
strains of IBV are nephropathogenic and are not protected against by current 




A study by Huang and Wang (2007) investigated amino acid changes in three strains 
of IBV after attenuation in embryonated eggs. The majority of changes occurred 
within the S glycoprotein.  Between 2 and 6 changes were observed in the S1 amino 
acid sequence, 2 – 3 changes were observed in the S2 amino acid sequence and 0 – 3 
changes were observed in the rest of the genome, excluding the replicase gene.  The 
S glycoprotein alone is sufficient to induce good protective immunity; however 
differences of just a few amino acids have a detrimental impact on cross-protection.  
It is thought, however, that it is the replicase that confers pathogenicity rather than 
the structural or accessory genes in IBV (Armesto et al., 2009).   
 
Each batch of attenuated virus is different and efficacy in vivo will not be identical.  
Virus growth on embryonated eggs is expensive and cumbersome, each egg only 
producing a small volume of allantoic fluid from which the virus is isolated.  The 
supply of embryonated eggs is not guaranteed to be reliable, which may affect 
production of large quantities of vaccine.  As demand for seasonal and pandemic 
influenza vaccines rises, the supply of embryonated eggs for the production of other 
vaccines may be reduced.   
 
Another concern about the use of embryonated eggs is the possible presence of 
adventitious viruses, which may compromise the vaccine stocks or cause pathology 
in the vaccinated chickens.  One such adventitious virus of chicken eggs is the 
retrovirus, avian leukosis virus (ALV; Harris et al., 1966).  Retroviruses are able to 
insert their genome into the host cell genome and some can induce oncogenic 
transformation (reviewed by Maeda et al., 2008).  Integration of the ALV genome 
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into the host cell genome can incorporate host genes into the viral genome, forming 
several related oncogenic viruses, including Rous sarcoma virus (RSV).   
 
In light of the numerous disadvantages of egg-based vaccine production, the ability 
to produce live vaccines on a cell line would be beneficial to the vaccine industry as 
well as the poultry industry.  Vaccine production on cell lines is faster and more 
efficient than on eggs and large volumes of vaccine can be produced using cell lines.   
Vero cells were isolated in 1962 from kidney epithelial cells extracted from an 
African green monkey (Cercopithecus aethiops).  They have already been validated 
for virus growth and diagnostic purposes and are licensed for use in human vaccine 
manufacture.  Vero cells are currently used in the production of polio and rabies 
vaccines (Frazatti-Gallina et al., 2004; Montagnon et al., 1981) and several influenza 
virus vaccines have been developed for growth on Vero cells (Govorkova et al., 
1995; Kistner et al., 1998).  Vero cells have been extensively tested for tumorigenic 
properties, can be grown in suspension or flat bed and it is possible to achieve 




Infectious bronchitis remains a major problem in the poultry industry, despite the 
existence of many different vaccines.  The advent of a reverse genetics system for 
IBV (Britton et al., 2005; Casais et al., 2001) will allow the rational design of more 
effective vaccines, however, these must still currently be grown on embryonated 
eggs, a cumbersome and expensive system. 
 
The IBV S glycoprotein has two roles during the course of infection.  The first is to 
attach to the host cells via host cell receptors and the second is to fuse the virus 
envelope with the host cell membrane, releasing the viral genome into the host cell 
cytoplasm.  The S glycoprotein is also involved in fusion of infected cells to form 
syncytia.  These steps are critical to the initiation of infection.  The aim of this thesis 
is to identify the amino acids involved in each of these steps, thus explaining the 
cellular tropism of IBV at a molecular level and enabling the rational design of IBV 
vaccines that may be grown on Vero cells.  In order to carry out these aims, two 
objectives were investigated: 
 
Objective 1 
To establish which subunit or domain of the S glycoprotein from the rIBV Beau-R 
strain is responsible for its ability to grow in Vero cells, an African green monkey 
kidney cell line.  
 
Objective 2 
To identify which amino acids on the S glycoprotein are involved in cell-cell fusion 
by cell culture adaptation of rIBV Beau-R for syncytia formation on Vero cells.  
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Chapter 2:  Materials and Methods 
 
Animal cell culture and virus stocks 
 
All primary cells and continuous cell lines were prepared by the Institute for Animal 
Health media and tissue culture department: 
Chick kidney (CK) cells are primary cells prepared by the trypsinisation of kidneys 
from two- to three-week-old, specific pathogen free (SPF), Rhode Island Red chicks.   
Vero cells are a continuous cell line originating from African green monkey 
epithelial and fibroblast kidney cells.   





Beau-R is a molecular clone of Beaudette-CK (Beau-CK), a CK cell-adapted 
Beaudette virus derived by multiple passages in embryonated chicken eggs and CK 
cells.  There are two nucleotide substitutions in Beau-R when compared to Beau-CK, 
C19666 → U and A27087 → G in the ORF 1b and N genes respectively.  Beau-R is 
apathogenic in adult birds and has an extended host range in cell culture.  Like Beau-
CK, Beau-R is able to grow on Vero and BHK-21 cells in addition to the ability to 
grow on primary chicken cells such as CK cells, but does not form syncytia. 
M41-CK is a pathogenic strain of IBV that has been passaged in CK cells.  This 
strain is only able to grow in primary chicken cells, not Vero cells. 
BeauR-M41(S) has the genetic background of Beau-R but the S gene from M41.  
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Like M41-CK, this strain is also unable to grow in Vero cells and can only grow in 
primary chicken cells. 
Beau-US was adapted from Beau-CK and like Beau-CK, also has an extended host 
range in cell culture, growing in Vero and BHK-21 cells as well as primary chicken 
cells.  Unlike Beau-R, Beau-US forms syncytia in cell culture. 
 
Cell culture medium  
 
Table 2.1. BES medium (1x) for cell culture of IBV on CK or Vero cells. Sterile 
water was added to a final volume of 100 ml. 
Ingredient Volume Final 
concentration 
10x Eagles’s MEM (Sigma) 10 ml 1x 
TPB  10 ml 10% 
Bovine serum albumen (BSA) fraction V  
(10% w/v filter sterilised; Sigma) 
2 ml 1% 
N,N-bis[2-hydroxethyl]-2-Aminoethanesulfonic 
acid (BES, 1 M filter sterilised; Sigma)  
2 ml 20 mM 
Sodium bicarbonate (7.5%) 2.8 ml 0.2% 
L-glutamine (100x; Gibco)  1 ml 2 mM 
Nystatin (100,000 U/ml; Sigma)  0.25 ml 250,000 U/l 
Penicillin and streptomycin  
(100,000 U/ml; Sigma) 









Table 2.2. BES medium (2x) for plaque assay of IBV on CK or Vero cells.  
Sterile water was added to a final volume of 100 ml. 
Ingredient Volume Final 
concentration 
10x Eagles’s MEM (Sigma) 20 ml 2x 
TPB  20 ml 20% 
BSA fraction V (10% w/v filter sterilised; Sigma) 4 ml 2% 
BES (1 M filter sterilised Sigma)  4 ml 40 mM 
Sodium bicarbonate (7.5%) 5.6 ml 0.4% 
L-glutamine (100x; Gibco)  2 ml 4 mM 
Nystatin (100,000 U/ml; Sigma)  0.5 ml 500,000 U/l 
Penicillin and streptomycin  
(100,000 U/ml; Sigma) 




Table 2.3. Eagle’s MEM (1x) for cell culture of VV on Vero cells.  Sterile water 
was added to a final volume of 100 ml.  
Ingredient Volume Final concentration 
10x Eagles’s MEM (Sigma) 10 ml 1 x 
Foetal Calf Serum (FCS, Sigma) 5 ml 5 % 
Sodium bicarbonate (7.5%) 2.3 ml 0.175 % 
L-glutamine (100x; Gibco)  1 ml 1 x 
Nystatin (100,000 U/ml; Sigma)  0.25 ml 250,000 U/l 
Penicillin and streptomycin  
(100,000 U/ml; Sigma) 







Table 2.4. Eagle’s MEM (2x) for plaque assay of VV on Vero cells. Sterile water 
was added to a final volume of 100 ml. 
Ingredient Volume Final concentration 
10x Eagles’s MEM (Sigma) 20 ml 2 x 
FCS (Sigma) 10 ml 10 % 
Sodium bicarbonate (7.5%) 4.6 ml 0.35 % 
L-glutamine (100x; Gibco)  2 ml 2 x 
Nystatin (100,000 U/ml; Sigma)  0.5 ml 500,000 U/l 
Penicillin and streptomycin  
(100,000 U/ml; Sigma) 
0.2 ml 200,000 U/l each 
 
 
Table 2.5. Glasgow MEM (1x) for cell culture of IBV or VV on BHK-21 cells. 
Ingredient Volume Final concentration 
G-MEM 360 ml 1x 
FCS (Sigma) 4 ml 1 % 
TPB 40 ml 0.29 % 
Nystatin (100,000 U/ml; Sigma) 2 ml 0.5 % 
Penicillin and streptomycin  
(100,000 U/ml; Sigma) 
0.4 ml 0.1 % 
 
 
Cells were washed with phosphate buffered saline a (PBSa) prepared by IAH media 
services.  PBSa Powder (119.4 g, BioWhittaker) was added to 10 litres SuperQ water 
and adjusted to pH 7.2 with 1M hydrochloric acid.  Solutions were autoclaved at 






Bacterial cultures  
 
SOC medium was used for culturing Escherichia coli (E. coli) following 
transformation with each plasmid. 
 
Table 2.6. SOC medium for transformation of E. coli.  Medium was prepared by 
IAH media services and autoclaved at 115°C for 20 minutes. 
Ingredients Quantity Final concentration 
SOB powder (Q-BIOgene) 31 g 1x 
1 M Glucose (Fisher) 20 ml 20 mM 
Water 1 L  
 
Luria-Bertani (LB) broth was used for culturing E. coli.  Broth was prepared by 
IAH media services by addition of LB Broth Base (Miller) to 1 L water then 
autoclaving at 115
o
C for 15 minutes. Ampicillin (Sigma-Aldrich) was added to the 
broth to a final concentration of 100 μg/ml to culture E. coli transformed with 
plasmids encoding β-lactamase for ampicillin resistance.  LB-agar plates were 
prepared with LB-broth containing 1.5 % Bacto agar plus 100 μg/ml ampicillin. 
 
DNA-based methods  
 
Small-scale plasmid DNA purification 
Escherichia coli, transformed with the required plasmid, was grown overnight in 5 
ml of LB broth containing ampicillin (100 μg/ml).  The Qiaprep Spin Miniprep Kit 
(Qiagen) was used for the DNA purification following the manufacturer’s protocol.  
Bacterial cells were lysed under alkaline conditions then plasmid DNA was adsorbed 
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onto silica-gel columns in the presence of high salt, which was subsequently 
removed with wash buffer.  DNA was eluted with nuclease-free water (Sigma). 
 
Large-scale plasmid DNA purification 
Escherichia coli, transformed with the required plasmid, was grown overnight in 200 
ml of LB broth containing ampicillin (100 μg/ml).  Cultures were centrifuged at 
2,000g for 25 minutes to pellet the bacteria.  DNA was isolated and purified using 
the Qiafilter plasmid maxi kit (Qiagen) according to manufacturer’s instructions.  
DNA was bound to DEAE contained on a silica-based resin.  Contaminants were 
removed with increased salt concentration; DNA was concentrated and salt removed 
by isopropanol precipitation.  DNA was eluted into water. 
 
PCR amplification of DNA fragments 
Polymerase chain reaction (PCR) was used to amplify specific IBV cDNA or VV 
DNA sequences.  
 
Table 2.7. PCR recipe 
Ingredients Volume Final concentration 
10 x Taq DNA polymerase buffer 5 μl 1 x 
50 mM MgCl2 2 μl 2 mM 
10 mM dNTP mix 1 μl 0.2 mM 
10 pmol forward oligonucleotide 1 μl 0.2 pmol 
10 pmol reverse oligonucleotide 1 μl 0.2 pmol 
template DNA 2 μl  
nuclease-free water (sigma) 37.5 μl  




PCRs were performed using a Px2 thermal cycler with hotlid (Thermo Electron 
Corporation) with the following cycles: 
95
o
C  2 minutes            
95
o
C  30 seconds  
X
o
C  30 seconds*                                       30 cycles  
72
o
C  1 minute per kb of DNA to be amplified 
72
o
C 5 minutes 
*Annealing temperature was dependent upon the melting temperature of the primers. 
 
Agarose gel electrophoresis 
DNA was separated and visualised by agarose gel electrophoresis in 0.8 – 1.2 % 
agarose and 1 x Tris borate EDTA (TBE) buffer (Invitrogen) with 0.1 μg ethidium 
bromide per ml of agarose gel.  Gels were run using a Galileo bioscience 9 x 11 cm 
horizontal submarine gel apparatus in 1 x TBE buffer at ~5 V/cm gel length.  DNA 
was visualised by exposure of the gel to 260 nm UV light. A 1 μg 1kb+ DNA ladder 
(Invitrogen) was used to establish DNA band sizes. 
  
Table 2.8. DNA loading buffer recipe 
Ingredient Amount 
Glycerol (BDH) 2 ml 
Ficoll 400 (Sigma) 50 mg 
Bromphenol blue (Sigma) 25 mg 
Water 3 ml 
 
Purification of DNA from PCR 
Prior to sequencing or ligation of the PCR products into the pGPT vectors, DNA was 
purified using the QIAquick PCR purification kit (Qiagen) according to 
manufacturer’s instructions.  DNA adsorbs to the QIAquick silica membrane in the 
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presence of high salt concentration, is washed by an ethanol-containing buffer during 
centrifugation and eluted into water. 
 
DNA restriction enzyme digestion 
Restriction enzyme digestions were performed at 37°C according to manufacturer’s 
protocol.  
 
DNA dephosphorylation for cloning 
Plasmid DNA was dephosphorylated using shrimp alkaline phosphatase (Promega) 




The quantities of vector DNA and PCR product were determined using a NanoDrop 
1000.  A 3:1 ratio of insert to vector was used.  Assuming vector and insert DNA 
solutions are of equimolar concentration: 
T4 DNA ligase (Invitrogen)     1 μl 
10x DNA ligase buffer (Invitrogen)    3 μl 
Vector DNA       1 μl 
PCR DNA       3 μl 
Nuclease-free water      22 μl 
 
Transformation of E. coli and plasmid screening 
One Shot® MAX Efficiency™ DH5α-T1R E. coli were transformed with the 
ligation mixture according to manufacturer’s instructions. Transformed E. coli were 
plated out on LB-agar plates containing ampicillin (100 μg/ml) and incubated 
overnight at 37
o
C.  Individual E. coli colonies were picked and cultured in 5 ml LB 
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broth containing ampicillin (100 μg/ml) overnight at 37oC then DNA was extracted 
and sequenced to check the insert was correct. 
 
RNA-based methods  
Purification of RNA from cells 
Cellular and viral RNA was purified from cell culture supernatant using an RNeasy 
mini kit (Qiagen) according to the manufacturer’s protocol. Guanidine isothiocyanate 
lysis buffer was used to lyse cells.  RNA was bound to the column in the presence of 
ethanol then washed and eluted with RNase-free water. 
 
Reverse transcription  
IBV cDNA was generated from isolated cellular RNA and specific regions were 
amplified by PCR.   
 
1 μl 10 mM dNTPs    
1 μl  10 pmol random primer  65°C, 5 minutes  
6 μl  sterile H2O (Sigma)  ice 
5 μl RNA 
 + 
4 μl  First strand buffer 
1 μl DTT    25°C, 10 minutes 
1 μl  RNase Out (Invitrogen)     50°C, 1 hour 








In order to detect IBV in cell culture supernatant, isolated RNA was analysed for the 
presence of IBV RNA by one-step reverse transcription-PCR (RT-PCR) using 
Ready-to-Go RT-PCR beads from GE Healthcare, manufacturer’s protocol followed. 
Each bead contains M-MuLV Reverse Transcriptase, RNase Inhibitor, buffer, 
nucleotides and Taq DNA polymerase.  The primers used were BG-69 
(GCTTTTGCCACTATTATCTTC) and BG-142 (AGGGATCAAATACTTCTGTG) 
located across the 3’ end of the S gene.  The PCR product spanned nucleotides 23666 
– 24137, and was 471bp in length.   
 
Table 2.9. RT-PCR recipe.  Reagents were added to the RT-PCR bead on ice. 
Ingredients Volume Final concentration 
0.5 μg/μl pd(N)6 random cDNA primer 2 μl 0.02 μg/μl 
10 pmol forward oligonucleotide 1 μl 0.2 pmol 
10 pmol reverse oligonucleotide 1 μl 0.2 pmol 
template RNA 5 μl  
nuclease-free water (Sigma) 41 μl   
 
RT-PCRs were performed using a Px2 thermal cycler with hotlid (Thermo Electron 
Corporation) with the following cycles: 
42°C 30 minutes 
95°C 5 minutes 
95°C 1 minute 
X°C 1 minute*     35 cycles 
72°C 1 minute per kb of DNA to be amplified 
72°C 5 minutes 
4°C hold 
*Annealing temperature was dependent upon the melting temperature of the primers. 
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Reverse genetics system 
 
Plasmids containing the chimaeric S gene, either whole or just the part being altered, 
and the xanthine-guanine phosphoribosyltransferase (gpt) gene from E. coli were 
constructed.  The plasmids were used to insert the chimaeric S gene into a 
recombinant vaccinia virus (rVV) containing either the entire full-length IBV cDNA 
genome or the full-length IBV cDNA genome minus the S gene.  Vaccinia virus was 
used as a vector for the IBV cDNA because it has the capacity to accept a large 
amount of foreign DNA into its genome without loss of stability (Thiel and Siddell, 
2005).   
 
The gpt gene from E. coli is used in the selection of recombinant viruses with the 
correct insert as it confers resistance to mycophenolic acid (MPA) in the presence of 
xanthine and hypoxanthine under the control of the vaccinia virus P7.5 promoter.  
MPA inhibits purine metabolism, preventing the formation of rVV plaques.  This is 
overcome by incorporating the gpt gene into the rVV genome and the addition of 








Figure 2.1. Diagram of purine biosynthesis in a eukaryotic cell.  MPA inhibits 
inosine monophosphate dehydrogenase, thereby preventing the formation of 
xanthosine 5’-monophosphate (XMP) and ultimately preventing the synthesis of 
guanosine 5’-triphosphate (GTP) via guanosine 5’-monophosphate (GMP).  This 
results in intracellular depletion of purine nucleotides and inhibition of cell growth 
(Mulligan and Berg, 1981). The gpt gene is able to synthesise GMP from 
hypoxanthine and xanthine.  Recombinant VV expressing gpt can grow in presence 




MPA (mycophenolic acid): 10 mg/ml in 0.1N NaOH (30 mM); 400X concentrated. 
Xanthine: 10 mg/ml in 0.1N NaOH (66 mM); 40x concentrated. 
Hypoxanthine: 10 mg/ml in 0.1N NaOH (73 mM); 667x concentrated. 
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Table 2.10.  MXH (gpt selection) medium for TDS. 
Ingredient Volume Final concentration 
2x E-MEM 50 ml 1x 
2 % agar 50 ml 1 % 
30 mM MPA  250 μl 75 µM 
66 mM Xanthine 2.5 ml 165 µM 
73 mM Hypoxanthine 149 μl 184 µM 
 
Generation of rVV by homologous recombination 
A general outline of the generation of rVVs containing IBV cDNA with chimaeric S 
genes is as follows (Figure 2.2).  Plasmids containing the chimaeric S genes were 
transfected into vaccinia virus infected-Vero cells using lipofectin from Invitrogen 
and gpt selection components were added to select for vaccinia viruses that have 
integrated the whole plasmid DNA into their genome.  Homologous recombination 
between the plasmids and the rVV genome inserted the chimaeric S gene into the rest 
of the IBV cDNA.  The gpt gene was also inserted.   
 
Vero cells were grown in six-well plates to approximately 70% confluency and 
infected with recombinant vaccinia virus at an moi of 0.2.  Cells were incubated at 
37°C in a CO2 incubator for 2 hours to allow the virus to adsorb to the cells.  The 
inoculum was removed and cells were washed with OPTIMEM 1 with 
GLUTAMAX-1 (GIBCO).  Each well was then transfected with 5 μg of the plasmid 
containing the gpt gene and the chimaeric S gene with 12 μl of Lipofectin 
(Invitrogen) in 3 ml OPTIMEM.  Cells were incubated for 60 – 90 minutes at 37°C 
then the transfection medium was replaced with 5ml of fresh cell culture medium.  
MXH components, 12.5 μl of MPA, 125 μl of Xanthine and 7.4 μl of Hypoxanthine, 
were added to each well after overnight incubation at 37°C and cells were further 
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incubated at 37°C until extensive VV cpe was observed.  Cells were scraped into the 
supernatant and pelleted by centrifugation at 13k rpm for 2 minutes.  Cell pellet was 
resuspended in 400 μl cell culture medium and stored at -80°C. 
 
 
Figure 2.2. Flow chart of recombinant virus isolation protocol.  Homologous 
recombination between plasmids containing the modified S gene sequence and the 
rVV genome inserts the chimaeric S gene into the rest of the IBV cDNA along with 
the gpt gene.  Gpt-positive recombinants are selected by plaque purification in the 
presence of MXH components then gpt-negative recombinants are selected by plaque 
purification in the absence of MXH components.  Recombinants are screened by 
PCR and sequencing then large stocks grown in BHK-21 cells, partially purified and 
rVV DNA extracted.  Recombinant IBVs are recovered in CK cells using rFPV-T7 




Transient dominant selection (TDS) 
TDS was used to generate rVVs which have integrated the plasmid DNA containing 
the chimaeric S gene (Figure 2.3; Britton et al., 2005).  The TDS involved 
integration of modified sequences and a dominant selectable marker, the E. coli gpt 
gene under the expression of a VV promoter, into defined sequences by homologous 
recombination.  Recombinant VV with a gpt+ phenotype were selected using MPA 
during three rounds of plaque purification.  Integration resulted in unstable tandem 
repeat sequences that were only maintained by presence of MPA in cell culture 
media.   
 
Three rounds of plaque purification were then carried out in the absence of gpt 
selection components to select rVVs that have recombined to lose the plasmid DNA 
but kept the chimaeric S gene.  The gpt+ rVV were intrinsically unstable due to the 
presence of direct repeat sequences and were subject to two potential double 
crossover recombination events.  One event resulted in the generation of the original 
IBV sequence and the second in the generation of IBV with chimaeric S gene.  The 
gpt gene is spontaneously lost in the absence of selection medium.  Both events 
should occur with the same frequency, resulting in 50% of the gpt- rVVs containing 
the chimaeric S gene.  Selective pressure was exerted on the IBV cDNA to 
recombine to form the full-length genome containing the chimaeric S gene sequences 







Figure 2.3. The transient dominant selection system.  A plasmid vector containing 
gpt is constructed from the altered S gene and parts of the neighbouring genes in the 
IBV genome. The plasmid is transfected into Vero cells infected with rVV 
containing the IBV genome minus the S gene. A single cross-over event results in the 
integration of the complete plasmid DNA and a highly unstable intermediate is 
produced due to the presence of repeat sequences.  A second cross-over event results 
in the loss of the plasmid DNA and the integration of the modified IBV cDNA into 
the vaccinia virus genome.  Three rounds of plaque purification in the presence of 
gpt selection components and three rounds in absence are carried out to select for 
rVV containing the altered S gene. Large virus stocks are prepared in BHK-21 cells 






Virus stocks from the homologous recombination steps were freeze-thawed three 
times and sonicated for 2 minutes.  Virus dilutions were prepared 10
-1
 – 10-3 in cell 
culture medium.  Confluent Vero cells in six-well plates were washed with PBS then 
inoculated in duplicate with 500 μl of each virus dilution per well.  Cells were 
incubated for 1 – 2 hours at 37°C. The inoculum was replaced with 3 ml cell culture 
medium overlay containing 1x MXH gpt selection medium and 1 % agar and further 
incubated for 4 days at 37°C.  Cells were stained with 0.01 % neutral red in 2 ml cell 
culture medium containing 1 % agar.  Approximately six well-isolated plaques were 
picked for each recombinant into 400 μl of cell culture media. 
 
Three plaque purifications were carried out in the presence of selection medium, 
taking 2 – 3 plaques forward from each recombinant at each stage.  Then three 
rounds of plaque purification were carried out in the absence of selection medium.  
The 10
-1





 dilutions were grown in the absence.  When no plaques form in the positive-
selection wells, it means that the rVV has lost the gpt gene.   
 
Growth of small rVV stocks 
After the third round of plaque purification in absence of gpt selection components, 
mini stocks of rVV were grown in Vero cells.  Confluent Vero cells in six-well plates 
were inoculated with 150 μl rVV plaque (freeze-thawed 3 times and sonicated for 2 
minutes) and 350 μl cell culture medium per well.  Cells were incubated at 37°C for 
1 hour then cell culture medium was topped up to 3 ml.  Cells were incubated at 
37°C until rVV cytopathic effect (cpe) reached 70 – 80 %.  Cells were scraped into 
the supernatant and centrifuged for 1 minute at 13K rpm.  The supernatant was 
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discarded and the cell pellet was resuspended in 500 μl of cell culture medium.  
Virus stocks were stored at -20°C.   
 
Small-scale DNA extraction 
DNA was extracted from rVV mini-stocks to ascertain whether the viruses still 
contained the gpt gene using the QIAamp DNA mini kit from Qiagen, 
manufacturer’s protocol followed.  The cells were scraped into the supernatant, 
centrifuged at 13k rpm for 3 minutes then the pellets were resuspended in cell culture 
medium.  The cell pellets were lysed using proteinase K then the DNA was adsorbed 
onto the QIAamp silica membrane during centrifugation.  Bound DNA was washed 
in buffers containing guanidine hydrochloride during subsequent centrifugation steps 
then eluted in water.  Further PCRs were carried out on the gpt negative viruses 
across the S gene and sequenced to check that the desired mutations were present.   
 
Growth of large rVV stocks 
Large stocks of rVV were grown in BHK-21 cells.  Vaccinia virus has a wide host 
range in cell culture but grows particularly well in BHK-21 cells so a large amount of 
viral DNA can be extracted in this way.  Ten T150 flasks of confluent BHK-21 cells 
were each inoculated with 2 ml rVV mini-stock at an moi of 0.1 – 1.  Cells were 
incubated for 1 hour at 37°C then 20 ml of cell culture medium was added to each 
flask.  Cells were further incubated until all cells showed cpe, then the flasks were 
smacked to detach the cells from the plastic.  The cells and supernatant were 
transferred to 50 ml Falcon tubes and pelleted by centrifugation for 15 minutes at 
1200 rpm in a refrigerated centrifuge (4°C) using sealed buckets.  The supernatant 
was discarded and the cell pellets were resuspended in 2 ml of 10mM Tris/HCl pH 
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9.0, 1 mM EDTA (TE; pH 9) per falcon and mixed well.  Resuspended cell pellets 
were pooled and stored at -80°C until virus purification was carried out. 
 
Vaccinia virus purification 
Large stocks of rVV were partially purified through a 30% (w/v) sucrose cushion 
prior to DNA extraction.   Cells were lysed by freeze-thaw three times (dry ice/37°C) 
and sonication for 2 minutes (cup form sonicator; continuous pulse at 70% duty 
cycle).  Cells were immediately placed on ice then centrifuged for 10 minutes at 2.5k 
rpm at 4°C to remove the nuclei.  The supernatant was made up to 13 ml with TE pH 
9 buffer then layered on 16 ml 30% sucrose (1 mM tris/HCl pH 9.0, filtered) in a 
Beckman ultra-clear (25 x 89mm) ultracentrifuge tube and centrifuged using a 
Superspin 630 rotor in a Sorvall OTD65B ultracentrifuge at 14k rpm for 60 minutes 
at 4°C.  All of the sucrose solution was removed and the pellet was resuspended in 5 
ml of 10 mM TE buffer pH 9 and stored at -80°C. 
 
Large-scale DNA extraction  
Stock Proteinase K solution (100X) was prepared in water to a concentration of 20 
mg/ml. The final concentration of Proteinase K in the reaction was 0.2 mg/ml.  
 
Table 2.11.  Proteinase K digestion buffer (x2) 
Ingredient Volume Final concentration 
NaCl 5 M 16 ml 200 mM 
Tris/HCl pH 7.5 1 M 40 ml 10 mM 
EDTA 0.5 M 4 ml 0.4% 
SDS 10% 8 ml 400 mM 




Recombinant vaccinia virus DNA was extracted by phenol-chloroform.  An equal 
volume of pre-warmed (50°C) 2x proteinase K buffer and 200 µl 20 mg/ml solution 
of proteinase K was added to the partially purified virus in a 50 ml Falcon tube and 
incubated for 2.5 hours at 50°C.  The vaccinia virus DNA solution was divided into 
two equal volumes in 15 ml Falcon tubes.  An equal volume of phenol-chloroform 
containing 8-hydroxy-quinoline was added to each tube and mixed carefully by 
inversion 5 – 10 times.  Samples were centrifuged at 2.5k rpm for 15 minutes in a 
refrigerated (4°C) centrifuge.  The upper phase was removed, without disturbing the 
interphase, to a clean 15 ml Falcon tube.  A second phenol-chloroform extraction 
was carried out followed by one chloroform extraction.  DNA was precipitated by 
the addition of 0.1 volumes of 3 M sodium acetate and 2.5 volumes of -20°C 
absolute ethanol to each tube.  Tubes were centrifuged at 3.5k rpm for 45 minutes.  
The supernatant was discarded then 10 ml of -20°C 70% ethanol was added to the 
DNA pellets, left on ice for 5 minutes for the ethanol to dissolve any salts and 
centrifuged at 3.5k rpm for 30 minutes.  The ethanol was removed and the tubes were 
placed at an angle in a fume cupboard for 20 – 30 minutes to allow any remaining 
ethanol to evaporate off.  Pellets were resuspended in 100 μl of water (Sigma) and 
left to re-dissolve overnight at 4°C then quantified using a NanoDrop 1000 (Thermo 
Scientific).  
 
Pulsed field gel electrophoresis (PFGE) 
Extracted vaccinia virus DNA, 1 μg, was digested with Sal1 in a 20 μl reaction 
volume, to check the amount and quality of the DNA.  A SalI restriction site is 
located either side of the rIBV cDNA, digestion results in an unique 28kb SalI 
restriction fragment in which the IBV genomic full-length cDNA is present (Figure 
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2.4).  A 0.8 % Bio-Rad pulsed field certified ultra pure DNA grade agarose gel was 
prepared with 0.5x TBE buffer (GIBCO).  Digested DNA was run with Bio-Rad 
CHEF DNA size standard ladder, 8 – 48 kb, to check that the rIBV cDNA was intact. 
This is shown by a band of ~34 kb (Figure 2.5).  Gel was run on CHEF-DR II PFGE 
apparatus (Bio-Rad).  Initial pulse time was set at 0.1 second and final pulse time 




Figure 2.4. Restriction map of vaccinia virus DNA digested with SalI.  There are 
26 SalI restriction sites within the vNotI/IBV genome producing fragments between 
213 – 34643 bp, the largest of which contains the complete rIBV cDNA inserted 





Figure 2.5. Agarose pulsed field gel analysis of extracted vaccinia virus DNA.  
DNA was extracted from large stocks of (1) vNotI/tk and (2) vNotI/IBV, vaccinia 
virus containing Beau-R cDNA, then digested with SalI and run on an agarose pulsed 
field gel overnight.  The band at around 34 kb shows the intact whole rIBV cDNA.  
DNA ladder is indicated by L.  Gel was stained with ethidium bromide. 
 
Rescue of recombinant IBV 
Following the isolation of a recombinant vaccinia virus containing the complete 
cDNA of the IBV genome including the correct S gene, the infectious rIBV was 
recovered from the rVV DNA.  Recombinant fowlpox virus (rFPV-T7) was used for 
the production of T7 RNA polymerase to generate infectious IBV RNA from the 
rVV DNA.  A plasmid containing the IBV N protein, pCi-Nuc, was used to aid the 




CK cells at 30 – 40 % confluency in six-well plates were infected with rFPV-T7 at 
an moi of 10 and incubated for 1 hour at 37°C.  The inoculum was removed and each 
well of CK cells was then transfected with 10 μg rVV DNA, 5 μg of pCi-Nuc, a 
plasmid containing the IBV nucleocapsid protein directed by CMV/T7 promoters, 
and 30 μl lipofectin (Invitrogen) in 3 ml OPTIMEM 1 with GLUTAMAX-1 
(GIBCO).  Cells were incubated at 37
o
C overnight then the transfection media was 
replaced with fresh cell culture media.  Once cpe was observed, cell culture medium 
was filtered through 0.22 microns to remove any rFPV-T7.  This was either used 




Figure 2.6. Recovery of rIBVs.  CK cells were infected with recombinant fowlpox 
virus, rFPV-T7, then transfected with rIBV cDNA within the rVV genome and a 
plasmid expressing the IBV N protein, pCi-Nuc.  Recombinant IBVs were released 




Passage of rescued rIBV on CK cells 
CK cells were grown to confluency in T25 flasks then washed with PBS.  Cells were 
inoculated with 1 ml of the filtered medium and incubated at 37°C for 1 hour.  The 
medium was topped up to 5 ml with fresh cell culture medium.  Cells were incubated 
until cpe was observed or for up to 72 hours, whichever came sooner, then 
supernatant was harvested and stored at -80°C until the next passage.  After two 
passages on CK cells, one replicate was chosen from each rIBV isolate and a large 
stock was grown in CK cells.  This comprised the third passage (P3) in CK cells.   
The P3 viruses were then used for three passages on confluent Vero cells, a 
continuous cell line originating from African green monkey epithelial and fibroblast 
kidney cells, grown in six-well plates. Two wells were used per isolate for each 
passage.  The cells were inoculated with 500 μl supernatant per well and topped up to 
3 ml with cell culture medium after incubating at 37°C for one hour.  The 




Photographs of Vero, CK and BHK-21 cells infected with rIBV were taken by 
bright-field microscopy using a Leica DM IRB inverted light microscope with a 
camera attached to a PC.   
 
Titrations 
Recombinant IBVs were titrated on CK cells and the number of plaque forming units 
per ml was calculated.  Virus supernatant was serially diluted 1:10 in cell culture 
medium.  Confluent CK cells in six-well plates were washed with PBS then 
inoculated with 500 μl diluted supernatant and incubated at 37°C for 1 hour.  
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Inoculum was replaced with 3 ml medium containing 1% agar and plates were 
incubated at 37°C for 48 – 72 hours.  Living cells were stained with 0.01% neutral 
red and plaques counted several hours later.   
 
Growth curves 
Vero, CK and BHK-21 cells were grown to confluency in 6-well plates then three 
wells per virus per time point were inoculated with Beau-R, M41-CK, BeauR-
M41(S), BeauR-M41(S1), BeauR-M41(S2), BeauR-S-M41-Hep and M41-S-BeauR-
Hep at a multiplicity of infection of 0.1. Cells were incubated with the inoculum for 
1 hour then the inoculum was replaced with cell culture medium.  The supernatant 
from three wells per virus was harvested at each time point, 1, 12, 24, 48 and 72 
hours post-infection.  The samples from each time point were titrated separately on 
CK cells and the titres averaged.  
 
Indirect immunofluorescence  
 
Infection 
CK, Vero or BHK-21 cells were grown on coverslips in 24-well plates.  Cells at 
approximately 50% confluency were inoculated with 150 μl IBV per well and 
incubated for 1 hour at 37
o
C then the cell culture medium was topped up to 500 μl. 
 
Fixing, permeabilisation and blocking 
Infected cells were fixed with 4% paraformaldehyde in PBS for 20 minutes then 
permeabilised with 0.5% Triton-X100 (PBS) for 10 minutes and blocked with 0.5% 




Primary antibodies used were rabbit anti-IBV polyclonal antibody, produced at IAH 
and thought to mainly label the IBV N protein, diluted 1:400.  Mouse anti-dsRNA J2 
IgG2a monoclonal antibody from English and Scientific Consulting Bt. recognizes 
dsRNA independent of the sequence and nucleotide composition, diluted 1:1000.  
Endoplasmic reticulum was labelled with mouse anti-PDI (protein disulphide 
isomerase) 1D3 monoclonal antibody from MBL International, diluted 1:400.   
Secondary antibodies used were AlexaFluor goat anti-mouse 488, goat anti-mouse 
568 and goat anti-rabbit 488, all diluted 1:200 (Invitrogen). 
 
Immunolabelling 
Primary antibodies were diluted in 0.5% BSA (PBS) to a final volume of 200 μl then 
added to fixed and permeabilised cells and incubated on an orbital shaker at room 
temperature (RT) for 1 hour.  Cells were washed twice with PBS then three times 
with PBS on an orbital shaker for five minutes.  Diluted secondary antibody (0.5% 
BSA (PBS), 200 μl) was added and cells were incubated on an orbital shaker at RT 
for 1 hour with the same wash procedure. The nuclei were stained with DAPI 
(Invitrogen) according to the manufacturer’s recommendations.  Cells on the cover 
slips were mounted onto glass slides using Vectashield mounting medium for 
Fluorescence (Vector Laboratories) and sealed with nail varnish.  Immunolabelled 
cells were examined using a Leica TCS SP5 DM6000 confocal microscope with the 
Leica Microsystems LAS AF software. 
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Chapter 3:  Investigation into the cellular tropism of the 




The IBV Beaudette strain is able to replicate in both primary CK cells and Vero 
cells, whereas the IBV M41 strain is able to replicate in CK cells only.  This is 
believed to be due to the S gene as BeauR-M41(S), a recombinant IBV with the S 
gene from M41 in the background of Beaudette, has the cellular tropism of M41, not 
Beaudette (Casais et al., 2003).  Two rIBVs with the genomic background of 
Beaudette and either the S1 or S2 subunit from M41 were generated using a vaccinia 
virus reverse genetics system and their growth characteristics and cellular tropism 
were investigated.  The Beaudette S2 subunit of the S glycoprotein was found to be 




The IBV spike glycoprotein, a 180-kDa membrane glycoprotein, is found as a homo-
trimeric structure in the virion membrane (Delmas and Laude, 1990) and is 
comprised of two subunits.    The N-terminal S1 subunit is responsible for binding to 
host cell receptors (Koch et al., 1990) and the C-terminal S2 subunit is responsible 
for cell-cell and virus-cell fusion (Luo and Weiss, 1998).  The two S subunits are 
cleaved during biosynthesis by a furin-like protease in the Golgi apparatus (de Haan 
et al., 2004) but remain non-covalently linked.   
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Beau-R is a molecular clone derived from the Beaudette-CK strain of IBV, which in 
turn was derived by multiple passage of the Beaudette isolate in embryonated eggs 
followed by passage on primary CK cells.  Beau-R is an apathogenic virus in adult 
birds that exhibits an ability to grow in an extended host range in cell culture 
including the ability to grow on Vero cells, an African green monkey kidney cell 
line.  M41 is a pathogenic strain of IBV, which only has the ability to grow on 
primary chicken cells such as CK cells and replicates well when inoculated into the 
allantoic cavity of developing chicken embryos.  Unlike Beau-R, M41 does not have 
the ability to grow on Vero cells.     
  
The S glycoproteins of the M41 and Beaudette strains share 96% amino acid identity 
(Figure 3.1) and it has been shown that it is the S glycoprotein only that confers 
tissue tropism as BeauR-M41(S), an rIBV containing the M41 S gene within a 







Figure 3.1.  Locations of the amino acid differences between the S glycoproteins 
of Beau-R and M41-CK.  There are 46 amino acid differences between the S 
glycoproteins of Beau-R and M41-CK.  The differences are fairly evenly distributed 
between the S1 and S2 subunits, with S1 containing 27 amino acid differences and 
S2 containing 19.   
 
 
In order to determine which subunit of the S glycoprotein from the IBV Beau-R 
strain is responsible for its ability to grow in Vero cells, two chimaeric rIBVs have 
been made (Figure 3.2).  As the amino acid differences between the S glycoproteins 
of Beau-R and M41-CK are fairly evenly spread between the S1 and S2 subunits, it 
was decided to swap the subunits between the two strains within the background of 
Beau-R.  Each recombinant has one subunit of the Beau-R S glycoprotein substituted 
for the equivalent subunit from the S glycoprotein of the M41 strain of IBV.  All 
other genes are from Beau-R.  The growth characteristics of the two rIBVs carrying 
the chimaeric S glycoproteins on different cell types have been investigated using 






Figure 3.2. Schematic diagram of the S genes of different strains of IBV.  The S1 
domain contains the receptor binding domain and the cleaved signal sequence (SS).  
The S2 domain contains two heptad repeats, HR1 and 2, a transmembrane (TM) 
domain and a cytoplasmic (Cyto) domain.  Beau-R also contains a putative heparan 
sulphate binding sequence (HSBS) not found in M41.  The S1 and S2 subunits of 







The S genes of Beaudette and M41 are contained within the plasmids pGPT-IBV-
StuI-BamHI and pGPT-M41S respectively (Figure 3.3).  The overlapping PCR 
strategy (Figure 3.4) was carried out to generate plasmids carrying the chimaeric S 
genes, pGPT-BeauR-S1-M41-S2 and pGPT-M41-S1-BeauR-S2 (Figure 3.5).  
Primers were designed within the replicase gene and gene 3 close to restriction sites 
already contained within the IBV genome.  The S1/S2 junction in IBV strains 
Beaudette and M41 is situated at the amino acid sequence RRFRR at amino acid 
position 552 (Cavanagh et al., 1986).  The S gene sequence is identical between 
Beau-R and M41 at the S1/S2 cleavage site so primers were also designed across this 
location.  Around 500 nucleotides were left either side of the S gene to allow for 
subsequent manipulations.  The S gene sequences in plasmids pGPT-BeauR-S1-
M41-S2 and pGPT-M41-S1-BeauR-S2 were sequenced to show that they contain the 
correct M41- and Beaudette-derived sequences. 






















Figure 3.3. Diagrams of pGPT-IBV-StuI-BamHI and pGPT-M41S.  The 
plasmids pGPT-IBV-StuI-BamHI and pGPT-M41S were used to amplify the Beau-R 
and M41 S1 and S2 subunits by PCR.  The replicase gene and gene 3 surrounding 
both S genes are derived from Beaudette.  The C-terminus of the M41 S gene in 
pGPT-M41S has been exchanged for the Beau-R S gene C-terminus because this is 
the region of the S glycoprotein that interacts with the M protein.  The C-terminal 
ends of the M41 and Beau-R S proteins are different to each other, so to enable 
interaction of the chimaeric S protein with the other structural proteins from Beau-R, 
it was decided to keep the Beau-R S gene C-terminus.  The Beau-R S gene was 
removed from pGPT-IBV-StuI-BamHI using restriction sites NsiI (located within the 
replicase gene) and BspEI (located within gene 3).  The chimaeric S genes were 
ligated to the remainder of pGPT-IBV-StuI-BamHI to create the plasmids pGPT-
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Figure 3.4. Generation of plasmids containing chimaeric S glycoprotein genes.  
The S1 and S2 subunits of Beau-R and M41 were amplified from two plasmids, 
pGPT-M41S and pGPT-IBV-StuI-BamHI (Figure 3.3), by PCR using primers 
located in the replicase gene, across the S1/S2 junction and gene 3.  Overlapping 
PCR was used to combine the subunits, forming the chimaeric S genes, which were 
then cut with NsiI (restriction site located in the replicase gene) and BspEI 
(restriction site located in gene 3).   The receiver plasmid, pGPT-IBV-StuI-BamHI, 
was also cut with NsiI and BspEI and the Beaudette S gene was separated by agarose 
gel electrophoresis and extracted using QIAquick gel extraction kit (Qiagen).  The 
chimaeric S genes were ligated into the remaining pGPT-IBV-StuI-BamHI backbone 





























Figure 3.5. Diagrams of pGPT-BeauR-S1-M41-S2 and pGPT-M41-S1-BeauR-
S2.  pGPT-BeauR-S1-M41-S2 contains the S1 subunit from Beau-R and the S2 
subunit from M41.  pGPT-M41-S1-BeauR-S2 contains the S1 subunit from M41 and 
the S2 subunit from Beau-R.  The M41 subunits were derived by PCR from pGPT-
M41S and the Beau-R subunits were derived from pGPT-IBV-StuI-BamHI. The 
replicase gene and gene 3 surrounding the S genes are derived from Beaudette.  As in 
pGPT-M41S (Figure 3.3), the C-terminus of the M41 S gene in pGPT-B1M2 has 
been exchanged for the Beau-R S gene C-terminus because this is the area that 
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Reverse genetics system and recovery of rIBV 
The plasmids pGPT-BeauR-S1-M41-S2 and pGPT-M41-S1-BeauR-S2 (Figure 3.5) 
were used to insert the chimaeric S gene into vNotI/IBVFL-ΔS, a recombinant 
vaccinia virus containing the full-length IBV cDNA genome minus the S gene.  After 
the third round of plaque purification in absence of gpt selection components, mini 
stocks of rVV were grown in Vero cells, the DNA extracted and PCRs carried out to 
identify whether the viruses still contained the gpt gene.  Further PCRs were carried 
out on the gpt negative viruses to check for the presence of the S gene, which is 
absent in the parent rVV.  Viruses that were both gpt negative and S gene positive 
were sequenced across the S gene and neighbouring genes to check that the internal 
sequences were correct.  Two lineages of rVVs for each type of modified S gene 
were identified as having the chimaeric S gene sequence correctly inserted into the 
IBV genome and were used for the recovery of rIBVs BeauR-M41(S1) and BeauR-
M41(S2) in CK cells.  After three passages in CK cells the rIBVs were then passaged 






Recovery and passage of rIBVs 
 
Rescue of rIBV BeauR-M41(S1) and BeauR-M41(S2) in CK cells 
DNA was extracted from two isolates of each rVV containing the full-length IBV 
cDNA with chimaeric S genes, digested with SalI and analysed by pulsed field gel 
electrophoresis to check that the full-length cDNA genomes were intact (Figure 3.6).  
This is indicated by the presence of a 30kb SalI fragment.  The chimaeric S gene 
sequences were verified by sequencing.  Two isolates of each rIBV BeauR-M41(S1), 
isolates 2 and 3, and BeauR-M41(S2), isolates 4 and 15, were rescued from CK cells.   
 
Figure 3.6.  Example agarose pulsed field gel analysis of extracted vaccinia virus 
DNA containing rIBV cDNA.  DNA was extracted from large stocks of two isolates 
each of vaccinia virus containing rIBV BeauR-M41(S1) (2 and 3) or BeauR-
M41(S2) (4 and 15) cDNA then digested with SalI and run on an agarose pulsed field 
gel overnight.  The band at around 30 kb shows the intact whole rIBV cDNA.  Lanes 
1 and 2 contain vaccinia virus DNA.  DNA ladders are indicated by L.  Gel was 




Sequencing of P3-CKC rIBVs 
The rescued viruses were passaged three times on CK cells.  At each passage on CK 
cells, RNA was extracted from the infected cell supernatant and RT-PCRs were 
carried out across the end of the S genes to confirm virus presence.  The entire S 
gene sequences of the P3-CKC viruses were checked (example areas shown in 
Figures 3.7 – 3.10). The BeauR-M41(S1) sequences corresponded to that of the M41 
sequence within the S1 subunit and the Beau-R sequence within the S2 subunit. The 
BeauR-M41(S2) sequences corresponded to that of the Beau-R sequence within the 





Figure 3.7. Sequencing to check the S1 subunit of BeauR-M41(S1) P3-CKC 
isolates.  RNA was extracted from BeauR-M41(S1) P3-CKC cell culture supernatant, 
RT-PCRs were carried out across the S gene, purified and sequenced in positive and 
negative directions.  The BeauR-M41(S1) sequences correspond to that of the M41 
sequence within the S1 subunit. The nucleotide positions are shown above each 
section of sequencing.  Nucleotides corresponding to the consensus sequence are 
shown by dots, differing nucleotides are shown by letter.  The highlighted nucleotide 







Figure 3.8. Sequencing to check the S2 subunit of BeauR-M41(S1) P3-CKC 
isolates.  RNA was extracted from BeauR-M41(S1) P3-CKC cell culture supernatant, 
RT-PCRs were carried out across the S gene, purified and sequenced in positive and 
negative directions.  The BeauR-M41(S1) sequences correspond to that of the Beau-
R sequence within the S2 subunit. The nucleotide positions are shown above each 
section of sequencing.  Nucleotides corresponding to the consensus sequence are 
shown by dots, differing nucleotides are shown by letter.  The highlighted nucleotide 








Figure 3.9. Sequencing to check the S1 subunit of BeauR-M41(S2) P3-CKC 
isolates.  RNA was extracted from BeauR-M41(S2) P3-CKC cell culture supernatant, 
RT-PCRs were carried out across the S gene, purified and sequenced in positive and 
negative directions.  The BeauR-M41(S2) sequences correspond to that of the Beau-
R sequence within the S1 subunit. The nucleotide positions are shown above each 
section of sequencing.  Nucleotides corresponding to the consensus sequence are 
shown by dots, differing nucleotides are shown by letter.  The highlighted nucleotide 
is indicated by a blue line on the sequence trace.   













Figure 3.10.  Sequencing to check the S2 subunit of BeauR-M41(S2) P3-CKC 
isolates.  RNA was extracted from BeauR-M41(S2) P3-CKC cell culture supernatant, 
RT-PCRs were carried out across the S gene, purified and sequenced in positive and 
negative directions.  The BeauR-M41(S2) sequences correspond to that of the M41 
sequence within the S2 subunit. The nucleotide positions are shown above each 
section of sequencing.  Nucleotides corresponding to the consensus sequence are 
shown by dots, differing nucleotides are shown by letter.  The highlighted nucleotide 
is indicated by a blue line on the sequence trace.   




Passage of P3-CKC rIBVs on Vero cells 
The P3-CKC rIBVs were passaged three times on Vero cells to determine whether 
virus replication could be maintained on this mammalian cell line.  At each passage, 
RNA was extracted and RT-PCRs were carried out across the end of the S genes to 
confirm virus presence (Figure 3.11).  RT-PCR results showed that both BeauR-
M41(S1) isolates grew on Vero cells at each passage.  Cytopathic effect in the form 
of rounded and floating cells were observed from around 24 hours post-infection and 
all PCRs were positive for virus presence.  In contrast, the RT-PCRs for the presence 
of BeauR-M41(S2) isolates were either very faint (isolate 4) or negative (isolate 15) 
by passage 3 when visualised by agarose gel electrophoresis.  
Figure 3.11. Agarose gel analysis of RT-PCR products from rIBV BeauR-
M41(S1) and BeauR-M41(S2) P1-3-Vero isolates. RNA was extracted from Vero 
cell culture supernatants of (A) rIBV BeauR-M41(S1) 2 and 3 and (B) rIBV BeauR-
M41(S2) 4 and 15 P1-3-Vero, RT-PCRs were carried out on each sample. A 
molecular size ladder (L) is shown to compare the sizes of DNA fragments.  Positive 
control (+) shows a band between 400-500 bp.  Negative control (-) shows no band.  
All passages of BeauR-M41(S1) have bands of correct sizes.  Band intensity 
decreases from P1-3 of BeauR-M41(S2) and P3 of isolate 15 can no longer be seen. 
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The BeauR-M41(S2) isolates caused no cytopathic effect (cpe) when grown on Vero 
cells (Figure 3.12).  BeauR-M41(S1) isolates were further passaged on Vero cells in 
order to establish whether this virus could further adapt to growth on Vero cells.  
Syncytia began to form in Vero cell culture from P5 (Figure 3.12).  It was determined 
that BeauR-M41(S1) replication on Vero cells was stable so no further passages were 
carried out after passage 7.  The S genes of the BeauR-M41(S1) P7-Vero isolates 
were sequenced to ascertain whether any nucleotide or amino acid changes had 






BeauR-M41(S1) 2 P7-Vero BeauR-M41(S1) 3 P7-Vero 
BeauR-M41(S2) 4 P3-Vero BeauR-M41(S2) 15 P3-Vero 
               
               
               
               
 
Figure 3.12.  Brightfield microscopy of rIBV growth on Vero cells. Vero cells 
infected with A. mock, B. Beau-R, C. M41-CK, D. BeauR-M41(S), E. BeauR-
M41(S1) 2 P7-Vero, F. BeauR-M41(S1) 3 P7-Vero, G. BeauR-M41(S2) 4 P3-Vero, 
H. BeauR-M41(S2) 15 P3-Vero.  Syncytia indicated by arrows. Photographs taken 48 







Sequencing of BeauR-M41(S1) P7-Vero S genes 
RNA was extracted from infected cell supernatant and RT-PCRs were carried out 
across the S gene.  These were then sequenced and compared to Beau-R and BeauR-
M41(S) sequences (Figure 3.13).  Five nucleotide differences were identified 
between the BeauR-M41(S1) P7-Vero isolates and the parent viruses, Beau-R and 
BeauR-M41(S), all of which are located within the S2 subunit.   
 
The first three changes are located at nucleotide positions 22243 – 5, GTT – AAC, 
and were identified in isolate 2, although isolate 3 appears to have a mixed 
population between AAC and GTT (Figure 3.13A).  These nucleotide changes result 
in an amino acid change of phenylalanine – threonine.  It also appears that there is a 
mixed population of several nucleotides downstream between AATATGG – 
TTTAAGT.   
 
The fourth nucleotide change occurs at position 23022 and was identified in isolate 3 
only (Figure 3.13B).  This results in an amino acid change of alanine – valine.  The 
fifth nucleotide change was identified in isolate 2 only and occurs at position 23387, 
resulting in an amino acid change of threonine – isoleucine (Figure 3.13C).   It is 
possible that these changes could contribute to the further adaptation of BeauR-
M41(S1) to growth on Vero cells and may be involved in syncytium formation.  
  
Figure 3.13. Sequencing of BeauR-M41(S1) P7-Vero S genes. RNA was extracted 
from BeauR-M41(S1) P7-Vero cell culture supernatant, RT-PCRs were carried out 
across the S gene, purified and sequenced in positive and negative directions.  Five 
nucleotide differences were observed in the S genes of BeauR-M41(S1) P7-Vero 
isolates when compared to Beau-R and BeauR-M41(S), all of which occurred within 
the S2 subunit.  The sequences otherwise corresponded to M41 in the S1 subunit and 
Beau-R in the S2 subunit.  The nucleotide positions are shown above each section of 
sequencing.  Nucleotides corresponding to the consensus sequence are shown by 
dots, differing nucleotides are shown by letter.  The highlighted nucleotide is 

















Titration of rIBVs on CK cells 
Isolates 2 and 3 of rIBV BeauR-M41(S1) P3-CKC, P3-Vero and P7-Vero and isolates 
4 and 15 of rIBV BeauR-M41(S2) P3-CKC and P3-Vero were titrated on CK cells 
and compared to parent strains of IBV, Beau-R, M41-CK and BeauR-M41(S) (Table 
3.1).   Beau-R and BeauR-M41(S) are recombinant strains of IBV, M41-CK is not.  
The titres for the P3-CKC recombinant viruses were comparable to those of 
laboratory strains Beau-R and M41-CK.  BeauR-M41(S) titre was lower than the 
others, as was BeauR-M41(S1) isolate 3.  It is possible that these titres could be 
increased by further passage in CK cells.   
 
The titres of all P3-Vero rIBV were lower than those of the P3-CKC rIBV, however 
further passage on Vero cells increased the titres of BeauR-M41(S1) isolates and by 
P7-Vero, titres were closer to the original P3-CKC and Beau-R titres.  In fact, the 
BeauR-M41(S1) 3 P7-Vero titre was actually greater than that of BeauR-M41(S1) 3 
P3-CKC.  The titres of the BeauR-M41(S2) P3-Vero isolates were dramatically lower 













Table 3.1.  Comparison of rIBV titres on CK cells.  Virus supernatant was serially 
diluted 1:10 in cell culture medium.  Confluent CK cells in six-well plates were 
infected with 500 μl diluted supernatant in duplicate and incubated at 37°C for 1 
hour.  Inoculum was replaced with 3 ml medium containing 1% agar and plates were 
incubated at 37°C for 48 – 72 hours.  Living cells were stained with 0.01% neutral 
red and plaques counted several hours later.  The number of plaque forming units 
(pfu) per ml was calculated.  The titres are an average of three separate experiments.     
Virus Titre (pfu/ml) 
Beau-R 9 x 10
9 
M41-CK 3 x 10
9 
BeauR-M41(S) 3 x 10
4 
BeauR-M41(S1) 2 P3-CKC 1 x 10
10 
BeauR-M41(S1) 2 P3-Vero 3 x 10
7 
BeauR-M41(S1) 2 P7-Vero 4 x 10
8 
BeauR-M41(S1) 3 P3-CKC 3 x 10
4 
BeauR-M41(S1) 3 P3-Vero 2 x 10
4
 
BeauR-M41(S1) 3 P7-Vero 5 x 10
7 
BeauR-M41(S2) 4 P3-CKC 5 x 10
9 
BeauR-M41(S2) 4 P3-Vero 4 x 10
2 
BeauR-M41(S2) 15 P3-CKC 4 x 10
9 




Analysis of rIBV growth phenotypes by confocal microscopy 
 
Chick kidney, Vero and BHK-21 cells on coverslips were infected with isolates 2 
and 3 of rIBV BeauR-M41(S1) P3-CKC, P3-Vero and P7-Vero and isolates 4 and 15 
of rIBV BeauR-M41(S2) P3-CKC and P3-Vero.  Cells were also infected with Beau-
R, M41-CK and BeauR-M41(S) for comparison (Figure 3.14).  Infected cells were 
immunolabelled with mouse anti-dsRNA, secondary antibody AlexaFluor 488 goat 
anti-mouse (green).  Nuclei were labelled with DAPI (blue). 
 
Many infected CK cells were observed in wells inoculated with the parent virus 
controls, Beau-R, M41-CK and BeauR-M41(S) (Figure 3.14).  Infected cells were 
often found clustered in infectious centres but some individual infected cells, 
presumably as a result of a second cycle of infection, were also seen.   
 
Many infected Vero and BHK-21 cells were observed in wells inoculated with Beau-
R.  As with CK cells, infected Vero cells were mainly found clustered in infectious 
centres but individual infected cells were also seen.  However infected BHK-21 cells 
were discrete from each other and no infectious centres were observed.  This growth 
pattern is different to that observed on CK and Vero cells.   
 
Only small numbers of infected Vero or BHK-21 cells were observed with M41-CK 
or BeauR-M41(S), many of which had low levels of immunofluorescence, and no 
infectious centres were observed.  Although it appears that M41-CK and BeauR-
M41(S) are able to replicate within Vero and BHK-21 cells, infectious progeny virus 
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does not infect neighbouring cells and there is no virus spread.  It is possible that 
progeny virus is unable to be released from the host cells or it may not be infectious.   
 
No fluorescent cells were observed in the mock-infected wells using an anti-dsRNA 
antibody.
  
Figure 3.14. Confocal microscopy of rIBV growth on CK, Vero and BHK-21 
cells.  Chick kidney cells were infected with A. mock, B. Beau-R, G. M41-CK and 
H. BeauR-M41(S).  Vero cells were infected with C. mock, D. Beau-R, I. M41-CK 
and J. BeauR-M41(S).  Baby hamster kidney-21 cells were infected with E. mock, F. 
Beau-R, K. M41-CK and L. BeauR-M41(S).   Infected cells were fixed 24 hours 
post-infection and immunolabelled with mouse anti-dsRNA, secondary antibody 
AlexaFluor 488 goat anti-mouse (green, Invitrogen).  Nuclei were labelled with 




             
             






























Figure 3.14. Confocal microscopy of rIBV growth on CK, Vero and BHK-21 
cells.  Chick kidney cells were infected with A. mock, B. Beau-R, G. M41-CK and 
H. BeauR-M41(S).  Vero cells were infected with C. mock, D. Beau-R, I. M41-CK 
and J. BeauR-M41(S).  Baby hamster kidney-21 cells were infected with E. mock, F. 
Beau-R, K. M41-CK and L. BeauR-M41(S).   Infected cells were fixed 24 hours 
post-infection and immunolabelled with mouse anti-dsRNA, secondary antibody 
AlexaFluor 488 goat anti-mouse (green, Invitrogen).  Nuclei were labelled with 
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Infectious centres were observed in CK and Vero cells infected with both BeauR-
M41(S1) P3-CKC isolates.  The rIBV also replicated in BHK-21 cells although as 
with Beau-R, single infected cells were mainly observed rather than infectious foci 
(Figure 3.15). 
 
BeauR-M41(S1) P3-Vero isolates also replicated in CK and Vero cells and infected 
cells were mainly observed in infectious centres.  Only a small number of infected 
BHK-21 cells were observed however, and none were observed in infectious centres 
(Figure 3.16).   
 
Many infectious centres were observed in CK and Vero cells infected with BeauR-
M41(S1) P7-Vero isolates.  As with the P3-CKC and P3-Vero isolates, infected BHK-
21 cells were observed singly rather than in infectious foci, although groups of 
infected cells did occur in the same field of vision (Figure 3.17).  
 
There appears to be no difference between the growth phenotypes of the different 
BeauR-M41(S1) isolates and Beau-R on CK, Vero and BHK-21 cells.  All isolates 
grew well on CK and Vero cells, forming infectious centres.  The isolates grew less 
well on BHK-21 cells and infected cells were not observed in infectious foci, rather 
singly.  Progeny virus from BHK-21 cells may be less infectious or less progeny 
virus may be released from BHK-21 cells.  
 
  
Figure 3.15. Confocal microscopy of rIBV BeauR-M41(S1) P3-CKC growth on 
CK, Vero and BHK-21 cells.  Chick kidney cells were infected with A. BeauR-
M41(S1) 2 P3-CKC, B. BeauR-M41(S1) 3 P3-CKC.  Vero cells were infected with C. 
BeauR-M41(S1) 2 P3-CKC, D. BeauR-M41(S1) 3 P3-CKC.  Baby hamster kidney-21 
cells were infected with E. BeauR-M41(S1) 2 P3-CKC, F. BeauR-M41(S1) 3 P3-
CKC.   Infected cells were fixed 24 hours post-infection and immunolabelled with 
mouse anti-dsRNA, secondary antibody AlexaFluor 488 goat anti-mouse (green, 
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Figure 3.16. Confocal microscopy of rIBV BeauR-M41(S1) P3-Vero growth on 
CK, Vero and BHK-21 cells.  Chick kidney cells were infected with A. BeauR-
M41(S1) 2 P3-Vero, B. BeauR-M41(S1) 3 P3-Vero.  Vero cells were infected with C. 
BeauR-M41(S1) 2 P3-Vero, D. BeauR-M41(S1) 3 P3-Vero.  Baby hamster kidney-21 
cells were infected with E. BeauR-M41(S1) 2 P3-Vero, F. BeauR-M41(S1) 3 P3-
Vero.   Infected cells were fixed 24 hours post-infection and immunolabelled with 
mouse anti-dsRNA, secondary antibody AlexaFluor 488 goat anti-mouse (green, 
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Figure 3.17. Confocal microscopy of rIBV BeauR-M41(S1) P7-Vero growth on 
CK, Vero and BHK-21 cells.  Chick kidney cells were infected with A. BeauR-
M41(S1) 2 P7-Vero, B. BeauR-M41(S1) 3 P7-Vero.  Vero cells were infected with C. 
BeauR-M41(S1) 2 P7-Vero, D. BeauR-M41(S1) 3 P7-Vero.  Baby hamster kidney-21 
cells were infected with E. BeauR-M41(S1) 2 P7-Vero, F. BeauR-M41(S1) 3 P7-
Vero.   Infected cells were fixed 24 hours post-infection and immunolabelled with 
mouse anti-dsRNA, secondary antibody AlexaFluor 488 goat anti-mouse (green, 
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Both BeauR-M41(S2) P3-CKC isolates grew well on CK cells, forming infectious 
centres.  Only a small number of infected Vero cells were observed, none of which 
were in infectious centres.  Groups of infected BHK-21 cells were seen in wells 
inoculated with BeauR-M41(S2) P3-CKC isolates.  All infected cells observed were 
singular, not clustered in infectious centres.  More infected BHK-21 cells were 
observed than infected Vero cells, although there did not appear to be any virus 
spread in either cell type (Figure 3.18). 
 
Infectious centres were observed in CK cells infected with BeauR-M41(S2) 4 P3-
Vero but no infected cells were observed in wells inoculated with BeauR-M41(S2) 
15 P3-Vero.  No infected Vero cells were observed in wells inoculated with BeauR-
M41(S2) P3-Vero isolates.  Only a small number of infected BHK-21 cells were 
observed following infection with BeauR-M41(S2) 4 P3-Vero and only infected cells 
with faint immunofluorescence were observed with BeauR-M41(S2)15 P3-Vero.  
Infected cells were all single, not in infectious centres (Figure 3.19).   
 
While BeauR-M41(S2) P3-CKC isolates grew well on CK cells and infected small 
numbers of Vero and BHK-21 cells, P3-Vero isolate 4 was only able to infect CK 
cells, forming infectious centres.  No infected cells were observed in wells infected 
with BeauR-M41(S2) 15 P3-Vero.  As indicated in Figure 3.7 and Table 3.1, passage 
of BeauR-M41(S2) on Vero cells significantly decreased the virus titre, in fact no 
BeauR-M41(S2) isolate 15 remained after three passages.  This is confirmed by 
confocal microscopy with indirect immunofluorescence as no infected cells of any 
type investigated were observed. 
  
Figure 3.18. Confocal microscopy of rIBV BeauR-M41(S2) P3-CKC growth on 
CK, Vero and BHK-21 cells.  Chick kidney cells were infected with A. BeauR-
M41(S2) 4 P3-CKC, B. BeauR-M41(S2) 15 P3-CKC.  Vero cells were infected with 
C. BeauR-M41(S2) 4 P3-CKC, D. BeauR-M41(S2) 15 P3-CKC.  Baby hamster 
kidney-21 cells were infected with E. BeauR-M41(S2) 4 P3-CKC, F. BeauR-
M41(S2) 15 P3-CKC.   Infected cells were fixed 24 hours post-infection and 
immunolabelled with mouse anti-dsRNA, secondary antibody AlexaFluor 488 goat 
anti-mouse (green, Invitrogen).  Nuclei were labelled with DAPI (blue).  Images 
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Figure 3.19. Confocal microscopy of rIBV BeauR-M41(S2) P3-Vero growth on 
CK, Vero and BHK-21 cells.  Chick kidney cells were infected with A. BeauR-
M41(S2) 4 P3-Vero, B. BeauR-M41(S2) 15 P3-Vero.  Vero cells were infected with 
C. BeauR-M41(S2) 4 P3-Vero, D. BeauR-M41(S2) 15 P3-Vero.  Baby hamster 
kidney-21 cells were infected with E. BeauR-M41(S2) 4 P3-Vero, F. BeauR-
M41(S2) 15 P3-Vero.   Infected cells were fixed 24 hours post-infection and 
immunolabelled with mouse anti-dsRNA, secondary antibody AlexaFluor 488 goat 
anti-mouse (green, Invitrogen).  Nuclei were labelled with DAPI (blue).  Images 
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Growth kinetics of rIBVs on CK, Vero and BHK-21 cells 
 
Chick kidney, Vero and BHK-21 cells were infected with Beau-R, M41-CK, BeauR-
M41(S), BeauR-M41(S1) 2 P3-CKC and BeauR-M41(S2) 4 P3-CKC at a multiplicity 
of infection of 0.1. Supernatant from the infected cells was harvested at 1, 12, 24, 48 
and 72 hours post-infection and titrated on CK cells.  Three replicates were 
performed and the averages taken (Figures 3.20 – 3.22).  RNA was extracted from 
selected samples, RT-PCRs were carried out across the S gene and sequenced to 
check that the correct virus was present.   
 
All viruses were shown to replicate to a similar titre on CK cells (Figure 3.20).  Peak 
titres for all viruses were observed at 48 hours post-infection.  Growth of BeauR-
M41(S1) and BeauR-M41(S2) was observed to be slower than the parent viruses 
between 1 – 24 hours post-infection.  At 24 hours post-infection, the titres of the 
parent virus controls were between 6 x 10
5 
pfu/ml (M41-CK) and 7 x 10
7
 pfu/ml 
(Beau-R), whereas the two recombinant virus titres were 1.5 x 10
2 
and 5 x 10
2
 pfu/ml 
for BeauR-M41(S1) and BeauR-M41(S2) respectively, a 10
3
 – 105 fold difference in 
titre.  The recombinant viruses reached similar titres to the parental viruses by 48 







Figure 3.20.  Growth kinetics of rIBVs on CK cells.  Chick kidney cells were 
infected with Beau-R, M41-CK, BeauR-M41(S), BeauR-M41(S1) 2 P3-CKC and 
BeauR-M41(S2) 4 P3-CKC at a multiplicity of infection of 0.1. Supernatant was 
harvested at 1, 12, 24, 48 and 72 hours post-infection and titrated on CK cells.  Three 
replicates were performed and the averages taken.  Error bars indicate standard error 











Beau-R replicated to the highest titre on Vero cells (Figure 3.21).  Growth of M41-
CK, BeauR-M41(S) and BeauR-M41(S2) did not reach titres greater than 1.5 log10 
pfu/ml on Vero cells.  BeauR-M41(S1) followed a similar growth curve to Beau-R 
on Vero cells but final titres of BeauR-M41(S1) were approximately 10
3
-fold lower 
than those of Beau-R.  Unlike on CK cells (Figure 3.20), replication of Beau-R and 
BeauR-M41(S1) did not peak at 48 hours post-infection but rather continued to 

























Figure 3.21. Growth kinetics of rIBVs on Vero cells.  Vero cells were infected 
with Beau-R, M41-CK, BeauR-M41(S), BeauR-M41(S1) 2 P3-CKC and BeauR-
M41(S2) 4 P3-CKC at a multiplicity of infection of 0.1. Supernatant was harvested at 
1, 12, 24, 48 and 72 hours post-infection and titrated on CK cells.  Three replicates 













Beau-R replicated to the highest titre on BHK-21 cells (Figure 3.22).  Unlike on CK 
cells (Figure 3.20), replication of Beau-R did not peak at 48 hours post-infection but 
rather continued to increase until 72 hours post-infection, the final time point 
measured.  This followed a similar pattern to growth of Beau-R on Vero cells (Figure 
3.21).  No growth of M41-CK was observed and BeauR-M41(S) did not reach titres 
greater than 10 pfu/ml on BHK-21 cells.   
 
BeauR-M41(S1) growth was very low for the first 24 hours post-infection then 
increased at 48 hours post-infection.  Final titres of BeauR-M41(S1) were 8.67 x 10
4 
pfu/ml, approximately 1700-fold lower than those of Beau-R.  No growth of BeauR-




















Figure 3.22. Growth kinetics of rIBVs on BHK-21 cells.  Baby hamster kidney-21 
cells were infected with Beau-R, M41-CK, BeauR-M41(S), BeauR-M41(S1) 2 P3-
CKC and BeauR-M41(S2) 4 P3-CKC at a multiplicity of infection of 0.1. 
Supernatant was harvested at 1, 12, 24, 48 and 72 hours post-infection and titrated on 
CK cells.  Three replicates were performed and the averages taken.  Error bars 





Two isolates each of the recombinant viruses, BeauR-M41(S1) and BeauR-M41(S2), 
were successfully rescued and passaged in CK cells, demonstrating that it is possible 
to generate viable rIBV with chimaeric S glycoproteins.   The S gene sequences were 
verified both prior to rescue and after three passages in CK cells.  The P3-CKC 
isolates of both BeauR-M41(S1) and BeauR-M41(S2) grew well on CK cells as 
shown by confocal microscopy (Figures 3.15 and 3.18) and replicated to a similar 
titre to the parent viruses on CK cells (Figure 3.20).   
 
These are the first rIBVs to have chimaeric S genes with one subunit from a different 
strain of IBV to the rest of the genome.  A previous study replaced the ectodomain of 
the S glycoprotein of Beaudette with that of M41 within the background of Beau-R, 
creating BeauR-M41(S) (Casais et al., 2005).  This virus exhibited the in vitro 
cellular tropism of M41, however did not replicate as well as M41 in the trachea and 
nose of infected birds and was apathogenic like Beau-R, not pathogenic like M41 
(Hodgson et al., 2004).   
 
The P3-CKC isolates of BeauR-M41(S1) and BeauR-M41(S2) were passaged on 
Vero cells.  In order to determine whether the rIBVs were able to sustain replication 
on the mammalian cell line, RNA was extracted from the cell culture supernatant of 
passages 1 – 3 and RT-PCRs carried out across the end of the S gene (Figure 3.11).  
The P3-Vero isolates were titrated on CK cells (Table 3.1).  The P3-Vero isolates 
were grown on CK, Vero and BHK-21 cells in order to assess their growth 
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phenotypes by confocal microscopy with indirect immunofluorescence (Figures 3.16 
and 3.19). 
 
Growth of BeauR-M41(S2) P3-CKC isolates on Vero and BHK-21 cells yielded very 
few infected cells (Figure 3.18) and the rIBVs were unable to sustain replication on 
Vero cells after three passages.  Titres and RT-PCR products were dramatically 
reduced by P3-Vero (Table 3.1 and Figure 3.11).  Unsurprisingly, when CK, Vero or 
BHK-21 cells were inoculated with BeauR-M41(S2) P3-Vero cell culture 
supernatant, very few infected cells were observed by confocal microscopy with 
indirect immunofluorescence (Figure 3.19). 
 
BeauR-M41(S1) was found to be able to replicate well on Vero cells and all RT-
PCRs were positive for virus presence (Figure 3.11).  Infectious centres were formed 
when BeauR-M41(S1) P3-CKC and P3-Vero isolates were grown on CK and Vero 
cells (Figures 3.15 and 3.16). BeauR-M41(S1) P3-CKC and P3-Vero isolates infected 
BHK-21 cells but did not form infectious centres.  
 
Four further passages of BeauR-M41(S1) P3-Vero isolates were carried out on Vero 
cells and virus replication was maintained.  The P7-Vero isolates were also titrated on 
CK cells (Table 3.1) and their growth phenotypes on CK, Vero and BHK-21 cells 
were assessed by confocal microscopy with indirect immunofluorescence (Figure 
3.17).  The growth phenotypes of the P7-Vero isolates were similar to that of the 
earlier passages, infectious centres were formed on CK and Vero cells but not BHK-




Titres of the P3-Vero isolates were lower than the P3-CKC isolates on CK cells, 
although these had increased by P7-Vero (Table 3.1). Additional passages on Vero 
cells further adapted the BeauR-M41(S1) isolates to growth on Vero cells and the P5-
Vero isolates began to form syncytia, a characteristic maintained at least until P7 
(Figure 3.12).  The S genes of the P7-Vero isolates were sequenced in order to 
identify any amino acid changes that could be responsible for this change in growth 
phenotype (Figure 3.13).   
 
Five nucleotide differences were identified between the P7-Vero isolates and the 
parent, Beau-R and M41-CK, S gene sequences.  These resulted in three amino acid 
changes, one of which was shared between both isolates.  All changes occurred 
within the S2 subunit of the S glycoprotein.  The S2 subunit is responsible for virus-
cell and cell-cell fusion (Luo and Weiss, 1998), and it is possible that one or more of 
these changes could be involved in syncytium formation in Vero cell culture.   
 
A recent study by Yamada et al., (2009) has suggested a number of amino acid 
substitutions in the S glycoprotein of IBV that may be involved in the acquisition of 
cell-cell fusion activity in vitro, however none of these correspond to the changes 
identified in the BeauR-M41(S1) P7-Vero S glycoproteins.   
 
In depth analysis of the growth kinetics of BeauR-M41(S1) and BeauR-M41(S2) P3-
CKC isolates on Vero and BHK-21 cells was carried out by growth curves (Figures 
3.21 and 3.22). Unlike on CK cells (Figure 3.20), titres did not peak at 48 hours post-
infection, rather continued to increase until the last time point at 72 hours post-
infection.  Beau-R grew to the highest titre on both Vero and BHK-21 cells, followed 
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by BeauR-M41(S1).  Although the peak titre of BeauR-M41(S1) on Vero cells was 
lower than that of Beau-R, it must be remembered that this was the first time that the 
P3-CKC isolate had been grown on Vero cells.  The titres of the P7-Vero isolates 
were higher than the titres of the P3-Vero isolates, and were within one – two log10 of 
the Beau-R titre on CK cells (Table 3.1).  It would be reasonable to suppose that 
growth curves carried out with a P7-Vero isolate rather than a P3-CKC isolate would 
be closer to those of Beau-R on Vero cells. 
 
As expected from the analysis of the growth phenotypes by confocal microscopy, 
BeauR-M41(S2) replicated very poorly on Vero and BHK-21 cells and followed a 
similar growth curve to M41-CK and BeauR-M41(S) on both cell types.    
 
It appears that while BeauR-M41(S1) is able to replicate on Vero cells, BeauR-
M41(S2) is not, indicating that it is the S2 subunit of Beau-R that confers the ability 
to grow on Vero cells.  
 
Although it was not anticipated that the S2 subunit would be the determinant of 
cellular tropism as it is the S1 subunit that contains the receptor binding domain 
(Cavanagh et al., 1986), a report by Koch et al., (1990) identified a neutralizing 
monoclonal antibody (MAb) against part of the IBV S2 subunit, suggesting that this 
area may be involved in binding or fusion of IBV to host cells.  
 
A study by de Haan et al., (2006) generated several recombinant viruses based on 
MHV-A59 but with chimaeric S glycoproteins where parts of the spike were derived 
from cell culture-adapted virus MHV/BHK.   It was determined that a combination 
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of amino acids in the S1 and S2 subunits were responsible for the extended host 
range of MHV/BHK in cell culture.  A previous study exchanging just an amino-
terminal section of the MHV-A59 spike for that of MHV/BHK resulted in a virus 
with the extended host range of MHV/BHK but unable to induce a second round of 
infection in nonmurine cells (Thackray and Holmes, 2004).   
 
Replication on BHK-21 cells may be controlled by different factors to replication on 
Vero cells.  Whereas BeauR-M41(S1) replicated well on Vero cells, the virus 
replicated to a much lower titre on BHK-21 cells and BeauR-M41(S2) was unable to 
replicate on either cell type.  Passage of BeauR-M41(S1) on BHK-21 cells may adapt 
the virus for growth on this cell type.   
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Chapter 4:  Investigation into the role of the Beaudette–




Two recombinant IBVs, with either the Beaudette-specific motif from Beau-R or the 
corresponding sequence from M41 within the S gene of the other strain and the 
genomic background of Beaudette, were generated using a vaccinia virus reverse 
genetics system.  The growth characteristics and cellular tropism of the rIBVs were 
investigated. The Beaudette-specific motif of Beaudette was found to be sufficient to 
confer the ability to grow on Vero cells to a rIBV with the M41 S glycoprotein.  
Replacement of the Beaudette-specific motif with the corresponding sequence from 




Results from Chapter 3 showed that the S2 subunit (Figure 4.1) of the S glycoprotein 
is responsible for the extended cellular tropism of Beau-R in cell culture.  In order to 
further narrow down the area of the S2 subunit involved in determination of tropism, 
additional recombinant viruses were created with chimaeric S genes.   
 
A heparan sulphate binding site was identified between amino acid residues 686 – 
691 within the S2 subunit of the Beaudette S glycoprotein by Madu et al., (2007).  
This binding site was not identified in any other strain of IBV investigated.  Results 
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from the work indicate that heparan sulphate might be involved as a cofactor in 




Figure 4.1.  Locations of the amino acid differences between Beau-R and M41-
CK within the S2 subunit of the S glycoprotein.  The S2 subunit contains 19 
amino acid differences between Beau-R and M41-CK, three of which comprise a 
putative heparan sulphate binding site, shown in blue.   
 
 
Heparan sulphate is a glycosaminoglycan (GAG) found on the surface of mammalian 
cells (Liu and Thorp, 2002).  The consensus sequence for a heparin-binding site is 
XBBXBX, where B is a basic amino acid and X is a hydropathic amino acid (Cardin 
and Weintraub, 1989).  The sequence identified in the Beaudette S glycoprotein was 
686SRRKRS691 or 686SRRRRS691 (Madu et al., 2007).  This sequence was not found 
in the S glycoprotein of any other strains of IBV, which is a possible explanation for 
the extended host range of Beaudette in comparison to M41.  A number of other 
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viruses are also able to use heparan sulphate as an adhesion receptor, including foot 
and mouth disease virus and herpes simplex virus (Liu and Thorp, 2002).  This 
Beaudette-specific motif, sequence RRRR690/S, was later also identified by Yamada 
and Liu (2009) as a potential second cleavage site. 
 
Taking into consideration work by Madu et al., (2007) that the Beaudette-specific 
motif may have a potential role in conferring the ability of Beaudette to grow on 
Vero cells, the sequences of several IBV strains were compared.  Due to the presence 
of an amino acid change immediately upstream of the motif identified by Madu et 
al., (2007), we decided to investigate an extended Beaudette-specific motif, 
686SRRKRSLIE694. 
 
Two recombinant IBVs were designed to investigate the role of the Beaudette-
specific motif on the ability of Beau-R to grow on Vero cells.  One virus, rIBV 
BeauR-S-M41-Hep, has the genomic background and S gene of Beau-R with the 
Beaudette-specific motif replaced with the corresponding sequence from M41, 
686SPRRRSFIE694.  The other virus, rIBV M41-S-BeauR-Hep, is based on BeauR-
M41(S) and has the S gene from M41 within the genomic background of Beau-R but 
with the Beaudette-specific motif, sequence 686SRRKRSLIE694, also from Beau-R 
(Figure 4.2).  The growth characteristics of these viruses were determined on various 







Figure 4.2. Schematic diagram of the S genes of different strains of IBV.  The S1 
domain contains the receptor binding domain and the cleaved signal sequence (SS).  
The S2 domain contains two heptad repeats, HR1 and 2, a transmembrane (TM) 
domain and a cytoplasmic (Cyto) domain.  Beau-R also contains a putative heparan 
sulphate binding sequence (HSBS) not found in M41.  The HSBS of Beau-R was 
introduced into the M41-CK S gene to create M41-S-BeauR-Hep and the equivalent 

















Two plasmids were designed, one with a section of the Beau-R S gene with the 
Beaudette-specific motif, 686SRRKRSLIE694, located within the S2 subunit replaced 
with the corresponding sequence from M41, 686SPRRRSFIE694, (pGPT-BeauCK-S-
M41-Hep).  The other plasmid has a section of the M41 S gene with the Beaudette-
specific motif, 686SRRKRSLIE694, replacing the corresponding M41 S gene 
sequence, 686SPRRRSFIE694, (pGPT-M41-S-BeauCK-Hep).  These sequences were 






















Figure 4.3. Diagram of pGPTNEB193.  The modified S genes were cloned into 
plasmid pGPTNEB193 to create pGPT-M41-S-BeauCK-Hep and pGPT-BeauCK-S-























Figure 4.4. Diagrams of pGPT-M41-S-BeauCK-Hep and pGPT-BeauCK-S-
M41-Hep.  The plasmids pGPT-M41-S-BeauCK-Hep and pGPT-BeauCK-S-M41-
Hep were used in the reverse genetics system to alter the sequence of BeauR-M41(S) 
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Reverse genetics system 
The plasmids pGPT-M41-S-BeauCK-Hep and pGPT-BeauCK-S-M41-Hep (Figure 
4.4) were used to insert the modified S gene sequence into vNotI/IBVfl-M41S, a 
recombinant vaccinia virus (rVV) containing the full-length IBV Beau-R cDNA 
genome with the S gene from M41, or vNotI/IBVfl, an rVV containing the full-
length IBV Beau-R cDNA genome, respectively.  Two rVVs containing the correctly 
modified S gene sequence for each type were identified for recovery of rIBVs; 
isolates 7 and 20 of rIBV BeauR-S-M41-Hep and isolates 5 and 26 of rIBV M41-S-
BeauR-Hep.  These were rescued and passaged three times on CK cells followed by 






Recovery and passage of rIBVs 
 
Rescue of rIBV BeauR-S-M41-Hep and M41-S-BeauR-Hep in CK cells 
DNA was extracted from two isolates of each rVV containing the rIBV cDNA with 
modified S gene sequences, digested with SalI and analysed by pulsed field gel 
electrophoresis to check that the entire rIBV cDNA genome was intact.  This is 
indicated by the presence of a 30kb SalI restriction fragment.  An example pulsed 
field gel is shown in Chapter 3, Figure 3.6.  The chimaeric S gene sequences were 
verified by sequencing then two isolates each of rIBV BeauR-S-M41-Hep, isolates 7 
and 20, and M41-S-BeauR-Hep, isolates 5 and 26, were rescued from CK cells.   
  
Sequencing of P3-CKC rIBVs 
The rescued viruses were passaged three times on CK cells.  At each passage on CK 
cells, RNA was extracted from the infected cell supernatant and RT-PCRs were 
carried out across the end of the S genes to confirm virus presence.  The entire S 
gene sequences of the P3-CKC viruses were confirmed by sequence analysis (Figures 
4.5 and 4.6). The BeauR-S-M41-Hep sequences correspond to that of the Beau-R 
sequence apart from the Beaudette-specific motif, which matches the M41 sequence.  
The M41-S-BeauR-Hep sequences correspond to that of the M41 sequence apart 





Figure 4.5. Sequencing to check the Beaudette-specific motif of BeauR-S-M41-
Hep P3-CKC isolates.  Sequence analysis of the BeauR-S-M41-Hep isolates showed 
that the Beaudette-specific motif in the Beau-R S gene had been changed to the 
corresponding M41 sequence, GC, AG and CT.  The rest of the S gene 
sequence corresponded to Beau-R. The nucleotide positions are shown above each 
section of sequencing.  Nucleotides corresponding to the consensus sequence are 
shown by dots, differing nucleotides are shown by letter. The highlighted nucleotide 




Figure 4.6. Sequencing to check the Beaudette-specific motif of M41-S-BeauR-
Hep P3-CKC isolates.  Sequence analysis of the M41-S-BeauR-Hep isolates showed 
that the Beaudette-specific motif had been introduced into the M41 S gene sequence, 
CG, GA and TC.  The rest of the S gene sequence corresponds to M41-CK.  
The nucleotide positions are shown above each section of sequencing.  Nucleotides 
corresponding to the consensus sequence are shown by dots, differing nucleotides are 
shown by letter. The highlighted nucleotide is indicated by a blue line on the 
sequence trace.   
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Passage of P3-CKC rIBVs on Vero cells 
The P3-CKC rIBVs were passaged three times on Vero cells to determine whether 
virus replication could be maintained on this mammalian cell line.  At each passage, 
RNA was extracted and RT-PCRs were carried out across the end of the S genes to 
confirm virus presence (Figure 4.7).  The RT-PCR results showed that both M41-S-
BeauR-Hep isolates grew on Vero cells at each passage.  Cytopathic effect in the 
form of rounded and floating cells were observed from around 24 hours post-
infection.  The RT-PCRs for the presence of BeauR-S-M41-Hep isolates were 
negative by passage 3. 
 
Figure 4.7. Agarose gel analysis of RT-PCR products from rIBV BeauR-S-M41-
Hep and M41-S-BeauR-Hep P1-3-Vero isolates. RNA was extracted from Vero cell 
culture supernatants of (A) BeauR-S-M41-Hep (BSMH) 7 and 20 and (B) M41-S-
BeauR-Hep (MSBH) 5 and 26 P1-3-Vero.  RT-PCRs were carried out on each. A 
molecular size ladder (L) is shown to compare the sizes of DNA fragments.  The 
positive control (+) shows a band between 400-500 bp.  Negative control (-) shows 
no band.  All passages of M41-S-BeauR-Hep have bands of correct sizes.  Band 
intensity decreases from P1-3 of BeauR-S-M41-Hep so that P3 of both isolates can no 




BeauR-S-M41-Hep isolates caused no cpe when grown on Vero cells (Figure 4.8).  
M41-S-BeauR-Hep P3-Vero isolates were further passaged on Vero cells to establish 
whether viral replication could be maintained on this cell type.  It was decided to 
stop passaging at P7 as M41-S-BeauR-Hep replication appeared to be stable on Vero 
cells.  Typical cpe produced by infection of Vero cells with M41-S-BeauR-Hep P7-
Vero isolates included rounded and floating cells and syncytia formation. 
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Figure 4.8. Brightfield microscopy of rIBV growth on Vero cells. Vero cells 
infected with A. mock, B. Beau-R, C. M41-CK, D. BeauR-M41(S), E. BeauR-S-
M41-Hep 7 P3-Vero, F. BeauR-S-M41-Hep 20 P3-Vero, G. M41-S-BeauR-Hep 5 P7-
Vero, H. M41-S-BeauR-Hep 26 P7-Vero.  Syncytia indicated by arrows.  







Sequencing of M41-S-BeauR-Hep P7-Vero S genes 
RNA was extracted from infected cell supernatant and RT-PCRs were carried out 
across the S gene.  These were then sequenced and compared to Beau-R and BeauR-
M41(S) sequences (Figure 4.9).  Three nucleotide differences were identified 
between the M41-S-BeauR-Hep P7-Vero isolates and the parent viruses, Beau-R and 
BeauR-M41(S); one is located within the S1 subunit and two are located within the 
S2 subunit.  None of the amino acid changes identified in the M41-S-BeauR-Hep P7-
Vero isolates correspond to those identified in BeauR-M41(S1) P7-Vero isolates 
(Chapter 3, Figure 3.13). 
 
The first nucleotide change is located at nucleotide position 21818.  Beau-R has an A 
at this position, M41 and M41-S-BeauR-Hep isolate 26 P7-Vero have a C at this 
position and M41-S-BeauR-Hep isolate 5 P7-Vero has a T (Figure 4.9A).  This 
results in an amino acid change of asparagine (Beau-R)/threonine (M41) to 
isoleucine.   
 
The second nucleotide change occurs at position 22227 and was identified in isolate 
26 only (Figure 4.9B).  This results in an amino acid change of aspartic acid to 
alanine.  The third nucleotide change was identified in isolate 5 only and occurs at 
position 22966, resulting in an amino acid change of glutamine to histidine (Figure 
4.9C).   It is possible that these changes could contribute to the further adaptation of 
M41-S-BeauR-Hep to growth on Vero cells. 
  
  
Figure 4.9.  Sequencing of M41-S-BeauR-Hep P7-Vero S genes.  RNA was 
extracted from M41-S-BeauR-Hep P7-Vero cell culture supernatant, RT-PCRs were 
carried out across the S gene, purified and sequenced in positive and negative 
directions.  Three nucleotide differences were observed in the S genes of M41-S-
BeauR-Hep P7-Vero isolates when compared to Beau-R and BeauR-M41(S); one 
occurred within the S1 subunit and two occurred within the S2 subunit.  The 
sequences of the S genes otherwise corresponded to M41, apart from the Beaudette-
specific motif in the S2 subunit.  The nucleotide positions are shown above each 
section of sequencing.  Nucleotides corresponding to the consensus sequence are 
shown by dots, differing nucleotides are shown by letter.  The highlighted nucleotide 















Titration of rIBVs on CK cells 
Isolates 7 and 20 of rIBV BeauR-S-M41-Hep P3-CKC and P3-Vero and isolates 5 
and 26 of rIBV M41-S-BeauR-Hep P3-CKC, P3-Vero and P7-Vero were titrated on 
CK cells and compared to parent strains of IBV, Beau-R, M41-CK and BeauR-
M41(S) (Table 4.1).  Beau-R and BeauR-M41(S) are recombinant IBV strains, M41-
CK is not.  The titres for the P3-CKC recombinant viruses were comparable to those 
of laboratory strains Beau-R and M41-CK.  No plaques were produced by BeauR-S-
M41-Hep P3-Vero isolates.  The titres of the M41-S-BeauR-Hep P3-Vero isolates 
were lower than those of the P3-CKC isolates, indicating that the Beaudette-specific 
motif alone may not confer the full ability to grow on Vero cells, when compared to 
the complete Beaudette S2 subunit (Chapter 3).   However, further passage of M41-
S-BeauR-Hep on Vero cells to P7 increased the titre to a similar level as the P3-CKC 


















Table 4.1.  Comparison of virus titres on CK cells.  Virus supernatant was serially 
diluted 1:10 in cell culture medium.  Confluent CK cells in six-well plates were 
infected with 500 μl diluted supernatant in duplicate and incubated at 37°C for 1 
hour.  Inoculum was replaced with 3 ml medium containing 1% agar and plates were 
incubated at 37°C for 48 – 72 hours.  Living cells were stained with 0.01% neutral 
red and plaques counted several hours later.  The number of plaque forming units 
(pfu) per ml was calculated.  The titres are an average of three separate experiments.     
Virus Titre (pfu/ml) 
Beau-R 9 x 10
9 
M41-CK 3 x 10
9 
BeauR-M41(S) 3 x 10
4 
BeauR-S-M41-Hep 7 P3-CKC 5 x 10
9 
BeauR-S-M41-Hep 7 P3-Vero 0 
BeauR-S-M41-Hep 20 P3-CKC 3 x 10
9 
BeauR-S-M41-Hep 20 P3-Vero 0 
M41-S-BeauR-Hep 5 P3-CKC 8 x 10
9 
M41-S-BeauR-Hep 5 P3-Vero 2 x 10
5 
M41-S-BeauR-Hep 5 P7-Vero 4 x 10
9 
M41-S-BeauR-Hep 26 P3-CKC 9 x 10
9 
M41-S-BeauR-Hep 26 P3-Vero 4 x 10
5 












Analysis of rIBV growth phenotypes by confocal microscopy 
 
Chicken kidney, Vero and BHK-21 cells on coverslips were infected with isolates 7 
and 20 of rIBV BeauR-S-M41-Hep P3-CKC and P3-Vero and isolates 5 and 26 of 
rIBV BeauR-M41-S-BeauR-Hep P3-CKC and P3-Vero.   Cells were also infected 
with Beau-R, M41-CK and BeauR-M41(S) for comparison (Chapter 3, Figure 3.14).  
Infected cells were immunolabelled with mouse anti-dsRNA, secondary antibody 
AlexaFluor 488 goat anti-mouse (green).  Nuclei were labelled with DAPI (blue). 
 
The parent virus controls, Beau-R, M41-CK and BeauR-M41(S) all replicated in CK 
cells, forming infectious centres.  Beau-R also replicated and formed infectious 
centres on Vero cells whereas infected BHK-21 cells were only observed singly. 
Only small numbers of infected Vero or BHK-21 cells were observed in wells 
infected with M41-CK or BeauR-M41(S) and no infectious centres were observed 
(Chapter 3, Figure 3.14).   
 
BeauR-S-M41-Hep P3-CKC isolates formed infectious centres in CK cells and only a 
small number of infected Vero cells were observed, none of which formed infectious 
centres.  There appeared to be a greater number of infected BHK-21 cells although 
these too did not form infectious centres (Figure 4.10).  No infected CK or Vero cells 
and just one infected BHK-21 cell were observed in wells infected with BeauR-S-
M41-Hep P3-Vero isolates (Figure 4.11).   
 
While BeauR-S-M41-Hep P3-CKC isolates grew well on CK cells and infected small 
numbers of Vero and BHK-21 cells, P3-Vero isolates infected very few cells of any 
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type and formed no infectious centres.  This is probably due to the reduction of virus 
titres to undetectable levels after three passages of BeauR-S-M41-Hep P3-CKC 
isolates on Vero cells, as indicated in Figure 4.7 and Table 4.1.  This confirms that 
replacement of the Beaudette-specific motif with the corresponding M41 sequence 
resulted in the loss of ability of the Beaudette S glycoprotein to confer growth on 
Vero cells.   
 
BeauR-S-M41-Hep P3-CKC isolates appeared to be able to infect more BHK-21 cells 
than Vero cells as there were a greater number of infected BHK-21 cells than Vero 
cells in separate wells infected with the same amount of virus inoculum.   No 
infectious foci were observed with either cell type. 
 
The BeauR-S-M41-Hep S2 subunit contains other amino acids that are different to 
M41 (Figure 4.1).  It appears that other regions apart from the Beaudette-specific 
motif may be involved in the ability to grow on BHK-21 cells.   
  
Figure 4.10.  Confocal microscopy of rIBV BeauR-S-M41-Hep P3-CKC growth 
on CK, Vero and BHK-21 cells.  Chick kidney cells were infected with A. BeauR-
S-M41-Hep 7 P3-CKC, B. BeauR-S-M41-Hep 20 P3-CKC.  Vero cells were infected 
with C. BeauR-S-M41-Hep 7 P3-CKC, D. BeauR-S-M41-Hep 20 P3-CKC.  Baby 
hamster kidney-21 cells were infected with E. BeauR-S-M41-Hep 7 P3-CKC, F. 
BeauR-S-M41-Hep 20 P3-CKC.  Infected cells were fixed 24 hours post-infection 
and immunolabelled with anti-dsRNA, secondary antibody AlexaFluor 488 goat anti-
mouse (green, Invitrogen).  Nuclei were labelled with DAPI (blue).  Images have 
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Figure 4.11. Confocal microscopy of rIBV BeauR-S-M41-Hep P3-Vero growth 
on CK, Vero and BHK-21 cells.  Chick kidney cells were infected with A. BeauR-
S-M41-Hep 7 P3-Vero, B. BeauR-S-M41-Hep 20 P3-Vero.  Vero cells were infected 
with C. BeauR-S-M41-Hep 7 P3-Vero, D. BeauR-S-M41-Hep 20 P3-Vero.  Baby 
hamster kidney-21 cells were infected with E. BeauR-S-M41-Hep 7 P3-Vero, F. 
BeauR-S-M41-Hep 20 P3-Vero. Infected cells were fixed 24 hours post-infection and 
immunolabelled with anti-dsRNA, secondary antibody AlexaFluor 488 goat anti-
mouse (green, Invitrogen).  Nuclei were labelled with DAPI (blue).  Images have 
been brightened for printing. 
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Infectious centres were observed in CK and Vero cells infected with both M41-S-
BeauR-Hep P3-CKC isolates.  A small number of infected BHK-21 cells were 
observed, however none were in infectious centres (Figure 4.12).  Replication of 
M41-S-BeauR-Hep P3-Vero isolates resulted in infectious centres in both CK and 
Vero cells.  No infectious centres were formed on BHK-21 cells though some 
infected cells were observed (Figure 4.13).  
 
There appears to be no difference between the growth phenotypes of the different 
M41-S-BeauR-Hep isolates on CK, Vero and BHK-21 cells.  All isolates grew well 
on CK and Vero cells, forming infectious centres.  The isolates grew less well on 
BHK-21 cells and infected cells were not observed in infectious foci, rather singly.  
Progeny virus from BHK-21 cells may be less infectious or less progeny virus may 
be released from BHK-21 cells.  
 Figure 4.12.  Confocal microscopy of rIBV M41-S-BeauR-Hep P3-CKC growth 
on CK, Vero and BHK-21 cells.  Chick kidney cells were infected with A. M41-S-
BeauR-Hep 5 P3-CKC, B. M41-S-BeauR-Hep 26 P3-CKC.  Vero cells were infected 
with C. M41-S-BeauR-Hep 5 P3-CKC, D. M41-S-BeauR-Hep 26 P3-CKC.  Baby 
hamster kidney-21 cells were infected with E. M41-S-BeauR-Hep 5 P3-CKC, F. 
M41-S-BeauR-Hep 26 P3-CKC. Infected cells were fixed 24 hours post-infection and 
immunolabelled with anti-dsRNA, secondary antibody AlexaFluor 488 goat anti-
mouse (green, Invitrogen).  Nuclei were labelled with DAPI (blue).  Images have 
been brightened for printing. 
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Figure 4.13. Confocal microscopy of rIBV M41-S-BeauR-Hep P3-Vero growth 
on CK, Vero and BHK-21 cells.  Chick kidney cells were infected with A. M41-S-
BeauR-Hep 5 P3-Vero, B. M41-S-BeauR-Hep 26 P3-Vero.  Vero cells were infected 
with C. M41-S-BeauR-Hep 5 P3-Vero, D. M41-S-BeauR-Hep 26 P3-Vero.  Baby 
hamster kidney-21 cells were infected with E. M41-S-BeauR-Hep 5 P3-Vero, F. 
M41-S-BeauR-Hep 26 P3-Vero. Infected cells were fixed 24 hours post-infection and 
immunolabelled with anti-dsRNA, secondary antibody AlexaFluor 488 goat anti-
mouse (green, Invitrogen).  Nuclei were labelled with DAPI (blue).  Images have 
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M41-S-BeauR-Hep 5 P3-Vero M41-S-BeauR-Hep 26 P3-Vero 
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Growth kinetics of rIBVs on CK, Vero and BHK-21 cells 
 
Chick kidney, Vero and BHK-21 cells were infected with Beau-R, M41-CK, BeauR-
M41(S), BeauR-S-M41-Hep 7 P3-CKC and M41-S-BeauR-Hep 26 P3-CKC at a 
multiplicity of infection of 0.1.  Supernatant from the infected cells was harvested at 
1, 12, 24, 48 and 72 hours post-infection and titrated on CK cells.  Three replicates 
were performed and the averages taken (Figures 4.14 – 4.16).  RNA was extracted 
from selected samples then RT-PCRs were carried out across the S gene and 
sequenced to check that the correct virus was present.   
 
All viruses were shown to replicate to a similar titre on CK cells (Figure 4.14).  Peak 
titres for all viruses were observed at 48 hours post-infection.  Growth of M41-S-
BeauR-Hep was seen to be slightly slower than the parent viruses between 1 – 24 
hours post-infection but reached as high a titre as the parent viruses by 48 hours post-
infection. At 24 hours post-infection, the titres of the parent virus controls were 
between 6 x 10
5 
pfu/ml (M41-CK) and 7 x 10
7
 pfu/ml (Beau-R), whereas the titre of 
M41-S-BeauR-Hep was 1 x 10
4 
pfu/ml.  This rapidly increased to 9 x 10
10 
pfu/ml at 
48 hours.  The titres of the parent virus controls were between 5 x 10
10 
pfu/ml 
(BeauR-M41(S)) and 5 x 10
11
 pfu/ml (M41-CK).  BeauR-S-M41-Hep growth 
followed the same trends as the parent viruses; the titre at 24 hours post-infection 
was 2 x 10
7
 pfu/ml and 7 x10
9
 pfu/ml at 48 hours post-infection.  Titres for all 









Figure 4.14.  Growth kinetics of rIBVs on CK cells.  Chick kidney cells were 
infected with Beau-R, M41-CK, BeauR-M41(S), BeauR-S-M41-Hep 7 P3-CKC and 
M41-S-BeauR-Hep 26 P3-CKC at a multiplicity of infection of 0.1. Supernatant was 
harvested at 1, 12, 24, 48 and 72 hours post-infection and titrated on CK cells.  Three 
replicates were performed and the averages taken.  Error bars indicate standard error 




Beau-R replicated to the highest titre on Vero cells (Figure 4.15).  Growth of M41-
CK and BeauR-M41(S) did not reach titres greater than 1.5 log10 pfu/ml on Vero 
cells.  BeauR-S-M41-Hep formed no plaques.    
 
M41-S-BeauR-Hep titre started to increase at 24 hours post-infection and reached a 
peak at 72 hours post-infection of 1 x 10
2
 pfu/ml.  Unlike on CK cells (Figure 4.14), 
replication of Beau-R did not peak at 48 hours post-infection but rather continued to 
increase until 72 hours post-infection, the final time point measured.  This trend was 
followed by M41-S-BeauR-Hep but final titres were approximately 10
6
-fold lower 






Figure 4.15.  Growth kinetics of rIBVs on Vero cells.  Vero cells were infected 
with Beau-R, M41-CK, BeauR-M41(S), BeauR-S-M41-Hep 7 P3-CKC and M41-S-
BeauR-Hep 26 P3-CKC at a multiplicity of infection of 0.1. Supernatant was 
harvested at 1, 12, 24, 48 and 72 hours post-infection and titrated on CK cells.  Three 
replicates were performed and the averages taken.  Error bars indicate standard error 
of the mean.   
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Beau-R replicated to the highest titre on BHK-21 cells (Figure 4.16). Unlike on CK 
cells (Figure 4.14), replication of Beau-R did not peak at 48 hours post-infection but 
rather continued to increase until 72 hours post-infection, the final time point 
measured.  No growth of M41-CK was observed and BeauR-M41(S) did not reach 
titres greater than 10 pfu/ml on BHK-21 cells.   
 
Growth of BeauR-S-M41-Hep began to increase at 24 hours post-infection, reaching 
a high titre of 2 x 10
5 
pfu/ml at 72 hours post-infection.  The growth curve followed 
the same pattern as Beau-R but the peak titre was approximately 10
3
-fold lower than 
that of Beau-R.  Second only to Beau-R, BeauR-S-M41-Hep had the highest peak 
titre on BHK-21 cells.   
 
M41-S-BeauR-Hep growth also followed a similar pattern to that of Beau-R and 
BeauR-S-M41-Hep, but titres were much lower.  Peak titre at 72 hours post-infection 
was approximately 10
6
-fold lower than that of Beau-R at 3 x 10
2 
pfu/ml but 33 times 
higher than parent virus, BeauR-M41(S).  
 
These results indicate that other amino acids in addition to the Beaudette-specific 












Figure 4.16.  Growth kinetics of rIBVs on BHK-21 cells.  Baby hamster kidney-21 
cells were inoculated with Beau-R, M41-CK, BeauR-M41(S), BeauR-S-M41-Hep 7 
P3-CKC and M41-S-BeauR-Hep 26 P3-CKC at a multiplicity of infection of 0.1. 
Supernatant was harvested at 1, 12, 24, 48 and 72 hours post-infection and titrated on 
CK cells.  Three replicates were performed and the averages taken.  Error bars 











Two isolates each of the recombinant viruses, BeauR-S-M41-Hep and M41-S-Beau-
Hep, were successfully rescued and passaged in CK cells.  The S gene sequences 
were verified both prior to rescue and after three passages in CK cells.  The P3-CKC 
isolates of both BeauR-S-M41-Hep and M41-S-BeauR-Hep grew on CK cells as 
shown by confocal microscopy (Figures 4.10 and 4.12) and replicated to a similar 
titre to the parent viruses on CK cells (Figure 4.14).   
 
Swapping the Beaudette-specific motif between the S glycoproteins of Beau-R and 
M41-CK has not hindered the replication of either recombinant on CK cells when 
compared to the growth of the parent viruses, Beau-R and BeauR-M41(S).  
 
The ability of the rIBVs BeauR-S-M41-Hep and M41-S-Beau-Hep to grow on Vero 
cells was analysed by serial passage of P3-CKC isolates on the mammalian cell line 
and virus presence was detected by RT-PCR at each stage (Figure 4.7).  The P3-Vero 
isolates were titrated on CK cells (Table 4.1) and growth phenotypes on CK, Vero 
and BHK-21 cells were investigated by confocal microscopy with indirect 
immunofluorescence (Figures 4.11 and 4.13).   
 
Growth of BeauR-S-M41-Hep P3-CKC isolates on Vero cells yielded very few 
infected cells, none in infectious centres (Figure 4.10), and the rIBVs were unable to 
sustain replication on Vero cells.  Titres and RT-PCR products were undetectable by 
P3-Vero (Table 4.1 and Figure 4.7).  Unsurprisingly, when CK or Vero cells were 
inoculated with BeauR-S-M41-Hep P3-Vero cell culture supernatant, no infected 
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cells were observed by confocal microscopy with indirect immunofluorescence 
(Figure 4.11).  
 
BeauR-S-M41-Hep P3-CKC isolates appeared to have a higher tropism for 
replication on BHK-21 cells than Vero cells, although no infectious centres were 
formed (Figure 4.10).  In fact, the only cell type infected by P3-Vero isolate 20 was 
BHK-21 cells (Figure 4.11).  
 
M41-S-BeauR-Hep isolates were found to be able to replicate well when passaged on 
Vero cells and all RT-PCRs were positive for virus presence (Figure 4.7). Infectious 
centres were formed when M41-S-BeauR-Hep P3-CKC and P3-Vero isolates were 
grown on Vero cells but not BHK-21 cells (Figures 4.12 and 4.13).  Additional 
passage of M41-S-BeauR-Hep isolates on Vero cells to P7 increased the virus titre on 
CK cells (Table 4.1).  A number of mutations were identified in the M41-S-BeauR-
Hep P7-Vero S glycoproteins that may play a role in further adapting the virus for 
growth on Vero cells (Figure 4.9).   
 
The M41-S-BeauR-Hep P3-Vero and P7-Vero isolates formed syncytia in Vero cell 
culture (Figure 4.8).  Yamada and Liu, (2009) suggested that the putative HSBS 
found in the Beau-R S glycoprotein might not be involved in heparan sulphate 
binding at all; rather this site might be used as a second furin-cleavage site and be 
concerned with syncytium formation.  While this could explain the ability of M41-S-
BeauR-Hep to form syncytia in Vero cell culture, it does not explain why Beau-R 
cannot.  It is possible that the M41 S glycoprotein is already fusogenic however, as 
M41 is unable to grow in Vero cells, this is unknown.   
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In depth analysis of the growth kinetics of BeauR-S-M41-Hep and M41-S-BeauR-
Hep P3-CKC isolates on Vero and BHK-21 cells was carried out by growth curves 
(Figures 4.15 and 4.16).  Unlike on CK cells (Figure 4.14), titres did not peak at 48 
hours post-infection, rather continued to increase until the last time point at 72 hours 
post-infection.  Beau-R grew to the highest titre on Vero cells, followed by M41-S-
BeauR-Hep.  Although the peak titre of M41-S-BeauR-Hep on Vero cells was lower 
than that of Beau-R, it must be remembered that this was the first time that the P3-
CKC isolate had been grown on Vero cells.  Further passage of M41-S-BeauR-Hep 
isolates on Vero cells increased their titres to similar levels to that of Beau-R (Table 
4.1).  It is possible that growth curves carried out with a Vero-passaged isolate rather 
than a P3-CKC isolate would be closer to those of Beau-R on Vero cells. 
 
As expected from the analysis of the growth phenotypes by confocal microscopy, 
BeauR-S-M41-Hep replicated very poorly on Vero cells and followed a similar 
growth curve to M41-CK and BeauR-M41(S) (Figure 4.15).   On BHK-21 cells 
however, BeauR-S-M41-Hep replicated well and reached a high titre, second only to 
Beau-R.  In contrast to growth on Vero cells, M41-S-BeauR-Hep replicated less well 
than BeauR-S-M41-Hep on BHK-21 cells.  The highest titre of M41-S-BeauR-Hep 
was not significantly greater than that of BeauR-M41(S) (Figure 4.16).   
 
Removing the Beaudette-specific motif from Beau-R completely eliminated the 
virus’ ability to grow on Vero cells.  This result differs from the study by Yamada 
and Liu, (2009), which claimed that the extended cell-tropism of Beau-R is not due 
to the HSBS, as a mutant virus with this site removed was still able to grow in Vero 
cells.  In fact, Yamada and Liu, (2009) rule out the possibility that Beau-R may 
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utilise heparan sulphate as an entry receptor.  This is in conflict with work by Madu 
et al., (2007) who used soluble heparin and mutant cell lines with no heparan 
sulphate expression to show that heparan sulphate is used as an attachment factor for 
the Beaudette strain of IBV on Vero cells.   
 
While it appears clear that the Beaudette-specific motif plays a role in the ability of 
Beau-R to grow on Vero cells, it may not be involved in the entire extended host 
range of Beau-R.  Removal of the Beaudette-specific motif from the Beau-R S 
glycoprotein had a much more subtle effect on the ability to grow on BHK-21 cells.  
Replication of BeauR-S-M41-Hep on BHK-21 cells was reduced in comparison to 
Beau-R but not abolished.  Introduction of the Beaudette-specific motif from Beau-R 
into BeauR-M41(S) allowed the virus to grow on Vero cells but did not improve the 
virus’ ability to grow on BHK-21 cells.  It would be interesting to passage the 
recombinant viruses BeauR-S-M41-Hep and M41-S-BeauR-Hep on BHK-21 cells to 
assess whether virus replication could be maintained.   
 
It seems that additional factors may play a role in the ability of Beau-R to grow on 
both Vero and BHK-21 cells.  There are a total of nineteen amino acid differences in 
the S2 subunits of Beau-R and M41 (Figure 4.1).  Only three of these are included in 
the Beaudette-specific motif and were swapped between Beau-R and BeauR-M41(S) 
to create the recombinant viruses BeauR-S-M41-Hep and M41-S-BeauR-Hep.  Any 
of the other amino acid differences may be involved in the ability of Beau-R to grow 




There is one other amino acid change from asparagine to threonine between the 
M41-CK and Beau-R S glycoproteins located close to the HSBS at position 683 that 
was not included in the swap to make recombinants BeauR-S-M41-Hep and M41-S-
BeauR-Hep.  It would be interesting to create two further recombinants including this 
amino acid change in the Beaudette-specific motif and find out whether this has any 
impact on the growth phenotype and kinetics of the new viruses when compared to 
BeauR-S-M41-Hep and M41-S-BeauR-Hep.   
 
Further work would be required in order to investigate the role of the HSBS in the 
extension of Beau-R cell tropism, whether it is involved in heparan sulphate binding 
or acts as a furin cleavage site. 
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Chapter 5:  Investigation into cell-to-cell fusion properties 
of the IBV Beau-R S glycoprotein 
 
Summary 
Although Beau-R is able to grow on Vero cells, it does not cause syncytia.  
Therefore, Beau-R was passaged on Vero cells in order to further adapt the strain for 
growth on this mammalian cell line.  Syncytia started to form after nine passages of 
Beau-R on Vero cells.  This new growth phenotype was initially identified by 
brightfield microscopy and subsequently by confocal microscopy using indirect 
immunofluorescence.  The P10 virus population was sequenced and deep amplicon 
sequencing was carried out using three Beau-R P10 isolates in order to compare the 
adapted Beau-R S gene sequences to the non-adapted Beau-R S gene sequences with 
the aim of determining which amino acids of the S glycoprotein are involved in cell-
cell fusion.  Sequence analysis showed that there were many amino acid differences 
however, few were shared between isolates.  This indicated that syncytia formation 
results from multiple amino acid changes and that no simple or common changes are 




Syncytia are formed by the fusion of cells to produce multinucleate giant cells.  This 
may be a normal physiological process, such as in placental development (West et 
al., 1995), or may be caused by certain viral infections e.g. human immunodeficiency 
virus (HIV; Sodroski et al., 1986) and respiratory syncytia virus, mediated by the F 
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glycoprotein (Kahn et al., 1999).  Viral fusion proteins are transported to the cell 
surface of infected cells and can bind to receptors on neighbouring cells, fusing the 
cell membranes to form multinucleate cells.  This allows infection of neighbouring 
cells without the release of infectious virions.   
 
In the case of HIV infection, HIV antigens are processed by infected T cells which 
insert gp120 into their cell surface.  Gp120 is then able to attach to CD4 on 
uninfected T cells and fuse the cells together to form syncytia.  One infected T cell is 
able to fuse with many uninfected T cells.  Fused cells lose immune function and 
quickly die due to compromised permeability of the plasma membrane or toxicity of 
viral replication (reviewed by Alimonti et al., 2003). 
 
A strain of IBV, Beau-US, was isolated at the Institute for Animal Health that is able 
to form syncytia in cell culture (Cavanagh et al., 1986).  IBV Beau-US is a Vero-
adapted isolate of Beau-CK and causes extensive syncytia.  A molecular clone of 
Beau-CK, Beau-R, is able to grow on Vero cells like Beau-CK but is unable to form 
syncytia in cell culture (Casais et al., 2001).  A comparison of the S gene sequences 
between Beau-US and Beau-R revealed just eight nucleotide differences, five of 
which are located in subunit S1 and three in subunit S2.  Of these nucleotide 
changes, six result in a change in amino acid sequence (Table 5.1; Casais et al., 
2001).   
 
In order to identify which amino acids on the S glycoprotein are involved in cell-cell 
fusion, Beau-R was serially passaged on Vero cells until the virus adapted to form 
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syncytia.  The adapted S glycoprotein genes were sequenced and compared to the 
original S gene sequence to identify amino acid changes.   
 
 











20421 T – C GCT – GCC None 
20480 G – A AGT – AAT S – N 
20731 T – A TTA – ATA L – I 
21403 T – A TCA – ACA S – T 
21711 G – A GTG – GTA None 
22252 G – A GGG – AGG G – R 
22415 A – C AAT – ACT N – T 
22612 T – A TTG – ATG L – M 
ORF 3a 23906 T – C TGT – TGC None 
ORF 3c (E) 24501 C – T CAA – TAA Q – STOP 
M gene 
24635 G – C AGT – ACT S – T 
24746 C – T GCA – GTA A – V 
Non-coding region 25227 C – T NA NA 
ORF 5a 25513 G – T AGA – ATA R – I 
N gene 27087 A – G GGA – GGG None 
 





Serial passage of Beau-R on Vero cells 
Vero cells in six-well plates were infected at ~100% confluency with Beau-R and the 
supernatant was harvested at 72 and 96 hours post-infection (two wells per time-
point, pooled) forming passage 1 (P1) virus.  Supernatant from both time points was 
used to infect fresh Vero cells and supernatant was harvested at 48 and 72 hours 
post-infection to form the next passage and repeated until P4 when the number of 
virus isolates reached sixteen.  From P5 onwards, supernatant was harvested at 48 
hours post-infection only (Figure 5.1). 
 
 
Figure 5.1.  The serial passage of Beau-R on Vero cells.  Confluent Vero cells in 
six-well plates were infected with Beau-R P0 and the supernatant was harvested at 72 
and 96 hours post-infection (hpi).  The supernatant was used to infect fresh Vero 
cells and supernatant was harvested at 48 and 72hpi until P4.  After this passage, the 
16 isolates were harvested at 48hpi only.  
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Photographs were taken of Beau-R P10-infected Vero cells by brightfield microscopy 
and confocal microscopy with indirect immunofluorescence.  RNA was extracted 
from all isolates at P10 and the S genes sequenced and compared to the non-adapted 
Beau-R sequence.   
 
Deep amplicon sequencing 
Three isolates of Beau-R P10, P10-4, 9 and 12, were selected for further investigation 
as they formed large numbers of syncytia in Vero cell culture.  Deep amplicon 
sequencing was carried out to identify changes in the S genes of individual viruses 
when compared to the parent S gene.   
 
RNA was extracted from each isolate using the Qiagen RNeasy Mini Kit 
(manufacturer’s protocol followed, described in Chapter 2 section: RNA-based 
methods) and reverse transcribed using Superscript III (Invitrogen, method described 
in Chapter 2, section: RNA-based methods).  Primers produced by Sigma were 
designed to cover the S gene in three overlapping sections of ~1250 – 1300bp each 
from nucleotide 20271, 97 bases upstream of the start of the S gene, to nucleotide 
23920, 64 bases downstream of the end of the S gene (Table 5.2).  The three sections 
were (1) 20271 – 21518 within the S1 subunit, (2) 21436 – 22700 over the S1/S2 
junction and (3) 22625 – 23920 within the S2 subunit. Sections 1 and 2 overlap by 82 
nucleotides and sections 2 and 3 overlap by 75 nucleotides (Figure 5.2).   
 
The S gene sections of each isolate were amplified by PCR using taq polymerase 
from Invitrogen to create single deoxyadenosine 3’ overhangs (manufacturer’s 
protocol followed, described in Chapter 2, section: DNA-based methods).  The PCR 
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products were cloned into pCR®4-TOPO®, which has single deoxythymidine 3’ T 
overhangs, using the TOPO TA Cloning® Kit for Sequencing (Invitrogen, 
manufacturer’s protocol followed) and 3µl was used to transform One Shot® Max 
Efficiency DH5α™-T1R competent E. coli (Invitrogen, manufacturer’s protocol 
followed).  Aliquots of transformation mixture were spread onto LB agar plates 
containing 100µg/ml ampicillin for selection and incubated overnight at 37°C.  
Colonies were picked and inoculated into 3ml LB medium containing 100µg/ml 
ampicillin.  Cultures were incubated on a shaker at 37°C overnight then plasmid 
DNA was extracted using a Qiagen Miniprep DNA extraction kit (manufacturer’s 
protocol followed).  Plasmids were digested with EcoR1 (New England 
Biosciences), restriction sites located either side of the insert, to identify plasmids 
containing the S gene insert.  Samples containing the correct size insert were 
sequenced by the Sequencing Service at the University of Dundee.  Approximately 




Table 5.2.  Primers used for deep sequencing of Beau-R P10 isolates. 
Primer name Nucleotide position Nucleotide sequence 
DS1 20271 – 20291 TTGAGATTGAAAGCAACGCC 
DS2 21498 – 21518  ACACCTTTACACAGCGAAGG 
DS3 21436 – 21456  GGTTGCAAGCAATCTGTCTT 
DS4 22680 – 22700 TAGCCTGCAGTTGTGTGGCA 
DS5 22625 – 22645 CTCTAGTAGCTTCTATGGCT 







Figure 5.2.  Schematic diagram of the Beau-R S gene showing the amino acid 
differences between the Beau-R and Beau-US S genes (above) and the regions 
cloned for deep amplicon sequencing (below).  There are eight nucleotide 
differences between the S genes of Beau-R and Beau-US, six of which are coding.  
Three are located within Region 1 and three are located within Region 2.  None are 
located in Region 3.  The numbers refer to the S glycoprotein amino acids with 




Consensus sequences for each of the clones were obtained using the Staden package 
and these were aligned by ClustalX (Larkin et al., 2007).  The aligned consensus 
sequences were compared using Genedoc (Nicholas et al., 1997) and diagrams 
showing nucleotide and amino acid differences were generated using Base-by-Base 





Adaptation of Beau-R to syncytia formation on Vero cells 
Beau-R was successfully adapted to form syncytia in Vero cell culture by serial 
passage.  Twelve passages of Beau-R on Vero cells were carried out (Figure 5.1) and 
syncytia were observed by light microscopy in several isolates from P9 onwards.  
 
Brightfield microscopy of cpe caused by Beau-R P10 
Vero cells were infected with Beau-R P10 and photographs were taken 48 hours post-
infection (Figure 5.3).  Non-adapted Beau-R causes extensive cpe in Vero cell 
culture in the form of rounded and floating cells and ‘balloon’ formation.  Selected 




              
 
     
 
               
 
Figure 5.3. Brightfield microscopy of Beau-R P10-infected Vero cells.  Vero cells 
were infected with A. mock, B. Beau-R P0, C. Beau-US, D. Beau-R P10-4, E. Beau-R 
P10-9, F. Beau-R P10-12. Cytopathic effect in the form of balloons and rounded cells 
can be seen in all but the mock-infected cells.  Syncytia are indicated by arrows.  
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Confocal microscopy of Beau-R P11-infected Vero cells  
Confocal microscopy with indirect immunofluorescence was used to visualise the 
syncytia formed by Beau-R in greater detail.  All Beau-R P11 isolates were grown on 
Vero cells on coverslips.   Non-adapted Beau-R and Beau-US were also grown on 
Vero cells for comparison (Figure 5.4).  Infected cells were immunolabelled with 
rabbit anti-IBV, secondary antibody AlexaFluor 488 goat anti-rabbit (Invitrogen, 
green).  The endoplasmic reticulum (ER) was labelled with mouse anti-PDI, 
secondary antibody AlexaFluor 568 goat anti-mouse (Invitrogen, red).  Nuclei were 
labelled with DAPI (blue). 
 
Non-adapted Beau-R infected many Vero cells forming infectious centres, however 
all cells were separate from each other. Infected cells may be touching but the 
divisions between them can be clearly seen (Figure 5.5).  This is in contrast to the 
cells infected with Beau-US, most of which have been incorporated to form giant 
syncytia.  There are few uninfected cells.  No infected cells were observed in mock-
infected samples.   
 
Syncytia were observed in the cell cultures inoculated with Beau-R P11 isolates 
(Figure 5.5) but single infected cells were also seen, indicating the possibility of a 
mixed population of viruses present in the culture.   
  
Figure 5.4. Confocal microscopy of Beau-R P11 growth on Vero cells.  Vero cells 
infected with A. mock, B. Beau-R P0, C. Beau-US, D. Beau-R P11-4, E. Beau-R P11-
9, F. Beau-R P11-12. Infected cells were fixed 24 hours post-infection and 
immunolabelled with anti-IBV, secondary antibody AlexaFluor 488 goat anti-mouse 
(green).  ER was labelled with mouse anti-PDI, secondary antibody AlexaFluor 568 
goat anti-mouse (red).  Nuclei were labelled with DAPI (blue).  Images have been 
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Figure 5.5. Comparison of growth phenotypes of adapted and non-adapted 
Beau-R on Vero cells.  Vero cells infected with A. Beau-R P0, B. Beau-R P11-12 
(magnified from Figure 5.4 B and F). Infected cells were fixed 24 hours post-
infection and immunolabelled with anti-IBV, secondary antibody AlexaFluor 488 
goat anti-mouse (green).  ER was labelled with mouse anti-PDI, secondary antibody 
AlexaFluor 568 goat anti-mouse (red).  Nuclei were labelled with DAPI (blue).  
Individual cells infected with non-adapted Beau-R can clearly be observed in A, 
whereas cells infected with adapted Beau-R have fused to form a syncytium in B.    




Beau-R P10 sequence confirmation 
In order to confirm that the changes in growth phenotype were due to adaptation of 
Beau-R to Vero cell culture and not a contaminating virus, RNA was extracted from 
P10 virus supernatant and RT-PCR was carried out on each sample.  The region 
around nucleotide 19666 was amplified and sequenced (Figure 5.6).  Beau-R is the 
only strain of IBV to possess a thymine (T) at nucleotide position 19666 and this is 
used as a marker in order to identify Beau-R samples by sequencing (Casais et al., 
2001). It was found that all Beau-R P10 samples also possessed a T at position 19666, 
confirming that they were derived from Beau-R.  This means that any changes in 












Figure 5.6. Beau-R P10 nucleotide sequences from 19641 – 19667.  RNA was 
extracted from Beau-R P10 samples and RT-PCR was carried out to amplify the 
region around the marker nucleotide 19666 (red), which was then sequenced and 
compared to the parent Beau-R sequence.  Beau-R is the only strain of IBV to 
possess a thymidine (T) at position 19666. As all P10 samples also possess a T at 
19666, this confirms that they are derived from Beau-R and not contaminated with 
another strain of IBV.  The corresponding region of the Beau-CK, used to generate 
Beau-R, and Beau-US sequences are included to show that they contain a cytidine 
(C) residue at position 19666. 
 
                   
                                                19650                 19660                19670         
  Beau-CK  TACACAACTTTGTCAATACCTTTCGAAAACAACAA 
  Beau-US                   TACACAACTTTGTCAATACCTTTCGAAAACAACAA 
  Beau-R      TACACAACTTTGTCAATACCTTTTGAAAACAACAA 
  Beau-R P10-1  TACACAACTTTGTCAATACCTTTTGAAAACAACAA 
  Beau-R P10-2  TACACAACTTTGTCAATACCTTTTGAAAACAACAA 
  Beau-R P10-3  TACACAACTTTGTCAATACCTTTTGAAAACAACAA 
  Beau-R P10-4    TACACAACTTTGTCAATACCTTTTGAAAACAACAA 
  Beau-R P10-5  TACACAACTTTGTCAATACCTTTTGAAAACAACAA 
  Beau-R P10-6  TACACAACTTTGTCAATACCTTTTGAAAACAACAA 
  Beau-R P10-7  TACACAACTTTGTCAATACCTTTTGAAAACAACAA     
  Beau-R P10-8  TACACAACTTTGTCAATACCTTTTGAAAACAACAA 
  Beau-R P10-9  TACACAACTTTGTCAATACCTTTTGAAAACAACAA     
  Beau-R P10-10 TACACAACTTTGTCAATACCTTTTGAAAACAACAA 
  Beau-R P10-11 TACACAACTTTGTCAATACCTTTTGAAAACAACAA 
  Beau-R P10-12 TACACAACTTTGTCAATACCTTTTGAAAACAACAA 
  Beau-R P10-13 TACACAACTTTGTCAATACCTTTTGAAAACAACAA     
  Beau-R P10-14 TACACAACTTTGTCAATACCTTTTGAAAACAACAA     
  Beau-R P10-15 TACACAACTTTGTCAATACCTTTTGAAAACAACAA     
  Beau-R P10-16 TACACAACTTTGTCAATACCTTTTGAAAACAACAA     






Beau-R P10 population sequencing 
As not all Beau-R P11-infected cells appeared to form syncytia when viewed by 
brightfield and confocal microscopy with indirect immunofluorescence (Figures 5.3 
and 5.4), it was speculated that a mixed population of viruses might be present in the 
culture.  Total cellular RNA was extracted from the cell culture supernatant of each 
isolate at passage 10 and the S genes of the Beau-R population were sequenced to 
determine the sequences of the dominant strains present (Table 5.3).   
 
 
Table 5.3.  Location of nucleotide and amino acid differences between Beau-R 
















20422 19 G A V – I  
9 
22114 583 A T N – Y  
7 
22822 818 A T L – F  
7 
22862 832 C T L – F  
11, 14, 15, 16 
(10, 12, 13 mixed 
G/T) 
23323 986 G T A – S  








Sequence comparison between Beau-R and Beau-US 
In order to find out whether any of the amino acid changes identified in the 
population sequencing corresponded to the Beau-US sequence, a comparison of the S 
gene sequences of Beau-US and Beau-R, both non-adapted and the P10 population, 
was carried out.  None of the amino acid differences between non-adapted Beau-R 
and Beau-US corresponded to the differences found in the Beau-R P10 population 






Figure 5.7. Schematic diagram of the Beau-US and Beau-R P10 population S 
genes showing the amino acid differences with Beau-R.  There are eight 
nucleotide differences between the S genes of Beau-R and Beau-US, six of which are 
coding (top). Three are located in the S1 subunit and three are located in the S2 
subunit.  There are seven coding nucleotide differences between the Beau-R and the 
Beau-R P10 population S gene sequences (middle).  One is located in the S1 subunit 
and six are located in the S2 subunit. None of the amino acid differences correspond 
between Beau-US and Beau-R P10.  The numbers refer to the S glycoprotein amino 





Deep amplicon sequencing 
 
Three isolates of Beau-R P10 that formed the most syncytia in cell culture were 
chosen for deep amplicon sequencing in order to determine whether other amino acid 
changes may be identified that did not predominate in the consensus sequence.  
Sections of the S genes were amplified by PCR then cloned into TOPO vectors 
(Invitrogen) and 16 – 21 individual clones of each section were sequenced per isolate 
and compared to non-adapted Beau-R and Beau-US sequences.  Poor quality 
sequences were discarded.  This approach was designed to identify any nucleotide or 
amino acid changes that occurred in single clones, and to find out if any of these 
were shared by more than one clone.   
 
Region 1 nucleotide and amino acid changes 
Region one comprises the first 368 amino acids of the S1 subunit.  The clone 
numbers used in region 1 do not correspond to clone numbers from the same isolate 
in regions 2 or 3.  The distribution of nucleotide differences between the Beau-R P10 
isolates and clones is shown in Figure 5.8 and the distribution of amino acid 
differences is shown in Figure 5.9.  All differences appear to be evenly distributed 
throughout region one.  
  
Region one of Beau-R P10-4 contains 80 nucleotide changes, 44 of which are coding 
and two result in stop codons (Appendix, Table A.1).  There are two deletions, one 
results in a stop codon and the other results in non-homologous sequence.   Two 
nucleotide substitutions are shared by two different clones each, only one is coding.  
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Region one of Beau-R P10-9 contains 22 nucleotide changes, 14 of which are coding 
(Appendix, Table A.2).  There are approximately 80 amino acids deleted from the 
start of isolate 8 in this region due to a mutated start codon at nucleotide position 
20370.  The protein starts at the second start codon.  None of the mutations are 
shared by more than one clone.   
 
Region one of Beau-R P10-12 contains 41 nucleotide changes, 23 of which are coding 
(Appendix, Table A.3).  There is one deletion resulting in a stop codon.  Five 
nucleotide substitutions are shared by more than one clone, two of which are coding.   
 
There is one nucleotide substitution shared between clones of different isolates.  
Clone 1 of Beau-R P10-9 and clone 33 of Beau-R P10-4 have a mutation from T – C at 
nucleotide position 20883, which is not coding.   
 
One nucleotide substitution (G – A) identified in Beau-R P10 isolate 12 by population 
sequencing (Table 5.3) was also identified in Beau-R P10-12 clones 2, 10, 38, 39 and 
54 at nucleotide position 20422.  This resulted in an amino acid mutation at position 
19 of valine to isoleucine.  No differences between non-adapted and adapted Beau-R 
were also shared with Beau-US, although the nucleotide substitution at position 
20422 in Beau-R P10-12 isolates 2, 10, 38, 39 and 54 is only one nucleotide 
downstream of the silent mutation T – C found in Beau-US. 
   
Figure 5.8. Nucleotide differences for all Beau-R P10 region 1 isolates and clones 
and Beau-US, compared to parent Beau-R sequence.  A. Beau-R P10 isolate 4 
clones, B. Beau-R P10 isolate 9 clones, C. Beau-R P10 isolate 12 clones.   
Substitutions are shown by a blue line and deletions are shown in red.  Nucleotide 
positions are indicated by numbers underneath.  Diagrams were generated using 
Base-by-base (Brodie et al., 2004) following alignment of individual clone 




A. Beau-R P10-4 region 1 
 
B. Beau-R P10-9 region 1 
 
C. Beau-R P10-12 region 1 
 
  
Figure 5.9. Amino acid differences for all Beau-R P10 region 1 isolates and 
clones and Beau-US, compared to parent Beau-R sequence.  A. Beau-R P10 
isolate 4 clones, B. Beau-R P10 isolate 9 clones, C. Beau-R P10 isolate 12 clones.   
Substitutions are shown by a blue line and deletions are shown in red.  Amino acid 
positions are indicated by numbers underneath.  Deletions indicated here are either 
due to a nucleotide substitution in the sequence resulting in termination of the amino 
acid sequence or loss of a nucleotide resulting in loss of the amino acid sequence.  
The deletions are not large nucleotide deletions, as per Figure 5.8.  Diagrams were 
generated using Base-by-base (Brodie et al., 2004) following alignment of individual 
clone sequences as described in the methods section.   
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A. Beau-R P10-4 region 1 
 
B. Beau-R P10-9 region 1 
 
 





Region 2 nucleotide and amino acid changes 
Region two spans the S1/S2 junction and the heparan sulphate binding site (HSBS) 
of Beau-R (Chapter 4, Figure 4.1) and comprises amino acids 367 – 777.  The clone 
numbers used in region 2 do not correspond to clone numbers from the same isolate 
in regions 1 or 3.  The distribution of nucleotide differences between the Beau-R P10 
isolates and clones is shown in Figure 5.10 and the distribution of amino acid 
differences is shown in Figure 5.11.  
 
Region two of Beau-R P10-4 contains eight nucleotide substitutions, none of which 
are coding (Appendix, Table A.4).  There are no deletions.  One nucleotide 
substitution is shared between two clones. 
 
There are ten nucleotide differences in Beau-R P10-9 region two, six of which are 
coding (Appendix, Table A.5).  One nucleotide change A – T identified by 
population sequencing also occurs in Beau-R P10-9 clones 17, 18, 19 and 20 at 
nucleotide position 22114.  This results in an amino acid change of asparagine – 
tyrosine at amino acid position 583.  There are no deletions. 
 
Beau-R P10-12 region two contains 14 nucleotide differences, six of which result in 
coding changes (Appendix, Table A.6).  One substitution is shared between two 
clones but is not coding.  Three clones share a deletion of three nucleotides resulting 




No changes are shared between isolates.  Mutations appear to be clustered around the 
centre of the region, the S1/S2 junction (Figures 5.10 and 5.11).  No mutations occur 
in the HSBS although there is a mutation from proline to serine immediately 
upstream at amino acid position 684 in Beau-R P10-9 clone 17.  This is adjacent to a 
mutation in Beau-US from asparagine to threonine at amino acid position 683.   
  
Figure 5.10. Nucleotide differences for all Beau-R P10 region 2 isolates and 
clones and Beau-US, compared to parent Beau-R sequence.  A. Beau-R P10 
isolate 4 clones, B. Beau-R P10 isolate 9 clones, C. Beau-R P10 isolate 12 clones.   
Substitutions are shown by a blue line and deletions are shown in red.  Nucleotide 
positions are indicated by numbers underneath.  Diagrams were generated using 
Base-by-base (Brodie et al., 2004) following alignment of individual clone 
sequences as described in the methods section.   
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A.  Beau-R P10-4 region 2 
 
 
B. Beau-R P10-9 region 2 
 




Figure 5.11. Amino acid differences for all Beau-R P10 region 2 isolates and 
clones and Beau-US, compared to parent Beau-R sequence.  A. Beau-R P10 
isolate 4 clones, B. Beau-R P10 isolate 9 clones, C. Beau-R P10 isolate 12 clones.   
Substitutions are shown by a blue line and deletions are shown in red.  Amino acid 
positions are indicated by numbers underneath.  Diagrams were generated using 
Base-by-base (Brodie et al., 2004) following alignment of individual clone 
sequences as described in the methods section.   
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A. Beau-R P10-4 region 2  
 













Region 3 nucleotide and amino acid changes 
Region three comprises the end of the S2 subunit from amino acid 776. The clone 
numbers used in region 3 do not correspond to clone numbers from the same isolate 
in regions 1 or 2.  The distribution of nucleotide differences between the Beau-R P10 
isolates and clones is shown in Figure 5.12 and the distribution of amino acid 
differences is shown in Figure 5.13. The nucleotide and amino acid differences 
appear to be evenly spread throughout. 
 
There are 21 nucleotide differences in Beau-R P10-4 region three, 12 of which are 
coding (Appendix, Table A.7).  One nucleotide substitution is shared between two 
clones, however this is not coding.  There are no deletions.  One area of nucleotide 
change results in non-homologous sequence.   
 
Beau-R P10-9 region three contains 30 nucleotide differences, 22 are coding 
(Appendix, Table A.8).  Two result in a stop codon and one results in non-
homologous sequence.  There are no deletions.  One nucleotide substitution at 
position 23325 is shared by two clones and results in an amino acid change of 
alanine – serine at position 986.    
 
Region three of Beau-R P10-12 contains 38 nucleotide differences, including three 
deletions (Appendix, Table A.9).  Twenty-four of the nucleotide substitutions are 
coding and one results in a stop codon.  Three substitutions are shared between more 
than one clone.  The first is shared by clones 1 and 12 and results in an amino acid 
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change of alanine – serine at position 986.  The second is shared by nine clones and 
results in an amino acid change of threonine – isoleucine at position 1004.  The last 
is shared by clones 6 and 7; clone 6 has a nucleotide substitution of T – C and results 
in an amino acid change of isoleucine – threonine and clone 7 has a nucleotide 
substitution of T – G and results in an amino acid change of isoleucine – serine, both 
at position 1090.  Clone 3 has a series of nucleotide substitutions and insertions and 
results in amino acid changes of IRVS – ARKCS from position 889.   
 
Beau-R P10-4 clone 16 and Beau-R P10-9 clone 11 share a nucleotide substitution of 
C – T resulting in an amino acid change of serine to phenylalanine at position 1005.  
Beau-R P10-4 clone 1 and Beau-R P10-12 clone 16 share a non-coding nucleotide 
substitution at amino acid position 922.  Clone 16 of Beau-R P10-4 and clone 7 of 
Beau-R P10-9 share a series of nucleotide substitutions and insertions from amino 
acid position 962 resulting in non-homologous sequence.  Clone 14 of Beau-R P10-9 
and clone 7 of Beau-R P10-12 share a nucleotide substitution of T – C that results in 
an amino acid change of isoleucine – threonine at position 1090.  Clone 6 of Beau-R 
P10-12 also has a nucleotide substitution at this position that results in a serine 
residue.   
 
A number of differences identified within region three by population sequencing 
(Table 5.3) were also identified as occurring in at least one clone by deep 
sequencing.  The G – T substitution identified in Beau-R P10 isolates 11, 14, 15, 16 
and as a mixed population in isolates 10, 12 and 13 was also identified in Beau-R P10-
-9 clones 11 and 13 and Beau-R P10-12 clones 1 and 12 and resulted in an amino acid 
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change of alanine – serine at position 986.  Nine different clones of Beau-R P10-12 
share the nucleotide substitution C – T resulting in a threonine – isoleucine change at 
position 1004 identified in Beau-R P10-12 by population sequencing. 
 
  
Figure 5.12. Nucleotide differences for all Beau-R P10 region 3 isolates and 
clones and Beau-US, compared to parent Beau-R sequence.  A. Beau-R P10 
isolate 4 clones, B. Beau-R P10 isolate 9 clones, C. Beau-R P10 isolate 12 clones.   
Nucleotide substitutions are shown by a blue line, deletions are shown in red and 
insertions are shown in green.  Nucleotide positions are indicated by numbers 
underneath.  Diagrams were generated using Base-by-base (Brodie et al., 2004) 
following alignment of individual clone sequences as described in the methods 
section.   
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A. Beau-R P10-4 region 3  
 
B. Beau-R P10-9 region 3 
 
C. Beau-R P10-12 region 3 
 
  
Figure 5.13. Amino acid differences for all Beau-R P10 region 3 isolates and 
clones and Beau-US, compared to parent Beau-R sequence.  A. Beau-R P10 
isolate 4 clones, B. Beau-R P10 isolate 9 clones, C. Beau-R P10 isolate 12 clones.   
Nucleotide substitutions are shown by a blue line and deletions are shown in red.  
Amino acid positions are indicated by numbers underneath.  Deletions indicated here 
are either due to a nucleotide substitution in the sequence resulting in termination of 
the amino acid sequence or loss of a nucleotide resulting in loss of the amino acid 
sequence.  The deletions are not large nucleotide deletions, as per Figure 5.12.  
Diagrams were generated using Base-by-base (Brodie et al., 2004) following 
alignment of individual clone sequences as described in the methods section.   
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A. Beau-R P10-4 region 3 
 
B. Beau-R P10-9 region 3 
 




Consensus nucleotide and amino acid sequences 
Consensus sequences for each Beau-R P10 isolate were constructed using the clone 
sequences and compared to the non-adapted Beau-R and Beau-US sequences 
(Figures 5.14 and 5.15).  Each Beau-R P10 isolate consensus nucleotide sequence has 
two changes, none are shared between isolates and all are coding.  One of the 
nucleotide differences in the Beau-R P10-12 consensus is adjacent to a silent mutation 
in the Beau-US sequence, however none of the coding changes are shared between 
the adapted Beau-R isolates and Beau-US.  Only one of the nucleotide and amino 
acid differences in the adapted Beau-R isolates is located in the S1 subunit.  The 
other nucleotide and amino acid differences are fairly evenly distributed throughout 
the S2 subunit.     
 






Figure 6.14. Consensus nucleotide sequences for all Beau-R P10 isolates, 
compared to parent Beau-R and Beau-US sequences.  Substitutions are shown by 
a blue line.  Nucleotide positions are indicated by numbers underneath.  Diagrams 
were generated using Base-by-base (Brodie et al., 2004) following alignment of 







Figure 6.15. Consensus amino acid sequences for all Beau-R P10 isolates, 
compared to parent Beau-R and Beau-US sequences.  Substitutions are shown by 
a blue line.  Amino acid positions are indicated by numbers underneath.  Diagrams 
were generated using Base-by-base (Brodie et al., 2004) following alignment of 








Beau-R was successfully adapted to form syncytia in Vero cell culture after nine 
passages.  The P10 virus population was sequenced and seven coding nucleotide 
substitutions were identified (Table 5.3).  One substitution occurred in the S1 subunit 
and six occurred in the S2 subunit.  None corresponded to any of the differences 
between non-adapted Beau-R and Beau-US.  It is likely however, that a mixed 
population of viruses was present in cell culture as not every infected cell formed 
syncytia as observed by confocal microscopy with indirect immunofluorescence 
(Figure 5.4).   
 
Deep amplicon sequencing was carried out on three Beau-R P10 isolates, 4, 9 and 12 
(Figures 5.8 – 5.13 and Appendix, Tables A.1 – A.9).  Of the six differences 
identified between the Beau-R P10 population and non-adapted Beau-R, four were 
also identified by deep sequencing.  The other two differences were identified in 
Beau-R P10-7, which was not deep sequenced.   
 
A total of 265 nucleotide substitutions were identified across the Beau-R P10 S genes 
by deep sequencing, 79 of which were shared by more than one clone.  Only 151 of 
the substitutions were coding, there were also nine nucleotide deletions and 3 
insertions.  As it is the S2 subunit that is involved in fusion, it was anticipated that 
this region might contain the most differences; however, this was not found to be the 
case.  Region two covering the S1/S2 junction had by far the fewest differences with 
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only twelve coding nucleotide substitutions identified; region one in the S1 subunit 
had the most with 81, while region three in the S2 subunit had 58.   
 
One amino acid change of interest from proline to serine in Beau-R P10-9 clone 17 
region 2 occurs immediately upstream of the HSBS, adjacent to a mutation in Beau-
US from asparagine to threonine at amino acid position 683.  This amino acid has 
been previously implicated in syncytium formation by Yamada et al., (2009), 
however they were unable to prove its involvement.    As this mutation is only found 
in one clone and was not identified in the population sequencing, it is unlikely to be 
involved in the acquisition of syncytium formation in this case.  No other mutations 
found in Beau-US were identified in Beau-R P10. 
 
A study by Yamada et al., (2009) indicated that a single point mutation from leucine 
to phenylalanine at amino acid position 857 is responsible for the acquisition of cell-
cell fusion activity in the IBV Beaudette spike.  Site-directed mutagenesis was used 
to create S gene constructs containing the L857F mutation and these were expressed 
in Vero cells.  The S glycoprotein containing the L857F mutation was able to induce 
syncytia formation, whereas the wild-type S glycoprotein could not.  A reverse 
genetics system was used to introduce the L857F mutation into the IBV genome, 
enabling the recombinant virus to form syncytia.  Further point mutations at positions 
523 (glutamine – leucine) or 769 (isoleucine – valine) were sufficient to restore the 
cell-cell fusion activity to an rIBV containing an F857L mutation.  Yamada et al., 
(2009) also identified a further point mutation from glycine to aspartic acid at 
position 405 that was shown to enhance the cell-cell fusion activity.   
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Our laboratory isolate of Beaudette contains the phenylalanine at amino acid position 
857 identified by Yamada et al., (2009) as being responsible for acquisition of cell-
cell fusion, although it does not form syncytia.  It is unlikely that this amino acid is 
involved in syncytium formation by our laboratory isolate of Beaudette according to 
this study.  None of the other amino acids involved in syncytia formation identified 
by Yamada et al., (2009) have been found to correspond to changes in Beau-R P10 in 
this study.   
 
The adaptation of BeauR-M41(S1) P7-Vero to syncytia formation on Vero cells is 
described in Chapter 3 and the S genes of both isolates were sequenced  (Figure 
3.13).  Interestingly, one of the amino acid changes identified in the BeauR-M41(S1) 
P7-Vero isolate 2 S glycoprotein sequence corresponds to a change of threonine to 
isoleucine at position 1004 identified by Beau-R P10  population sequencing.  This 
change was also identified by deep sequencing in nine clones of isolate 12 region 
three (Appendix, Table A.9).  None of the amino acid changes identified in the M41-
S-BeauR-Hep P7-Vero isolates correspond to any changes identified in Beau-R P10 or 
BeauR-M41(S1) P7-Vero isolates. 
 
One limitation of this deep sequencing approach is that the whole S gene from 
different clones cannot be analysed, as clones from different regions do not 
correspond to each other.  It would be interesting to be able to observe whether any 
changes in one region of the S gene are concurrent with other changes in different 
regions.  Some nucleotide differences observed may be the result of PCR error, 
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especially those deletions resulting in non-homologous sequence or stop codons as 
they are unlikely to encode S glycoproteins present in viable virions. 
 
In order to further investigate the effect of amino acid changes on cell-cell fusion, 
two approaches could be utilised.  Site-directed mutagenesis coupled with the IBV 
reverse genetics system could be used to construct rIBVs expressing S glycoproteins 
containing combinations of the amino acid differences identified in this study and the 
growth phenotypes and kinetics of the resulting viruses could be analysed.  
Alternatively, modified S glycoproteins could be expressed on the cell-surface of 
Vero cells in order to observe whether they fuse to form syncytia.  One drawback of 
this method is that the IBV S glycoprotein is not translocated to the cell surface 
efficiently due to the presence of an ER retention signal (Youn et al., 2005) and 
transport of spikes not incorporated into virions through the Golgi is very slow 
(Vennema et al., 1990).  
 
As most of the differences between non-adapted Beau-R and Beau-R P10 isolates 
occur in just one clone and none are shared by more than nine out of a total of 140 
clones sequenced, it seems likely that the acquisition of syncytium formation ability 
is a complex process, possibly involving a range of mutations.  The structure of the 
IBV S glycoprotein is not currently known so it is only possible to speculate as to 
which areas of the spike might interact.  It is feasible that areas involved in cell-cell 









While the IBV strain Beau-R is able to replicate in Vero and BHK-21 cell lines as 
well as primary chicken cells, the IBV M41 strain is only able to replicate in primary 
cells.  Casais et al., (2003) determined that cellular tropism is conferred by the S 
glycoprotein by creating an rIBV with the M41 spike in the genomic background of 
Beau-R that has the cellular tropism of M41.  The first objective of this study was to 
determine which part of the S glycoprotein is responsible for the extended host range 
of Beau-R.   
 
The first step on the road to achieving this was to passage rIBV BeauR-M41(S) on 
Vero cells with the intention to adapt the virus to replication on Vero cells and 
identify any amino acid changes within the S glycoprotein.  Despite several attempts, 
the adaptation of BeauR-M41(S) to growth on Vero cells was unsuccessful.   
 
The second approach was to create two rIBVs with chimaeric S genes in the genomic 
background of Beau-R with either the S1 or S2 subunit from M41 using the IBV 
reverse genetics system.  This was successful and the two resulting rIBVs, BeauR-
M41(S1) and BeauR-M41(S2), were able to replicate as well as the parent viruses on 




As the S1 subunit is responsible for receptor binding, it was anticipated that this 
subunit would be responsible for the ability of Beau-R to replicate in Vero and BHK-
21 cells rather than the S2 subunit, which is involved in virus-to-cell and cell-to-cell 
fusion.  A previous study has mapped the extended host range of a variant of MHV 
to the S1 subunit (Schickli et al., 2004).  Surprisingly, it was determined that the 
ability to replicate in Vero and BHK-21 cells was conferred by the Beaudette S2 
subunit, not the S1 subunit, although BeauR-M41(S1) did not replicate to as high a 
titre on Vero or BHK-21 cells as Beau-R (Chapter 3, Figures 3.21 – 22).  Seven 
passages of BeauR-M41(S1) on Vero cells increased the titre (Chapter 3, Table 3.1) 
and resulted in a number of amino acid changes which may improve growth on the 
cell line (Chapter 3, Figure 3.13) .  
 
In order to further investigate the role of the S2 subunit in determining cellular 
tropism, a sequence comparison was carried out between Beau-R and M41 to 
identify potential amino acid differences within the S2 subunit that could be involved 
(Chapter 4, Figure 4.1).  Three amino acid changes were identified in close proximity 
to each other and were named the Beaudette-specific motif.  Part of this motif has 
also been noted by other groups as being a putative heparan sulphate binding site 
(Madu et al., 2007) or a potential furin cleavage site (Yamada and Liu, 2009).    
 
Madu et al., (2007) carried out bioinformatic analysis of the S glycoproteins of 
different strains of IBV and identified a putative heparan sulphate binding consensus 
sequence within the S2 subunit of the Beaudette S glycoprotein.  This was not 
present in the thirteen other strains of IBV analysed.  Infection of CK and BHK-21 
cells by Beaudette was shown to be inhibited by soluble heparin and infection of 
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heparan sulphate-deficient cells by Beaudette was restricted.  M41 infection was 
unaffected by the presence or absence of heparin, however infection of CK cells by 
both Beaudette and M41 strains was inhibited by neuraminidase treatment.  These 
results indicate that sialic acid is an attachment factor for both Beaudette and M41 
strains of IBV, however only Beaudette is able to utilise heparan sulphate as a 
selective attachment factor.  The putative heparan sulphate binding consensus 
sequence identified within the S2 subunit of the Beaudette S glycoprotein forms part 
of the Beaudette-specific motif investigated by this study.   
 
Yamada and Liu, (2009) suggested that a second furin cleavage site may be located 
within the putative heparan sulphate binding consensus sequence of the IBV 
Beaudette strain identified by Madu et al., (2007).  This XXXR/S motif was shown 
to be conserved between different coronavirus species.  Vero cells were infected with 
rIBVs with Flag-tagged S glycoproteins to demonstrate that the Beaudette spike is 
cleaved at two furin sites, the S1/S2 junction and the XXXR/S motif within the S2 
subunit.  Point mutations introduced into the potential furin cleavage site within the 
S2 subunit resulted in loss of cleavage and loss of cell-to-cell fusion in the absence of 
trypsin when the mutated spikes were expressed in HuH-7 and Vero cells 
respectively.   Yamada and Liu, (2009) stated that the extended host range of 
Beaudette is not due to the presence of the second furin site and that Beaudette does 
not utilise heparan sulphate as an attachment factor, although no data is shown to 
support this. 
 
Another coronavirus with extended host range has been identified as using heparan 
sulphate as an entry receptor (de Haan et al., 2005).  The MHV-A59 strain was 
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serially passaged in vitro to produce a new variant, MHV/BHK, which was 
demonstrated to have an extended host range (Schickli et al., 1997).  Comparison of 
the S gene sequences of MHV-A59 and MHV/BHK revealed that the S gene of 
MHV/BHK has 56 amino acid substitutions and a seven amino acid insert (Schickli 
et al., 2004), of which only 22 amino acid substitutions and the seven amino acid 
insert are required for host range extension (Thackray and Holmes, 2004).  The 
extended host range of the MHV/BHK S glycoprotein was further investigated by de 
Haan et al., (2005), who identified two putative heparan sulphate binding sites not 
present in MHV-A59.  The predicted furin cleavage site between the S1 and S2 
subunits also corresponded to a novel heparan sulphate binding site.  This did not 
interfere with the furin consensus sequence, although the S glycoprotein of 
MHV/BHK was no longer cleaved at this site.  Infectivity of a recombinant MHV 
expressing the MHV/BHK spike was reduced in the presence of heparin and after 
heparinase treatment of cells whereas infectivity of a recombinant MHV expressing 
the A59 spike was unaffected, indicating that heparan sulphate binding is involved in 
the extended host range of MHV/BHK.   
 
In a study of FCoV strains with varying host range, heparan sulphate binding motifs 
were also identified at the S1-S2 boundaries (de Haan et al., 2008).  Strain UCD of 
FCoV, which is unable to grow in cell culture, did not bind heparin but was cleaved 
at the S1/S2 junction.  Strain UCD1 of FCoV, which was adapted for cell culture and 
has an extended host range, did bind heparin but was not cleaved at the S1/S2 
junction.  Trypsin treatment of the UCD1 spike resulted in cleavage although 
infectivity was reduced.  It appears that the heparan sulphate binding site only 
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functions as long as the spike is not cleaved and UCD1 has swapped cleavage for the 
ability to utilise heparan sulphate as an entry receptor.   
 
In order to investigate the role of the Beaudette-specific motif of the Beaudette S2 
subunit on the extended cellular tropism of Beau-R, two further rIBVs were created 
with chimaeric S genes in the genomic background of Beau-R (Chapter 4, Figure 
4.2).  The first rIBV, BeauR-S-M41-Hep, has the S gene from Beau-R but with the 
Beaudette-specific motif swapped for the corresponding sequence from M41.  The 
second rIBV, M41-S-BeauR-Hep, has the S glycoprotein from M41 with the 
Beaudette-specific motif from Beau-R.  Both recombinant viruses replicated as well 
as their parent viruses on CK cells (Chapter 4, Figure 4.14), and the Beaudette-
specific motif was found to be sufficient to confer the ability to grow on Vero cells to 
M41-S-BeauR-Hep (Chapter 4, Figure 4.15).  Replacement of the Beaudette-specific 
motif with the corresponding sequence from M41 in BeauR-S-M41-Hep resulted in 
the loss of ability to grow on Vero cells.  Seven passages of M41-S-BeauR-Hep on 
Vero cells increased the titre (Chapter 4, Table 4.1) and resulted in a number of 
amino acid changes which may improve growth on the cell line (Chapter 4, Figure 
4.9).  
 
Although there is a clear indication of the involvement of the Beaudette-specific 
motif in the ability of Beau-R to replicate on Vero cells, it doesn’t appear to affect 
growth on BHK-21 cells in the same way (Chapter 4, Figure 4.16).  While M41-S-
BeauR-Hep and BeauR-M41(S2) replicated poorly on BHK-21 cells, BeauR-S-M41-
Hep replicated well and achieved a peak titre of over two log greater than that of 
BeauR-M41(S1).  This indicates that the Beaudette-specific motif may not be the 
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only region of the Beau-R S glycoprotein that is responsible for the extended host 
range of Beau-R in mammalian cells other than Vero cells.    
 
Several other coronaviruses have been studied with an expanded cellular tropism.  
The ability to infect macrophages is a virulence factor for FCoV pathogenesis.  A 
strain of FCoV unable to infect macrophages causes mild enteritis in cats whereas a 
strain of FCoV that is able to infect macrophages causes fatal peritonitis.  The ability 
to infect macrophages was mapped to the C-terminal region of the S glycoprotein, 
suggesting a role for fusion in host range expansion (Rottier et al., 2005).     
 
McRoy and Baric, (2008) studied another strain of MHV, V51, with extended host 
range and determined that the amino acid changes within the S2 subunit, specifically 
within and adjacent to the HR1 domain, were exclusively responsible for the 
determination of cellular tropism.  No heparan sulphate binding sites were identified 
with the MHV-V51 S glycoprotein and the virus infected both cells expressing 
heparan sulphate and those that did not with a similar infectivity.  It was postulated 
that the extended host range of MHV-V51 may be due to changes in the class I 
fusion mechanism conferred by the alterations in the S2 subunit.      
 
A similar observation has been made in a study of the tropism of an avian retrovirus 
(Rainey et al., 2003).  Avian sarcoma-leukosis virus (ASLV) has a class I fusion 
protein with a similar structure to those of the coronavirinae with SU and TM 
subunits corresponding to S1 and S2 subunits.  The extended host range of an ASLV 
strain was mapped to a single amino acid substitution in the HR1 domain.  The 
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involvement of the HR1 domain of ASLV in host range expansion was confirmed by 
Amberg et al., (2006). 
 
A study by de Haan et al., (2006) discovered that mutations in both the S1 and the S2 
subunits are required for the extended host range of the A59 strain of MHV.  As the 
structure of the IBV S glycoprotein has yet to be established, it is possible that 
regions far apart in the sequence may interact to extend the host range of Beau-R.   
 
The second objective of this study was to identify the regions of the S glycoprotein 
that are involved in cell-to-cell fusion.  In order to achieve this, Beau-R was adapted 
to form syncytia in Vero cell culture (Chapter 5, Figure 5.1).  Beau-R is an rIBV 
derived from the Beaudette-CK strain of IBV.  Beaudette-CK is a virus that has been 
adapted to grow on CK cells and has the ability, like all Beaudette-derived strains of 
IBV, to grow on Vero cells but does not cause syncytia formation without further 
adaptation to replication on Vero cells.  Beau-R, like Beaudette-CK, was found to 
grow on Vero cells but not to cause syncytia (Casais et al., 2001).    
 
The Beau-R P10 population S gene was sequenced (Chapter 5, Figure 5.7) and deep 
amplicon sequencing was used to determine the S gene sequences of individual 
Beau-R P10 clones (Chapter 5, Figures 5.8 – 13).  These were compared to the S gene 
sequences of non-adapted Beau-R and Beau-US, a strain of IBV that already forms 
syncytia in cell culture.  Although numerous amino acid changes were identified, few 
were shared between Beau-R P10 clones and no specific areas appeared to be 
adapted.  It appears that cell-to-cell fusion may be a complex process, possibly 
involving distinct regions of the IBV S glycoprotein. 
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Other studies have attempted to elucidate the region of the IBV S glycoprotein 
involved in cell-to-cell fusion.  Yamada et al., (2009) used site-directed mutagenesis 
to produce S gene constructs to investigate the induction of fusion by different 
isolates of IBV Beaudette.  Beaudette was previously adapted to growth on Vero 
cells by Fang et al., (2005), resulting in 26 amino acid substitutions in the S 
glycoprotein.  Yamada et al., (2009) cloned the S genes from several isolates of the 
Vero-adapted Beaudette strain and found upon expression that all except the original 
egg-derived isolate induced syncytia formation.  One point mutation within HR1, 
L857F, was found to be responsible for the acquisition of cell-to-cell fusion activity 
in the Vero-adapted isolates.  Introduction of the L857F mutation into the spike of 
the Beaudette egg-derived isolate by site directed mutagenesis conferred fusogenicity 
and reversion of the mutation (F857L) in a Vero-adapted isolate abolished the fusion 
activity.  Recombinant IBVs were produced using an IBV reverse genetics system 
and the F857L mutation was introduced to the Vero-adapted isolate.  This 
recombinant was not fusogenic, however, two compensatory mutations, Q523L and 
I769V, were sufficient for restoration of cell-to-cell fusion to occur.  When these 
mutations were in turn introduced into the spike of the Beaudette egg-derived isolate, 
both induced cell-to-cell fusion.  A further amino acid substitution, G405D, was 
implicated in enhancement of cell-to-cell fusion; when this mutation was introduced 
into the spike of the Beaudette egg-derived isolate, syncytia formation was also 
induced.  The study was unable to pinpoint the definitive region of the IBV S 
glycoprotein that is responsible for the induction of cell-to-cell fusion.   
 
The laboratory isolates of Beaudette utilised by the present study, Beaudette-CK and 
its derivative Beau-R, contain the L857F mutation identified by Yamada et al., 
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(2009) as being responsible for syncytia formation; however these isolates are unable 
to induce cell-to-cell fusion.  This supports the conclusion that it is likely that the 
induction of cell-to-cell fusion by the IBV S glycoprotein is a complex process, 
possibly involving several different regions of the spike. 
 
The ability to form syncytia by the MHV S glycoprotein has been mapped to several 
different regions including the transmembrane domain (Bos et al., 1995), the signal 
peptide and cleavage site (Yamada et al., 1997) and the leucine zipper domain within 
HR2 (Britton, 1991; Luo et al., 1999).  Matsuyama and Taguchi, (2002a) studied the 
entry of soluble receptor resistant mutants of MHV to BHK cells expressing different 
MHV receptors, CEACAM1a and 1b.  Amino acid substitutions within both the 
RBD in the S1 subunit and at position 1114 in the S2 subunit were found to be 
important for efficient fusion activity with cells expressing CEACAM1b.   
 
It might be expected that forming syncytia in cell culture would increase the virus 
yield, potentially making the ability to form syncytia advantageous for vaccine 
production.  It has been found, however, that a non-fusogenic strain of MHV 
replicates to a higher titre than a fusogenic strain of MHV in the same cell type (Zhu 
et al., 2009).  The viruses were determined to have similar infectivities; however, the 
genome of the non-fusogenic strain arrived at the ER earlier than the genome of the 
fusogenic strain.  This indicates a role for the S glycoprotein in viral genome 
transport from the cell surface to the ER during infection but it is unclear how this is 




While it is currently uncertain exactly how the S2 subunit, in particular the 
Beaudette-specific motif, of Beaudette is involved in extended tropism, this 
knowledge can be exploited utilising the IBV reverse genetics system to grow IBV 




This project has revealed a number of areas for further research, which are outlined 
below, and has been awarded a grant from the BBSRC follow on fund in order to 
pursue these.  In addition to this, rIBV BeauR-M41(S1) will be assessed by Intervet 
for its ability to grow in cell culture, stability during storage and immunogenicity as 
an inactivated vaccine formulation. 
 
Extension of the Beaudette-specific motif in rIBV M41-S-BeauR-Hep 
Other Beaudette-specific amino acids in addition to the Beaudette-specific motif will 
be investigated to ascertain whether they are involved in the tropism for Vero cells.  
A number of other Beaudette-specific amino acids have been identified in the S2 
domain, which will be introduced into rIBV M41-S-BeauR-Hep using the IBV 
reverse genetics system by the replacement of the M41 amino acids with the 
Beaudette-specific amino acids.  The growth phenotype and kinetics of the resulting 
rIBV on Vero cells will be investigated in comparison with M41-S-BeauR-Hep.  
Identification of a minimal sequence for the conferment of tropism for Vero cells 
will be beneficial as this will reduce the possibility of instability of complete S1 and 
S2 subunits from two different and more distantly related S proteins.  The S1 
subunits of different IBV isolates can vary by 5 – 50%.   
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Introduction of different S1 subunits into Beau-R  
To develop the principle of using an rIBV with a chimaeric S gene as a vaccine 
strain, the S1 subunits from a common IBV live attenuated vaccine strain and a 
virulent field isolate of IBV will be introduced into the Beau-R genome using the 
IBV reverse genetics system.  The resulting rIBVs will be used to confirm that the 
ability to grow on Vero cells is conferred by the S2 subunit as well as proving that 
the S1 subunit of an IBV vaccine or field strain can be expressed by an rIBV capable 
of growth in cell culture rather than embryonated eggs.  This will be beneficial as the 
resulting potential vaccine will not require a lengthy attenuation step, will have a 
known genetic background and will be able to grow in cell culture rather than being 
restricted to embryonated eggs.   
 
The role of heparan sulphate in the extended host range of Beau-R 
There are a numbers of ways to investigate whether binding to heparan sulphate 
plays a role in the extended host range of Beau-R.  Plaque reduction assays could be 
carried out in which Beau-R and the two rIBVs, BeauR-M41(S1) and M41-S-BeauR-
Hep, are incubated in the presence of soluble heparin sodium salt at various 
concentrations 0 – 20 mg/ml before being used to carry out plaque assays on CK, 
Vero or BHK-21 cells.  The number of plaques produced would indicate whether the 
presence of heparin at varying concentrations has any effect on the ability of the 
viruses to grow on that cell type. 
 
Confocal microscopy with indirect immunofluorescence could be used to observe the 
effect of heparin on IBV infection by incubating different strains of IBV in the 
presence of heparin sodium salt at 15 mg/ml and in absence before infecting Vero, 
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CK and BHK-21 cells.  The number of cells infected by viruses that were incubated 
with heparin can be compared to the number of cells infected by viruses that were 
incubated without heparin to establish if the degree of infection is affected.    
 
The role of the putative second cleavage site in extended host range of Beau-R 
In order to determine whether the Beau-R S glycoprotein is cleaved at the Beaudette-
specific motif, the spike could be expressed, purified then run on a SDS PAGE gel to 
visualise whether it is cleaved at the S1/S2 junction only or also within the S2 
subunit. 
 
Further investigation of the amino acid changes in Beau-R P10 S glycoproteins 
that could be involved in syncytia formation 
Two approaches could be utilised in order to further investigate the effect of amino 
acid changes in Beau-R P10 on cell-to-cell fusion.  The IBV reverse genetics system 
could be used to construct rIBVs expressing S glycoproteins containing the amino 
acid differences identified in this study and the growth phenotypes and kinetics of the 
resulting viruses could be analysed.  Alternatively, modified S glycoproteins could 
be produced using site-directed mutagenesis and expressed on the cell-surface of 
Vero cells in order to observe whether they fuse to form syncytia.   
 
In order to determine whether the ability to form syncytia in Vero cell culture 
conveys a replicative advantage to Beau-R P10 over non-syncytia-forming isolates, 
growth curves could be carried out on Vero cells to compare the growth kinetics of 






Table A.1.  Beau-R P10-4 deep sequencing region 1 nucleotide and amino acid 
differences.  Nucleotide and amino acid differences identified in more than one 
isolate are shown in red, deletions are indicated by *, non-homologous sequence is 













23 20382 C T 5 P - P 
23 20385 C T 6 L - L 
35 20426 C T 20 L - S 
10 20459 T A 31 Q - L 
34 20485 A T 40 W - R 
28 20508 A T 47 Y - STOP 
29 20544 G A 59 A - A 
3 20560 C T 65 C - R 
29 20563 G A 66 T - A 
23 20583 C T 72 G - G 
33 20620 A G 85 A - T 
24 20622 G A 85 A - A 
34 20630 T C 88 S - L 
9 20634 C T 89 G - G 
21 20645 T C 93 S - F 
3 20669 G A 101 H - R 
32 20676 C T 103 N - N 
21 20691 C A 108 T - T 
25 20727 A T 120 C - STOP 
2 20744 C T 126 L - P 
22 20745 C T 126 L - L 
29 20747 G A 127 Q - R 
35 20758 G A 131 I - V 
9 20779 G A 138 N - D 
31 20787 A G 140 Q - Q 
9 20789 C T 141 L - P 
22 20805 T A 146 T - T 
8 20835 C A 156 R - S 
40 20855 G A 163 N - S 
32 20858 C T 164 L - S 
29 20862 T A 165 T - T 
23 20870 G A 168 Y - C 
33 20883 C T 172 D - D 
28 20903 G A 179 E - G 















8 20935 C T 190 F - L 
22 20952 G T 195 P - P 
30 20954 C T 196 I - T 
30 21046 C A 226 R - R 
25 21058 A G 230 A - T 
10 21060 G A 230 A - A 
9 21066 A G 232 Q - Q 
9 21073 T A 235 T - S 
36 21124 G A 252 K - E 
9 21134 C T 255 F - S 
40 21136 G A 256 I - V 
8 21137 C T 256 I - T 
32 21165 C T 265 T - T 
28 21168 C T 266 T - T 
40 21177 * A 269 L - ? 
20 21188 C T 273 I - T 
33 21188 C T 273 I - T 
25 21189 C T 273 I - I 
9 21204 A T 278 T - T 
25 21246 A T 292 T - T 
23 21250 TT CA 294 Q - L 
30 21253 C A 295 T - P 
35 21255 G A 295 T - T 
29 21266 G A 299 Q - R 
35 21270 C T 300 S - S 
36 21276 * T 302 Y - ? 
33 21279 C T 303 Y - Y 
36 21314 G A 315 Y - C 
8 21322 C T 318 S - P 
9 21325 G A 319 N - D 
32 21328 C T 320 F - L 
20 21329 C T 320 F - S 
35 21335 G A 322 Y - C 
34 21342 C T 324 S - S 
8 21356 A G 329 C - Y 
40 21375 C T 335 T - T 
10 21379 G A 337 N - D 
29 21408 T A 346 S - S 
24 21441 C T 357 G - G 
10 21453 A T 361 S - S 
3 21460 G A 364 K - E 
40 21470 T C 367 A - V 
35 21493 A T 375 Y - N 
32 21501 C T 377 G - G 




Table A.2.  Beau-R P10-9 deep sequencing region 1 nucleotide and amino acid 
differences.  Nucleotide deletions are indicated by *, non-homologous sequence is 











8 20370 A T 1 M - K 
20 20572 C T 68 G - G 
39 20773 C T 135 A - A 
39 20810 G A 148 S - G 
12 20815 G A 149 V - V 
7 20852 G A 162 N - D 
1 20884 C T 172 D - D 
14 21021 C T 218 V - V 
27 21051 C T 228 L - S 
39 21066 T A 233 Y - F 
21 21080 CC TT 238 F - P 
27 21106 A T 246 T - T 
39 21107 G A 247 N - D 
24 21146 G A 260 N - S 
38 21159 G A 264 N - S 
21 21252 T C 295 T - I 
20 21283 C T 305 F - F 
39 21288 C T 307 F - S 
39 21356 G A 330 K - E 
27 21398 C T 344 S - P 
28 21433 T A 355 Q - H 













Table A.3. Beau-R P10-12 deep sequencing region 1 nucleotide and amino acid 
differences.  Nucleotide and amino acid differences identified in more than one 
isolate are shown in red, deletions are indicated by *, non-homologous sequence is 










41 20406 C T 13 C - C 
10 20422 A G 19 V - I 
38 20422 A G 19 V - I 
2 20422 A G 19 V - I 
39 20422 A G 19 V - I 
54 20422 A G 19 V - I 
57 20430 C T 21 Y - Y 
39 20439 C T 24 S - S 
54 20439 C T 24 S - S 
2 20448 C T 27 V - V 
16 20497 A G 43 G - R 
51 20561 T G 65 C - F 
5 20580 C T 71 H -H 
51 20590 A G 75 V - I 
57 20604 C T 79 S - S 
39 20604 C T 79 S - S 
54 20604 C T 79 S - S 
6 20635 G A 90 M - V 
51 20636 C T 90 M - T 
1 20704 G A 112 T - T 
39 20704 G A 112 T - T 
54 20704 G A 112 T - T 
59 20774 G A 136 M - V 
6 20791 C T 141 L - L 
1 20793 C T 142 F - S 
59 20793 C T 142 F - S 
41 20802 C T 145 L - S 
59 20900 G A 178 N - D 
41 20904 G A 179 E - G 
59 20970 * A 201 M - ? 
39 21038 C T 224 S - P 
54 21038 C T 224 S - P 
57 21156 C T 262 S - S 
57 21172 G A 268 T - A 
1 21262 C G 298 A - P 
57 21309 C T 313 F - F 
59 21310 A G 314 V - I 
1 21311 C T 314 V - A 
10 21388 C T 340 L - L 
7 21438 C T 356 G - G 
184 
 
Table A.4.  Beau-R P10-4 deep sequencing region 2 nucleotide and amino acid 
changes.  Nucleotide and amino acid differences identified in more than one isolate 













4 21567 C T 400 Y -Y 
15 21573 C T 402 T - T 
11 21912 C T 515 T - T 
12 21912 C T 515 T - T 
15 21987 C T 540 T - T 
6 21996 C T 543 V - V 
18 22020 C T 551 Y -Y 




Table A.5.  Beau-R P10-9 deep sequencing region 2 nucleotide and amino acid 
changes.  Nucleotide and amino acid differences identified in more than one isolate 













19 22041 C T 558 P - P 
17 22048 C T 561 S - P 
17 22114 T A 583 N - Y 
18 22114 T A 583 N - Y 
20 22114 T A 583 N - Y 
19 22114 T A 583 N - Y 
18 22258 C T 630 P - P 
18 22348 C T 660 A - A 
17 22418 T C 684 P - S 






Table A.6. Beau-R P10-12 deep sequencing region 2 nucleotide and amino acid 
changes.  Nucleotide differences identified in more than one isolate are shown in 













11 21541 G A 391 H - R 
9 21554 C T 395 C - C 
16 21561 C T 398 L - L 
12 21561 C T 398 L - L 
20 21607 T C 413 T - I 
17 21752 G A 461 A - A 
14 21755 C T 463 G - G 
3 21893 C T 508 I - I 
8 21899 C T 510 T - T 
13 21948 T C 526 I - I 
10 22061 G A 564 T - A 
16 22209 T*TG**TG TATGTTTG 613 YV – L* 
12 22209 T*TG**TG TATGTTTG 613 YV – L* 





Table A.7. Beau-R P10-4 deep sequencing region 3 nucleotide and amino acid 
changes.  Nucleotide and amino acid differences identified in more than one isolate 
are shown in red, deletions are indicated by *, non-homologous sequence is indicated 













12 22832 G A 822 Q - R 
13 22856 T C 830 A - V 
5 22860 A T 831 I - I 
18 22866 A T 833 T - T 
16 22988 C T 874 L - S 
3 23019 T A 884 K - M 
1 23082 C T 905 C - C 
11 23102 A G 912 R - K 
1 23133 C T 922 V - V 
19 23199 G T 944 S - R 
16 23252 * A 962 S - ? 
12 23259 C T 964 Y - Y 
19 23259 C T 964 Y - Y 
16 23381 T C 1005 S - F 
1 23403 C T 1012 S - S 
11 23438 G A 1024 N - S 
3 23472 G A 1035 K - K 
11 23478 T G 1037 W - C 
6 23647 C T 1094 W - R 
19 23684 C T 1106 I - T 





Table A.8. Beau-R P10-9 deep sequencing region 3 nucleotide and amino acid 
changes.  Nucleotide and amino acid differences identified in more than one isolate 
are shown in red, deletions are indicated by *, non-homologous sequence is indicated 













6 22675 T C 770 P - S 
7 22694 G A 776 Q - R 
2 22758 A T 797 A - A 
9 22765 C T 800 F - L 
19 22799 C T 811 F - S 
5 22801 T A 812 R - * 
17 22819 C T 818 L - L 
7 22865 T C 833 T - I 
3 22883 A T 839 L - H 
9 23081 C T 905 C - R 
7 23096 T C 910 S - F 
9 23151 G A 928 N - D 
5 23177 G A 936 I - M 
7 23254 * A 962 S - ? 
18 23320 C T 984 I - T 
11 23325 T G 986 A - S 
13 23325 T G 986 A - S 
11 23383 T C 1005 S - F 
10 23407 C T 1013 V - A 
3 23435 G A 1022 V - V 
7 23461 G A 1031 D - G 
13 23475 A T 1036 W - R 
11 23576 C T 1069 V - V 
14 23638 C T 1090 I - T 
11 23727 G T 1120 C - G 
12 23764 T C 1132 P - L 
12 23798 A T 1143 Y - STOP 
5 23802 G A 1145 T - A 
12 23847 G A 1160 K - E 








Table A.9.  Beau-R P10-12 deep sequencing region 3 nucleotide and amino acid 
changes.  Nucleotide and amino acid differences identified in more than one isolate 










5 22722 * C 785 T - * 
7 22733 C T 790 L – L 
4 22749 * A 794 E - * 
9 22832 T C 822 Q - * 
7 22843 C T 825 V - V 
5 22917 C T 850 I - T 
3 22950 T A 861 Q - L 
7 22957 C T 863 N - N 
5 23000 C T 878 S - P 
3 23033 GCTAGAAAGTGTAG ATTAG**AGTGTCA 889 IRVS - ARKCS 
18 23047 G A 893 Q - Q 
11 23055 C A 896 E - A 
16 23134 C T 922 V - V 
5 23215 C T 949 T - T 
12 23324 T G 986 A - S 
1 23324 T G 986 A - S 
16 23379 T C 1004 T - I 
7 23379 T C 1004 T - I 
5 23379 T C 1004 T - I 
3 23379 T C 1004 T - I 
18 23379 T C 1004 T - I 
8 23379 T C 1004 T - I 
6 23379 T C 1004 T - I 
9 23379 T C 1004 T - I 
11 23379 T C 1004 T - I 
15 23380 C T 1004 T - T 
17 23440 C T 1024 N - N 
3 23454 C T 1029 F - S 
16 23464 G A 1032 E - E 
16 23470 T A 1034 S - S 
6 23600 T A 1078 I - L 
7 23637 C T 1090 I - T 
6 23637 G T 1090 I - S 
16 23666 G A 1100 I - V 
8 23712 C T 1115 F - S 
1 23741 *** GTT 1125 GC – G* 
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